Investigation of the effects of different mTOR inhibitors on protein synthesis by Huo, Yilin
University of Southampton Research Repository
ePrints Soton
Copyright © and Moral Rights for this thesis are retained by the author and/or other 
copyright owners. A copy can be downloaded for personal non-commercial 
research or study, without prior permission or charge. This thesis cannot be 
reproduced or quoted extensively from without first obtaining permission in writing 
from the copyright holder/s. The content must not be changed in any way or sold 
commercially in any format or medium without the formal permission of the 
copyright holders.
  
 When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given e.g.
AUTHOR (year of submission) "Full thesis title", University of Southampton, name 
of the University School or Department, PhD Thesis, pagination
http://eprints.soton.ac.uk1 
 
 
 
 
UNIVERSITY OF SOUTHAMPTON 
 
FACULTY OF NATURAL AND ENVIRONMENTAL SCIENCES 
Biological Sciences 
 
INVESTIGATION OF THE 
EFFECTS OF DIFFERENT mTOR 
INHIBITORS ON PROTEIN 
SYNTHESIS 
 
 
 
 
 
by 
 
Yilin Huo 
 
 
 
 
 
 
 
 
 
 
 
Thesis for the degree of Doctor of Philosophy 
December  2011 
 
 
 
 
 2 
 
UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
FACULTY OF NATURAL AND ENVIRONMENTAL SCIENCES 
                                            Biological Sciences 
Doctor of Philosophy 
INVESTIGATION OF THE EFFECTS OF DIFFERENT mTOR 
INHIBITORS ON PROTEIN SYNTHESIS 
 
by Yilin Huo 
 
The  mammalian  target  of  rapamycin  (mTOR),  which  controls  diverse  cellular 
processes, is regulated by the integration of many signals. Rapamycin strongly inhibits 
the proliferation of many cancer cell lines and there is a high level of interest in its 
potential use as an anti-cancer agent. However, some tumours and cancer cells are 
resistant to rapamycin. This has prompted the development of mTOR kinase inhibitors 
(mTOR-KIs), such as PP242 and AZD8055, which compete with ATP for binding to 
the kinase domain in mTOR. In this research, I have studied whether the effects of 
mTOR-KIs on cell signalling and protein synthesis differed in comparison to those of 
rapamycin. My data shows that mTOR-KIs have strikingly different effects on proteins 
(including  formation  of  the  eIF4F  translation  factor  complex)  that  control  mRNA 
translation. Furthermore, while rapamycin only has a very small inhibitory effect on 
the  rate  of  protein  synthesis,  mTOR-KIs  have  a  much  bigger  effect.  A  new  mass 
spectrometric approach, ‗pSILAC‘, was applied to explore the effects of rapamycin 
and mTOR-KIs on the synthesis of specific proteins. The data from pSILAC reveal (i) 
mTOR-KIs impair synthesis of many proteins; (ii) rapamycin always inhibits less than 
mTOR-KIs; (iii) their effects are strongest for proteins encoded by 5‘-TOP mRNAs, 
but  mTOR-KIs  again  inhibit  more  strongly;  (iv)  synthesis  of  some  other  proteins 
which are not encoded by known 5‘-TOP mRNAs shows a similar pattern of inhibition 
to 5‘-TOP mRNAs. These data show that pSILAC is a valuable tool for studying the 
control of the synthesis of specific proteins. I have also investigated the effects of 
disruption of eukaryotic translation initiation factor 4E (eIF4E) phosphorylation on (i) 
its  modification  by  SUMO-1  (ii)  TNFʱ  biosynthesis  in  macrophages  and  (iii)  the 
interaction with specific mRNAs encoding protumourigenic factors. 
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1.1 mTOR signalling pathway 
1.1.1 The structure and composition of TOR 
mTOR, which is also known as FRAP (FKBP-rapamycin-associated protein), RAPT1 
(rapamycin  and  FKBP  target)  or  RAFT1  (rapamycin  target),  is  the  mammalian 
homologue of the yeast TOR (the target of rapamycin) proteins (reviewed in Hay and 
Sonenberg, 2004). The  yeast  genes,  TOR1  and TOR2, were identified in  a genetic 
screen  for  resistance  to  the  immunosuppressant  drug  rapamycin  in  Saccharomyces 
cerevisiae (Kunz et al., 1993, Helliwell et al., 1994). Rapamycin was first discovered 
as a natural product of the bacterium Streptomyces hygroscopicus in a soil sample from 
Easter Island — an island also known as Rapa Nui (Vezina et al., 1975). Shortly after 
the discovery of yeast TORs, the mammalian TOR (mTOR) was identified and cloned 
(Brown et al., 1994, Chiu et al., 1994, Sabatini et al., 1994). mTOR is a large (~289 
kDa)  atypical  kinase  belonging  to  the  phosphatidylinositol  kinase-related  kinase 
(PIKK) family. Like other members in this family, mTOR contains a C-terminal kinase 
domain  (Fig.  1.1),  which  has  significant  homology  to  the  lipid  kinase 
phosphatidylinositol  3-kinase  (PI3K).  However,  unlike  PI3K,  mTOR  and  the 
remaining  PIKK  members  are  exclusively  protein  kinases.  The  C-terminal  end 
contains a FATC (for FRAP, ATM, TRRAP) domain that might have a role in its 
redox-dependent regulation and stability (Peterson et al., 2000, Dames et al., 2005). 
Immediately upstream of the kinase domain is the FRB (FKBP12/rapamycin binding) 
domain and the relatively large FAT domain. In the N-terminal half of mTOR, there 
are a large number of tandem HEAT (originally found in Huntingtin, elongation factor 
3, protein phosphatase 2A, and the yeast PI3-kinase TOR1) repeat subunits (Andrade 
and Bork, 1995). Each HEAT repeat consists of two ʱ helices of 37~43 amino acids 
that  form  a  rod-like  helical  structure  and  have  been  implicated  in  protein-protein 
interactions (Andrade and Bork, 1995). 
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Figure 1.1. Two mTOR complexes. 
A large number of tandem HEAT (originally found in Huntingtin, elongation factor 3, 
protein phosphatase 2A, and the yeast PI3-kinase TOR1) tandem repeats are located in 
the C-terminal of mTOR. mTORC1 contains the core component mTOR, the large 
protein Raptor and mLST8/GβL; mTORC2 also contains mTOR and mLST8/GβL, but 
it associates with several unique subunits: Rictor, Sin1 and Protor. FAT: a domain 
structure shared by FRAP, ATM, TRRAP; FRB: FKBP12/rapamycin binding domain; 
Raptor:  regulatory  associated  protein  of  mTOR;  Rictor:  rapamycin-insensitive 
companion of mTOR; mLST8: mammalian lethal with SEC13 protein 8; Sin1: stress-
activated protein kinase-interacting protein 1. Protor: protein observed with Rictor-1. 
DEPTOR: DEP domain containing mTOR-interacting protein. 
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mTOR  exists  as  at  least  two  heteromeric  complexes,  mTORC1and  mTORC2, 
which  are  differentially  regulated,  have  distinct  substrate  specificities,  and  are 
differentially sensitive to rapamycin (Fig. 1.1). mTORC1 contains the core component 
mTOR, the large protein Raptor (Hara et al., 2002, Kim et al., 2002) and mLST8/GβL 
(Kim  et  al.,  2003;  Fig.  1.1).  Raptor  is  an  evolutionarily-conserved  protein  which 
contains a novel N-terminal domain (named RNC), followed by three HEAT repeats 
and seven WD40 repeats (approximately 40 amino acids with conserved  W  and D 
forming four anti-parallel β strands) in the C-terminal half (Kim et al., 2002, Neer et 
al., 1994). Raptor has been proposed to interact with mTOR through multiple contact 
points (multiple regions on Raptor and at least the HEAT repeats of mTOR; Kim et al., 
2002, Yang and Guan, 2007). Amino acid withdrawal (mimicked by removing leucine 
from the culture medium) markedly increased the amount of Raptor bound to mTOR 
and this effect was reversed by a 10 min addition of leucine (Kim et al., 2002). Kim et 
al. (2002) have reported that increased Raptor binding to mTOR negatively regulated 
mTOR kinase activity through decreasing S6K1 phosphorylation and increasing the 
amount of 4E-BP1 bound to eIF4E. However, Raptor has also been reported to be a 
scaffolding protein to recruit substrates for mTOR and positively modulates the mTOR 
kinase reaction in vivo (Hara et al., 2002) 
    mLST8/GβL was identified later than Raptor and possibly associates with the kinase 
domain of mTOR (independently of Raptor; Kim et al., 2003). Like Raptor, the 36-
kDa  mLST8/GβL  is  conserved  among  all  eukaryotes.  Because  of  the  possible 
interaction with the kinase domain of mTOR, mLST8/GβL was initially proposed to 
regulate  mTOR  kinase  activity.  For  example,  knocking  down  mLST8/GβL  in  cell 
culture resulted in decreased phosphorylation of S6K1 and 4E-BP1 (Kim et al., 2003). 
However, more recent studies indicate that the precise role of mLST8/GβL remains 
ambiguous. Guertin et al. (2006) found that basal phosphorylation of S6K1, ribosomal 
protein S6 or 4E-BP1 was normal in mLST8 null mouse embryo fibroblasts (MEFs). 
Also, mLST8/GβL was found not necessary for S6K1 phosphorylation in response to 
insulin or serum stimulation. Furthermore, the loss of mLST8/GβL does not alter the 
regulation of mTORC1 signalling by rapamycin or nutrients (Guertin et al., 2006). 
Further studies are needed to elucidate the exact role of mLST8/GβL in mTORC1 
signalling.  
mTORC2 was discovered more recently and its function is not yet fully understood 
because  of  the  lack  of  an  effective  mTORC2  inhibitor.  Compared  to  mTORC1, 19 
 
mTORC2 has a distinctive composition and physiological role. mTORC2 also contains 
mTOR and mLST8/GβL, but it associates with several unique subunits: rapamycin-
insensitive companion of mTOR (Rictor, also known as mAVO3), Sin1 (also named as 
Mip1) and Protor. Rictor is a large protein (~190 kDa) and was first identified as a 
unique component of mTORC2 (Jacinto et al., 2004, Sarbassov et al., 2004). It shares 
regions of homology with pianissimo from D. discoidieum, STE20p from S. pombe, 
and  AVO3p  from  S.  cerevisiae  (Sarbassov  et  al.,  2004).  The  interaction  between 
Rictor and mTOR is not affected by short-term rapamycin treatment (Sarbassov et al., 
2004). Rictor has also been implicated in regulating the actin cytoskeleton (Sarbassov 
et  al.,  2004).  The  finding  that  Rictor  null
  mouse  embryos  were  developmentally 
delayed and died around e10.5 (embryonic day 10.5) suggests a possible role of Rictor 
in fetal vascular development (Guertin et al., 2006).  
Sin1  is  required  for  mTORC2  assembly  and  function.  Knocking  down  Sin1 
decreases the interaction between mTOR and Rictor in MEFs, supporting the idea that 
Sin1 is an essential component of mTORC2 (Jacinto et al., 2006). Moreover, loss of 
Sin1  in  MEFs  abolishes  the  phosphorylation  of  Akt  (also  known  as  PKB, 
serine/threonine protein kinase B) at Ser473 (mTORC2 is the kinase for AKT Ser473 
phosphorylation in the hydrophobic motif; Jacinto et al., 2006, Sarbassov et al., 2005). 
mLST8/GβL was first identified in mTORC1 and later also found in mTORC2 (Kim et 
al.,  2003).  The  loss  of  mLST8/GβL  completely  eliminates  the  interaction  between 
mTOR  and  Rictor  in  MEFs,  indicating  that  mLST8/GβL  is  essential  to  maintain 
mTORC2  integrity  (Guertin  et  al.,  2006).  mLST8/GβL-deficient  embryos  lost 
mTORC2-dependent Akt phosphorylation at Ser473 and also died around e10.5 like 
Rictor null mice (Guertin et al., 2006). Protor was identified as a novel Rictor-binding 
subunit of mTORC2 (Pearce et al., 2007). Protor-1 and Protor-2 are two closely related 
isoforms  which  are  encoded  by  different  genes  and  interact  with  Rictor  through  a 
conserved N-terminal region (Pearce et al., 2007, Woo et al., 2007, Thedieck et al., 
2007).  Pearce et al. (2011) have recently suggested that Protor-1 may play a role in 
enabling mTORC2 to efficiently activate SGK1, at least in the kidney. 
 DEPTOR (DEP domain containing mTOR-interacting protein) is described as an 
mTOR-interacting  protein  which  normally  inhibits  the  mTORC1  and  mTORC2 
pathways (Peterson et al., 2009). Unlike mTORC1, mTORC2 is resistant to inhibition 
by short-term treatment of rapamycin. However, prolonged treatment of rapamycin can 
inhibit mTORC2 assembly and function in some cell lines (Sarbassov et al., 2006).  20 
 
1.1.2 mTOR signalling network 
1.1.2.1 Signalling through mTORC1 
mTORC1 activity is regulated by various inputs including growth factors, nutrients 
and energy metabolism. Multiple upstream effectors are involved in the regulation. 
The following gives a detailed description. 
 
1.1.2.1.1 Regulation of mTORC1 by growth factors 
The IRS proteins 
Insulin or insulin-like growth factors (IGFs) initiate signalling at the insulin receptor 
(IR) or IGF-receptor (IGFR), which are transmembrane glycoproteins with intrinsic 
protein tyrosine kinase activities (reviewed in Corradetti and Guan, 2006). Tyrosine 
phosphorylation  mediates  many  processes  by  directly  controlling  the  activity  of 
receptors or enzymes at an early stage in signalling pathways, or by organising the 
assembly  of  signalling  complexes  around  activated  receptors  or  docking  proteins 
(White, 1998). Binding of insulin or IGFs to their receptors leads to recruitment and 
phosphorylation of insulin receptor substrate (IRS). IRS-1 was initially identified as a 
docking  protein  (White  et  al.,  1985)  and  other  identified  members  in  this  family 
include IRS-2, IRS-3, IRS4, IRS-5 and IRS-6 (reviewed in Mardilovich et al., 2009). 
This family shares several common domains (Fig. 1.3). IRS-1, which exists in most 
cell types, has a calculated molecular weight of 132 kDa (White, 1998). IRS-2 is about 
10 kDa larger than IRS-1 and is also ubiquitously expressed. These two proteins are 
primary  mediators  in  the  cellular  response  to  microenvironmental  stimuli.  The  N-
terminus of IRS-1 and IRS-2 has a well conserved pleckstrin homology (PH) domain 
that is followed by a phosphotyrosine binding (PTB) domain. Many studies suggest 
that IRS-1 and IRS-2 may mediate distinct signalling cascades (Withers et al., 1998, 
Sun et al., 1997, Schubert et al., 2003, Withers et al., 1999). A recent study found that 
IRS-1 and IRS-2 played opposite roles in breast cancer metastasis (Nagle et al., 2004, 
Sachdev et al., 2004). IRS-3 also contains a PH domain followed by a PTB domain in 
its N-terminus. It was recently reported that IRS-3 was located in both the nucleus and 
cytosol (Kabuta et al., 2010). IRS-4 is only expressed in human and found in brain, 
kidney, thymus and liver (Lavan et al., 1997). Although possessing conserved PH and 
PTB  domains,  IRS-5  and  IRS-6  have  truncated  C-termini  and  are  more  distantly 21 
 
related IRS family members (Mardilovich et al., 2009). A schematic diagram of IRS1-
6 domain structures is shown in Fig. 1.2. 
 
The tumour suppressor: PTEN 
Once  the  IRS  proteins  are  bound  to  cell  surface  receptors  through  their  PH/PTB 
domains, they are phosphorylated on tyrosine residues. Subsequently, PI3K binds to 
IRS  and  converts  phosphatidylinositol-4,5-bisphosphate  (PIP2)  to 
phosphatidylinositol-3,4,5-trisphosphate  (PIP3).  The  accumulation  of  PIP3  is 
antagonized by PTEN (phosphatase and tensin homolog on chromosome 10), which 
removes phosphates from PIP3 to generate PIP2. Discovered by Li et al. (1997), PTEN 
is a 47 kDa protein that contains an N-terminal phosphatase domain with a catalytic 
core motif. Five phosphorylation sites (Ser370, Ser380, Thr382, Thr383 and Ser385) 
are located in the C-terminal non-catalytic domain and the phosphorylation of these 
sites can lead to the degradation of PTEN (Raftopoulou et al., 2004, Torres and Pulido, 
2001).  The  significance  of  PTEN  as  a  phosphatase  and  a  regulator  of  the  PI3-K 
signalling pathway has been established over the past few years (Leslie and Downes, 
2002, Salmena et al., 2008, Sulis and Parsons, 2003). However, while it is clear that 
PTEN has many diverse biological effects, some of these effects are not obviously 
linked to its lipid phosphatase activity, and a number of studies have supported an 
additional role of PTEN as a protein phosphatase (Gildea et al., 2004, Mahimainathan 
and Choudhury, 2004, Leslie et al., 2007). PTEN was first observed to be mutated in 
cell lines derived from several cell cancers (Lynch et al., 1997, Risinger et al., 1997, 
Rhei et al., 1997). Now a wide range of cancers have been found to be accompanied by 
the  deregulation  of  PTEN,  including  lung  cancer,  gastric  cancer,  thyroid  cancer, 
colorectal cancer and prostate cancer (reviewed in Steelman et al., 2004). Studying the 
mechanisms  of  PTEN  stimulation  or  reintroducing  functional  PTEN  may  provide 
novel approaches for cancer therapy. 
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Figure 1.2. IRS protein family members. 
Interaction domains of the IRS  proteins are indicated. The IRS proteins share their 
homology in their N-termini, which containing two conserved domians, PH and PTB 
domian. IRS-5 and IRS-6 have truncated C-termini. PH: pleckstrin homology domain; 
PTB: phosphotyrosine binding domain; KRLB: kinase regulatory loop binding sites; 
Grb2: growth factor receptor-binding protein-2 binding site; SHP2:  SH2-containing 
tyrosine phosphatase binding site. 
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PDK1 
PIP3, the lipid product of PI3K, recruits Akt to the plasma membrane through its PIP3 
binding PH domain (Corradetti and Guan, 2006). Whether PDK1 also translocates to 
the plasma membrane is controversial (McManus et al., 2004, Currie et al., 1999). The 
binding of Akt to PIP3 can induce a conformational change that either generates a 
PDK1 interaction site and/or exposes Thr308 in Akt. Both PDK1 and Akt belong to 
the AGC (protein kinase A/protein kinase G/protein kinase C) kinase family, which 
also  includes  PKA,  PKG,  PKC,  S6Ks,  serum  and  glucocorticoid-induced  protein 
kinase  (SGK)  and  p90  RSKs.  PDK1  is  a  556-amino  acid  containing  enzyme 
possessing a kinase domain at its N-terminus (residue 70-539) and a PH domain at its 
C-terminus (residues 459-550) (Alessi et  al., 1997a). PDK1 also possesses another 
regulatory hydrophobic PIF pocket (Biondi, 2004).  
     PDK1 knockout mice are embryonic lethal, suggesting the importance of PDK1 in 
controlling cellular responses, especially in regulating AGC family signal transduction 
(Lawlor et al., 2002). Because it is not possible to identify the downstream effectors of 
PDK1 using the PDK1 knockout mice, mice with a mutant PH domain (Lys465Glu) 
were generated (Bayascas et al., 2008), in which the non-PIP3 binding form of PDK1 
was expressed at physiological levels. Embryonic stem (ES) cells from these mutant 
mice were stimulated with IGF1, resulting in weak activation of Akt. This reveals that 
the binding of PDK1 to PIP3 is essential to activate Akt effectively. However, the 
activation of Akt in these mutant mice was not abolished, and was still detected at 
approximately 25% of the wild type levels. The crystal structure of the isolated PDK1 
PH domain from these mutant mice revealed that the phosphoinostide binding sites 
were disrupted completely, suggesting that a pool of PDK1 constitutively associated 
with the plasma membrane may exist (Bayascas, 2008, Bayascas et al., 2008).  
 
The central regulator: Akt 
Once  activated,  Akt  is  transiently  localized  to  the  plasma  membrane  and 
phosphorylates numerous targets to promote cell growth and survival. The Akt family 
is comprised of three highly homologous isoforms:  Akt1 (PKBʱ), Akt2 (PKBβ) and 
Akt3 (PKBγ) (Jones et al., 1991b, Jones et al., 1991a, Konishi et al., 1995, Brodbeck 
et al., 1999). These proteins are products of three separate genes located on distinct 
chromosomes and are widely expressed with a few isoform-specific features. All the 
isoforms have a conserved PH domain in their N-terminus, a central-located kinase 24 
 
domain, and a C-terminal regulatory domain. As discussed above, Akt interacts with 
the lipid products of PIP3 via its PH domain, demonstrating the important function of 
the PH domain in recognition by upstream kinases. The central kinase domain shares 
high homology with other members of AGC family. In the region of C-terminus, all 
isoforms possesses the F-X-X-F/Y-S/T-Y/F hydrophobic motif (where X is any amino 
acid; Song et al., 2005). In mammals, this motif is identical (FPQFSY) and deletion of 
this motif abolishes the enzymatic activity of Akt (Andjelkovic et al., 1997).  
Indeed,  many  studies  have  shown  that  agonists  activate  AGC  kinases  by 
introducing their phosphorylation at three highly conserved residues. The three sites 
are located in the activation loop in the kinase domain, in the middle of a tail/linker 
region C terminal to the kinase domain, and within a hydrophobic motif (HM) at the 
end of the tail region (Hauge et al., 2007). In the case of Akt, it can be phosphorylated 
at Thr308 in the activation loop (also known as T-loop) by PDK1 (Alessi et al., 1997b, 
Stokoe et al., 1997) and Ser473 in the hydrophobic motif (HM) by PDK2 or mTORC2 
(Sarbassov et al., 2005). Akt has another threonine phosphorylation site in the turn 
motif (TM) (Hiraoka et al., 2011).  
The opinions on the interplay between the two sites Ser473 and Thr308 appear 
diverse. Transient disruption of Rictor in mice ablates Akt phosphorylation of both 
Ser473 and Thr308 (Yang et al., 2006) while in the MEFs derived from Rictor null 
mice, there was little effect on the phosphorylation of Akt at Thr308. Furthermore, 
regulation of Akt Thr308 phosphorylation by insulin remains normal in mTORC2-
deficient MEFs (Guertin et al., 2006). These results indicate two different models. One 
is that Ser473 phosphorylation is important for Thr308 phosphorylation (perhaps as a 
docking site). The other is that these two phosphorylation sites are independent of each 
other.  Although  the  interplay  between  Ser473  and  Thr308  still  needs  further 
investigation,  Akt  does  need  the  phosphorylation  at  both  sites  to  reach  maximum 
activity (Alessi et al., 1996). It has been suggested that Thr308 is indispensable for 
kinase activity, whereas Ser473 enhances Akt activity by around 5-fold (Andjelkovic 
et al., 1997). 
The studies in Akt isoform-specific knockout mice indicate that the diverse effects 
of Akt might be due to the different functions among the isoforms. Disruption of the 
Akt1 gene in mice led to growth retardation and the cells displayed higher rates of 
apoptosis, indicating an essential role for Akt1 in cell normal growth (Chen et al., 
2001). Male Akt2 null mice exhibited insulin resistance and progressed to a severe 25 
 
form of type  II diabetes accompanied by pancreatic β cell failure (Garofalo et al., 
2003),  which  suggests  a  critical  role  for  Akt2  in  the  maintenance  of  glucose 
homeostasis. In contrast to Akt1 or Akt2 null mice, Akt3 null mice are viable and have 
normal  growth  and  glucose  metalism,  however,  they  display  impaired  brain 
development (a reduction in brain size and weight in AKT3 null mice at the age of 1 
month; Garofalo et al., 2003). Although these studies strongly demonstrate the distinct 
roles  of  Akt  isoforms  in  growth  regulation,  glucose  homeostasis  and  brain 
development, they do possess some overlapping functions. For example, like Akt1 null 
mice,  mice  lacking  Akt2  exhibited  slow  growth  rate,  showing  that  Akt2  also 
participates in the regulation of growth.  
   Manning et al. (2007) have done a careful search of the literature examining reported 
Akt substrates and summarized the characteristics and experimental evidence of 18 
substrates.  The  reported  substrates  include  Bcl2-associated  agonist  of  cell  death 
(BAD), forkhead box protein O (FOXO), glycogen synthase kinase 3 (GSK3), proline-
rich Akt substrate of 40 kDa (PRAS40), tuberous sclerosis complex 2 (TSC2), and 
murine double minute clone 2 (MDM2; HDM2 in humans) which are implicated in 
diverse cellular functions. For example, Akt promotes cell survival by blocking the 
function of proapoptotic effectors like the BH3 (Bcl-2 homology 3)-only proteins such 
as  BAD,  which  exert  their  proapoptotic  effects  by  binding  to  and  inactivating 
prosurvival Bcl-2 family members (Datta et al., 1997, del Peso et al., 1997, Datta et al., 
2000). Akt can also inhibit the expression of the BH3-only proteins through effects on 
transcription factors, such as FOXO1, FOXO3a and FOXO4. The phosphorylation of 
FOXO displaces it from its targets and induces export from the nucleus. Through this 
mechanism,  Akt  blocks  FOXO-induced  transcription  of  various  proapoptotic  genes 
and finally enhances cell survival (reviewed in Tran et al., 2003). MDM2 is an E3 
ubiquitin  ligase  which  is  a  key  regulator  of  the  transcription  factor  P53.  Akt  also 
phosphorylates MDM2 and promotes its translocation to the nucleus, which triggers 
P53 degradation (Zhou et al., 2001).  GSK3 (glycogen synthase kinase 3) is another 
important target of Akt. GSK3 has two isoforms, GSK3ʱ and GSK3β, which have 
extensive homology, especially at the kinase domain. Akt phosphorylates GSK3ʱ at 
Ser21 and GSK3β at Ser9 and this phosphorylation results in inactivation of GSK3 
(Cross et al., 1995). Inactive GSK3 relieves glycogen synthase (GS) inhibition and 
eIF2B phosphorylation, leading to active forms of GS and eIF2B, which results in 
increased glycogen and protein synthesis (reviewed in Rayasam et al., 2009) .  26 
 
Another  important  effect  of  Akt  is  its  role  in  promoting  cell  growth.  The 
predominant  mechanism  appears  to  be  through  mTORC1.  The  tuberous  sclerosis 
proteins, TSC1 (hamartin) and TSC2 (tuberin), have been shown to be the critical 
negative regulators of mTORC1 signalling (Gao and Pan, 2001, Tapon et al., 2001). 
Tuberous sclerosis is an autosomal dominant genetic disease which frequently causes 
non-malignant tumours (termed harmatomas) in multiple organ systems like the brain 
(Ridler et al., 2004), kidney (O'Hagan et al., 1996), heart (Webb et al., 1993) and skin 
(Hamilton  and  Tonkovic-Capin,  2011).  A  combination  of  symptoms  may  include 
developmental  delay,  learning  difficulties,  behavioural  problems  and  skin 
abnormalities. This disease is caused by a mutation in genes encoding either TSC1 or 
TSC2. About 400 different mutations of the TSC genes have been described (Cheadle 
et al., 2000). TSC1 and TSC2 interact through their N-termini and form a complex in 
cells. In this complex, TSC1 stabilizes TSC2 by preventing its degradation (Chong-
Kopera et al., 2006), whereas TSC2 works as a GTPase-activating protein for the small 
GTPase Rheb (Ras homolog enriched in brain). By promoting the conversion of the 
active form Rheb-GTP into the inactive form Rheb-GDP, the TSC1/2 complex inhibits 
mTORC1 and its downstream signalling (reviewed in Manning and Cantley, 2003). 
Therefore, TSC1/2 is a critical negative regulator of mTOR. Although functions for 
either  individual  TSC1  or  TSC2  have  been  proposed,  whether  they  can  work 
independently  from  the  complex  is  still  controversial.  Overexpression  of  TSC1  or 
TSC2 alone in Drosophila is not able to induce a phenotype, but overexpression of 
both genes can dramatically reduce cell growth (Potter et al., 2001). The phenotype 
induced by loss of TSC1 is identical to that due to loss of TSC2 (Zhang et al., 2003a). 
TSC2 is dramatically reduced in TSC1-null cells (Zhang et al., 2003a).  
Inoki  et  al.  (2002)  and  and  Manning  et  al.  (2002)  found  that  Akt  directly 
phosphorylated two sites (Ser939 and Thr1462) on TSC2 in mammalian cells, which 
are conserved and phosphorylated in Drosophila TSC2.  A mutant of TSC2, in which 
Ser939  and  Thr1462  residues  are  substituted  by  alanine,  can  block  growth  factor-
induced S6K1 activation (Manning et al., 2002), suggesting the phosphorylation of 
TSC2 mediated by Akt is required to activate mTORC1. Moreover, in TSC2 null cells, 
both  S6K  and  4E-BP1  are  constitutively  phosphorylated,  which  is  sensitive  to  the 
inhibition of rapamycin. Despite the abundance of data implying that Akt functions by 
relieving the inhibitory  effect of TSC1/2 on mTOR, the mechanism by which  Akt 
phosphorylation affects the function of TSC1/2 is not clear. Some studies suggest that 27 
 
the phosphorylation on TSC2 disrupts TSC1/TSC2 heterodimer formation (Inoki et al., 
2002, Potter et al., 2002). However, other studies do not support this model (Dan et al., 
2002). Notably, whether TSC2 phosphorylation by Akt is sufficient to fully activate 
mTORC1 also remains unresolved.  
Apart from TSC2, a second Akt substrate has been found to be involved in the 
regulation  of  cell  growth  by  mTORC1.  The  proline-rich  Akt  substrate  of  40  kDa 
(PRAS40), which is a 14-3-3 binding protein, was detected using the Akt phospho-
substrate antibody (Kovacina et al., 2003). Kovacina et al. (2003) showed that (1) 
PRAS40 was phosphorylated in vitro by purified Akt on the same site which was 
phosphorylated  in  insulin-stimulated  cells;  (2)  activation  of  an  inducible  Akt  was 
sufficient  to  stimulate  the  phosphorylation  of  PRAS40;  and  (3)  cells  without  Akt 
exhibit a diminished ability to phosphorylate this protein. Akt directly phosphorylates 
PRAS40  at  Thr246,  which  leads  the  binding  of  this  protein  to  14-3-3  protein 
(Kovacina et al., 2003). More importantly, PRAS40 has been found to associate with 
mTORC1  and  inhibit  the  signalling  from  mTORC1  to  its  physiological  substrates 
(Sancak et al., 2007, Vander Haar et al., 2007). These studies place PRAS40 upstream 
of mTORC1. On the other hand, phorbol esters, which can activate mTORC1, do not 
induce phosphorylation of PRAS40 at Thr246 (Fonseca et al., 2008). The binding of 
PRAS40 to 14-3-3 protein, which requires both amino acids and insulin, is inhibited by 
TSC1/2 and is stimulated by Rheb in a rapamycin-sensitive manner (Fonseca et al., 
2008). Knockdown of PRAS40 impairs both the amino acid- and insulin-stimulated 
phosphorylation  of  4E-BP1  and  phosphorylation  of  rpS6,  without  inhibiting  the 
phosphorylation  of  Akt  or  TSC2  (Fonseca  et  al.,  2007).  These  data  indicate  that 
PRAS40 may not be involved in controlling mTORC1, but rather be a downstream 
target of mTORC1.  
 
Rheb: an activator of mTORC1 
Another important finding during genetic screens in Drosophila is the identification of 
Rheb (Ras homolog enriched in brain) as a positive regulator of mTORC1 (Saucedo et 
al., 2003, Stocker et al., 2003). Rheb GTPases represent a unique family of the Ras 
superfamily of G-proteins. TSC2 was shown to weakly accelerate the intrinsic rate of 
GTP hydrolysis of Rheb, converting Rheb from the GTP-bound to the GDP-bound 
form, which suggests that Rheb is a directly target of TSC2 GAP activity (Tee et al., 
2003, Garami et al., 2003, Inoki et al., 2003a). Knocking down Rheb in Drosophila S2 28 
 
cells inhibits S6K1 phosphorylation (Zhang et al., 2003b), while overexpression of 
Rheb increases S6K1 and 4E-BP1 phosphorylation in the absence of growth factors or 
in the presence of wortmannin (Inoki et al., 2002, Castro et al., 2003, Garami et al., 
2003, Tee et al., 2003). Furthermore, overexpression of a dominant-negative form of 
Rheb blocks activation of mTOR by growth factors and insulin as measured by p70- 
S6K activity (Tabancay et al., 2003). In TSC2 null cells, the level of GTP-bound form 
of Rheb is increased (Garami et al., 2003).  All these data strongly suggest that (1) 
Rheb  is  a  downstream  effector  of  the  TSC1/TSC2  heterodimer  and  that  TSC2 
negatively regulates its activity as a GAP for Rheb; (2) Rheb is an upstream positive 
regulator of mTOR.  
Strikingly,  Akt activity  is increased in Rheb-deficient Drosophila cells in which 
TOR activity is decreased  (Stocker et al., 2003). Consistent with this finding, Akt 
activity  is  decreased  in  Rheb-overexpressed  Drosophila  cells  in  which  TOR  is 
activated (Stocker et al., 2003). It is possible that the interplay between Rheb and Akt 
activities is mediated by a feedback loop mechanism through S6K that appears to be 
conserved in both mammals and Drosophila. 
 
 
MEK/Erk and p90 RSK 
The  Ras/Raf/MEK/Erk  pathway,  which  is  also  stimulated  upon  the  binding  of 
extracellular growth factors to their respective transmembrane RTKs (receptor tyrosine 
kinases), plays important roles in the transfer of proliferative signals from membrane 
bound receptors. In this pathway, both Erks and the Erk-activated 90-kDa ribosomal 
S6 kinases (p90 RSKs) have been proposed to control mTORC1 signalling. One report 
suggests that this involves the direct phosphorylation of TSC2 by Erks (Ma et al., 
2005). This report showed that Erk-dependent phosphorylation led to the dissociation 
of TSC1/2 complex and markedly impaired TSC2 inhibition of S6K. Other studies 
indicate that TSC2 is phosphorylated and inactivated by p90 RSK (Roux et al., 2004, 
Rolfe et al., 2005, Ballif et al., 2005). p90 RSK interacts with and phosphorylates 
TSC2, resulting in increased mTOR signalling to S6K. Besides TSC2 phosphorylation, 
TSC1  has  been  indicated  as  an  additional  point  of  regulation  in  the  control  of 
MEK/Erk  over  mTORC1  (Fonseca  et  al.,  2011).  Fonseca  et  al.  also  showed  that 
MEK/Erk  are  likely  required  (whereas  p90  RSK  are  dispensable)  for  mTORC1 
activation in human embryonic kidney (HEK) 293 cells by phorbol esters. 29 
 
Activation of p90 RSKs is reportedly required for rpS6 phosphorylation downstream 
of the Ras/Erk signalling cascade. Roux et al. (2007) demonstrated that while S6K1 
phosphorylates  rpS6  at  all  sites,  p90  RSK  exclusively  phosphorylates  rpS6  at 
Ser235/236 in vitro and in vivo using an mTOR-independent mechanism. It has also 
been reported that p90 RSK phosphorylates Raptor and thereby activates mTORC1 
signalling  (Carriere  et  al.,  2008).  Moreover,  mTORC1  inhibition  leads  to  Erk 
activation through a negative feedback loop stemming from S6K1 in solid tumours, 
indicating the potential of a combined therapeutic approach of combined mTORC1 and 
MAPK inhibition (Carracedo et al., 2008). 
 
1.1.2.1.2 Regulation of mTORC1 by amino acids. 
Amino  acids,  fundamental  nutrients  for  all  cells,  are  also  essential  for  mTORC1 
signalling. In response to amino acid depletion, mTORC1 activity is rapidly abolished 
(Hara et al., 1998). Among amino acids, leucine and glutamine are two most important 
for mTORC1 activity (Hara et al., 1998, Nakajo et al., 2005). Although both insulin 
and amino acids activate mTORC1, amino acids do not activate Akt/PKB signalling 
(Campbell et al., 1999). Since TSC2 lies downstream of Akt, it was conceivable that 
the effects of amino acids on mTORC1 were mediated through TSC2. However, it is 
evident that amino acid depletion still impairs mTORC1 signalling in TSC2 null cells 
(Roccio  et  al.,  2006,  Smith  et  al.,  2005).  Nobukuni  and  colleagues  (2005)  have 
observed  similar  results  in  TSC2  null  MEFs.  These  findings  support  the  idea  that 
amino acids actually do not signal  to mTORC1 through TSC2. Therefore, how do 
amino acids affect mTORC1?   
 
Role of hVps34 in the amino acid-mediated activation of mTORC1. 
Vps34 (vacuolar protein sorting protein 34) is a Class III PI 3-kinase. Vps34 was first 
identified in a Saccharomyces cerevisiae (budding yeast) screen for proteins involved 
in vesicle-mediated vacuolar protein sorting (Herman and Emr, 1990). Vps34 and its 
homologue human Vps34 (hVps34; which is encoded by the PIK3C3 gene), play a 
positive  role  in  protein  breakdown  (autophagy)  (Kihara  et  al.,  2001).  However, 
Nobukuni  et  al.  (2005)  have  shown  that  hVps34  positively  regulates  mTORC1 
signalling. They found that overexpression of hVps34 in mammalian cells increased 
the  phosphorylation  of  S6K1  and  4E-BP1  while  knocking  down  hVps34  by  RNA 30 
 
interference impaired the ability of amino acids to activate mTORC1 (Nobukuni et al., 
2005). The two findings concerning the functions of hVps34 in controlling autophagy 
and mTORC1 appear at odds. Nobukuni et al. (2005) suggested one possibility, which 
is  that  hVps34  operates  through  distinct  complexes  and  differentially  regulates 
autophagy and mTORC1. The above observations also suggest that hVps34 functions 
upstream of mTORC1 in amino acid sensing. Interestingly, ablation of dVps34 has no 
effect on cell growth mediated by dTORC1 in Drosophila fat body  (Juhasz et al., 
2008). These observations place Vps34 downstream of dTORC1-dependent nutrient 
signalling in Drosophila. Therefore, future studies using in vivo mammalian system 
will  be  necessary  to  clarify  the  role  of  hVps34  in  amino  acid-sensitive  mTORC1 
regulation. 
 
Role of MAP4K3 in the amino acid-mediated activation of mTORC1. 
A  study  using  a  genome-wide  RNA  interference  approach  in  Drosophila  cells 
identified  the  homologue  of  the  mammalian  protein  kinase  MAP4K3  (mitogen-
activated  protein  kinase  kinase  kinase  kinase  3)  as  a  positive  regulator  of  TOR 
signalling  (Findlay  et  al.,  2007).  Overexpression  of  MAP4K3  activates 
phosphorylation  of  S6K1  at  Thr389  and  4E-BP1  at  Thr70  without  affecting  the 
phosphorylation  of  Akt  at  Ser473  in  serum-deprived  HEK-293T  cells.  These  data 
demonstrate  that  MAP4K3  is  a  specific  positive  regulator  of  mTORC1  signalling. 
Amino acid withdrawal rapidly decreases phosphorylation of S6K1 at Thr389 (Hara et 
al., 1998), whereas overexpression of MAP4K3 significantly delays the amino acid 
withdrawal-induced inactivation of S6K1, indicating that S6K1 is partially relieved 
from the inhibitory effect of amino acid depletion (Findlay et al., 2007). Moreover, 
MAP4K3 activity is impaired by starving cells of amino acids and enhanced by adding 
them back. A more recent study has shown that PR61ε, a PP2A-targeting subunit, 
plays an important role in the regulation of MAP4K3 phosphorylation in response to 
amino acids (Yan et al., 2010). Together these data indicate that MAP4K3 is involved 
in the control of mTORC1 signalling by amino acids. 
 
Roles of Rag GTPases in the control of mTORC1 by amino acids 
The identification of the Rag small GTPase family is another important development 
elucidating  the  molecular  mechanism  by  which  amino  acids  enhance  mTORC1 
signalling. The mammalian Rag subfamily of GTPases consists of Rag A, B, C, and D, 31 
 
and belongs to the super-family of Ras-related GTPases (Sekiguchi et al., 2001). RagA 
or RagB forms a heterodimer with RagC or RagD and functions as a heterodimeric 
complex. Sancak et al. (2008) found that the Rag proteins interacted with Raptor in an 
amino acid sensitive manner. A RagA/B mutant, which is constitutively bound to GTP, 
interacted strongly with mTORC1 and its expression within cells made the mTORC1 
pathway resistant to amino acid deprivation (Sancak et al., 2008).  
How do Rag GTPases regulate mTORC1 activity in response to amino acids? In in 
vitro studies, purified active Rag GTPases are not able to stimulate mTORC1 kinase 
activity, suggesting that the Rag proteins do not directly stimulate the kinase activity of 
mTORC1 (Sancak et al., 2008). Moreover, the Rag proteins have been implicated in 
the movement of mTORC1 to a compartment that also contains its activator Rheb 
(Sancak et al., 2008). Recently, Sanack et al. reported that lysosomal surface is the 
compartment where the Rag proteins reside (Sancak et al., 2010). Amino acids induce 
the  translocation  of  mTORC1  to  lysosomal  membranes,  and  a  complex  termed  as 
Ragulator  recruits  the  Rag  GTPases  to  lysosomes.  This  Rag-Ragulator-mediated 
translocation of mTORC1 to lysosomal membranes is considered as the key event in 
amino acid signalling to mTORC1. 
 
1.1.2.1.3 Regulation of mTORC1 by energy signals 
The ability of insulin to activate mTOR is impaired by a reduction in cellular ATP 
levels, suggesting that cellular energy also regulates mTOR activity  (Dennis et al., 
2001). The AMP-activated protein kinase (AMPK) is a key cellular energy sensor and 
regulates  a  large  number  of  cellular  responses  upon  energy  starvation.  AMPK  is 
activated by increased cellular AMP levels (Hardie et al., 1999). AMPK activation also 
requires  phosphorylation  by  the  tumour  suppressor  protein  LKB1  (Hawley  et  al., 
2003), which forms a complex with sterile-20 related adaptor (STRAD) and mouse 
protein 25 (MO25), which maintains LKB1 in an active state (Zeqiraj et al., 2009). 5‘-
aminoimidazole-4-carboxamide riboside (AICAR) can activate AMPK, leading to a 
dramatic reduction of S6K and 4E-BP1 activity. Also, culturing cells in low glucose 
caused reduction of mTOR activity (Bolster et al., 2002, Kimura et al., 2003, Krause et 
al., 2002). It was shown that AMPK regulated mTORC1 via phosphorylation of TSC2 
(Inoki et al., 2003b). However, cells lacking TSC2 remain responsive to energy stress, 
suggesting  that  additional  AMPK  substrates  may  directly  or  indirectly  modulate 32 
 
mTORC1  activity.  AMPK  was  reported  to  phosphorylate  Raptor  on  two  well-
conserved serine residues and the phosphorylation of Raptor by AMPK was required 
for the inhibition of mTORC1 and cell cycle arrest induced by energy stress (Gwinn et 
al., 2008). GSK3 has also been implicated in the regulation of mTORC1 by energy 
signals through its role in TSC2 phosphorylation (Inoki et al., 2006). . 
 
1.1.2.1.4 Regulation of mTORC1 by hypoxia 
A reduction in the normal level of tissue oxygen tension (hypoxia) has a profound 
inhibitory impact on mTORC1 activity (Tinton and Buc-Calderon, 1999, Arsham et al., 
2003).   
The  hypoxia-inducible  transcription  factor  (HIF)  plays  a  central  role  in  oxygen 
homeostasis.  The  HIF-1  transcription  factor  is  a  heterodimer  that  consists  of  the 
hypoxic  response  factor  HIF-1ʱ  and  the  constitutively  expressed  aryl  hydrocarbon 
receptor  nuclear  translocator  (ARNT;  also  known  as  HIF-1β;  Wang  and  Semenza, 
1995). Under hypoxia, HIF-1ʱ becomes stabilized, allowing dimerization with HIF-1β 
and  translocation  of  the  HIF  complex  into  the  nucleus,  where  it  associates  with 
promoters bearing hypoxia-response elements (HRE) (Maxwell et al., 1999, Wang and 
Semenza, 1993). The HIF-1ʱ subunit  is  regulated by hydroxylation at  two proline 
residues  by  family  members  of  oxygen-sensitive  enzymes,  prolyl  4-hydroxylases 
(PHD) (Cockman et al., 2000).  There are also modifications other than hydroxylation 
that regulate HIF-1ʱ stability and activity, like desumoylation (Cheng et al., 2007). 
Ataxia telangiectasia mutated (ATM), one of the key transducers of the stress response, 
has been identified as the product mutated or inactivated in ataxia telangiectasia (AT) 
patients (Tichy et al., 2010, Ivanov et al., 2009, Lavin, 1999). Interestingly, Cam and 
colleagues  (2010)  showed  that  hypoxia  induced  ATM  kinase  activity,  and  ATM 
phosphorylated HIF-1ʱ at Ser696 that affected their stabilization. 
A 25-kDa protein, regulated in development and DNA damage response 1 (REDD1; 
also referred to as DDIT4) is also involved in mTORC1 regulation by hypoxia. In 
response to hypoxia, REDD1 expression is upregulated by  HIF-1  (Shoshani et al., 
2002).  Importantly,  REDD1-induced  mTORC1  inhibition  requires  the  TSC1/2 
complex (Brugarolas et al., 2004, Sofer et al., 2005). TSC2 was previously reported to 
interact with 14-3-3 proteins (Cai et al., 2006, Shumway et al., 2003). REDD1, which 
contains a putative 14-3-3 protein binding motif, was proposed directly binding to and 33 
 
sequestering 14-3-3 proteins away from TSC2 (DeYoung et al., 2008). However, the 
mechanism by which REDD1 sequesters 14-3-3 proteins is unclear. 
  
1.1.2.1.5 Downstream targets of mTORC1 
mTORC1 plays a role in various cellular processes in yeast and in higher eukaryotes. 
The  following  mainly  describe  its  effects  on  translation,  transcription,  ribosome 
biogenesis and autophagy.  
 
1.1.2.1.5.1 Translation 
Activation of mTORC1 positively stimulates mRNA translation via its downstream 
substrates:  4E-BPs  and  S6  kinases  (S6Ks).  eIF4E  is  the  rate-limiting  translation 
effector which binds to the cap structure, m
7GpppN (where N is any nucleotide), at the 
5‘-end of mRNA. Phosphorylation of 4E-BP1 by mTORC1 results in its dissociation 
from eIF4E, promoting the binding of eIF4E to eIF4G. The role of S6Ks in translation 
has remained controversial.  
4E-BPs 
While Drosophila only expresses one 4E-BP, mammals have been found to contain 
three 4E-BPs isoforms, namely, 4E-BP1, 4E-BP2 and 4E-BP3, which are encoded by 
three different genes (Lin et al., 1994, Pause et al., 1994, Poulin et al., 1998, Bernal 
and  Kimbrell,  2000,  Miron  et  al.,  2001).  4E-BP3,  which  exhibits  57%  and  59% 
identity  to  4E-BP1  and  4E-BP2,  respectively,  was  the  last  of  the  eIF4E-binding 
proteins  to  be  identified  (Poulin  et  al.,  1998).  The  4E-BPs  compete  with  eIF4G 
proteins for an overlapping site on eIF4E, thus blocking the binding of eIF4E to eIF4G 
and the formation of initiation factor complexes (Haghighat et al., 1995, Mader et al., 
1995, Marcotrigiano et al., 1999). The affinities of 4E-BPs to eIF4E are controlled by 
their phosphorylation state (Pause et al., 1994). Whereas hypophosphorylated 4E-BPs 
bind with high affinity to eIF4E, the hyperphosphorylation of 4E-BPs  prevent this 
interaction. 
Of the  three  4E-BPs, 4E-BP1 is  by far the best  understood.  Its phosphorylation 
occurs  at  multiple sites.  So far, seven phosphorylation sites  have been  reported in 
human 4E-BP1 (Thr37, Thr46, Ser65, Thr70, Ser83, Ser101, and Ser112; Fig. 1.3). 
Phosphorylation  of  these  sites  is  a  complicated  hierarchical  process,  whereby  the 34 
 
phosphorylation at some sites is required for others (Gingras et al., 1999, Gingras et al., 
2001,  Mothe-Satney  et  al.,  2000,  Wang  et  al.,  2003).  For  example,  Thr37/46 
phosphorylation is thought to be a priming event, which is required for subsequent 
phosphorylation  of  Thr70  followed  by  Ser65  (Hay  and  Sonenberg,  2004).  
Phosphorylation of Thr70 appears to play a major role in the release of 4E-BP1 from 
eIF4E  (Fadden  et  al.,  1997),  while  phosphorylation  of  Ser65  may  prevent  the 
reassociation  of  eIF4E  and  4E-BP1  (Karim  et  al.,  2001,  Lin  et  al.,  1994). 
Phosphorylation at Ser83 does not significantly contribute to the control of 4E-BP1 in 
vivo. It has been suggested that the phosphorylation of Ser83 is not required for the 
release of 4E-BP1 from eIF4E (Choi et al., 2003). Ser101 and Ser112 are located in 
the C-terminus  of 4E-BP1, which is  far away from  the eIF4E-binding  sites  in  the 
unfolded structure of 4E-BP1 (Wang et al., 2003). These two sites are unique to 4E-
BP1, since neither 4E-BP2 nor 4E-BP3 contains residues equivalent to these two sites 
(Wang et al., 2003). Based on their location in 4E-BP1, the finding that Ser101 and 
Ser112 are important to the control of 4E-BP1 seems surprising. Ser101 plays a key 
role  in  the  insulin-induced  phosphorylation  of  Ser65  while  Ser112  is  required  for 
insulin-induced release  of 4E-BP1 from eIF4E  (Wang  et  al., 2003,  Heesom  et  al., 
1998). Thus, at least two priming events, phosphorylation of Ser101 as well as of 
Thr70, are required for phosphorylation of Ser65.  
Two regulatory motifs have been identified in the N and C termini of 4E-BP1 (Fig. 
1.3).  The  N  terminus  contains  the  ―RAIP‖  motif  (Arg–Ala–Ile–Pro,  hence  RAIP), 
which lies in the first 24 residues of 4E-BP1 (Tee and Proud, 2002). This motif is 
found in 4E-BP1 and 4E-BP2, but is absent in 4E-BP3. Studies show that the RAIP 
motif is required for the phosphorylation of Thr37/46 as well as Ser65 and  Thr70 
(Beugnet et al., 2003). Because phosphorylation of 4E-BP1 is a rather complicated 
hierarchical process, it is likely that the impacts of the RAIP motif on phosphorylation 
of Ser65 and Thr70 are not direct. The extreme C terminus contains a TOR-signalling 
(TOS) motif that is also found in S6Ks (Schalm and Blenis, 2002), HIF1ʱ (Land and 
Tee, 2007) and PRAS40 (Wang et al., 2007a). The TOS motif is required for the 
binding of these proteins to Raptor and therefore regulation by mTORC1. Mutation or 
deletion of this motif significantly impairs the insulin-stimulated phosphorylation of 
4E-BP1 at Ser65 and Thr70 (Wang et al., 2003, Tee and Proud, 2002, Schalm et al., 
2003). So far there is no evidence for a direct interaction between Raptor and the RAIP 
motif. 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Domain structure of human 4E-BP1. 
The RAIP and TOS motifs, the eIF4E-binding sites and seven phosphorylation sites 
discussed  in  the  text,  Thr37,  Thr46,  Ser65,  Thr79,  Ser83,  Ser101  and  Ser112,  are 
presented  in  this  diagram.  The  N-terminal  RAIP  motif  is  required  for  the 
phosphorylation of Thr37/46 as well as Ser65 and Thr70. The C-terminal TOS motif is 
important for the binding of 4E-BP1 to Raptor. RAIP: Arg–Ala–Ile–Pro, hence RAIP; 
TOS: TOR-signalling motif. 
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    The importance of 4E-BPs in regulating translation is highlighted by their ability to 
control  cell  growth,  size  and  proliferation.  Expression  of  a  phosphorylation  site- 
defective mutant of 4E-BP1 results in a reduction in cell size whereas coexpression of 
eIF4E and this mutant of 4E-BP1 blocks the effects of eIF4E on cell size (Fingar et al., 
2002). This mutant also inhibits G1-phase progression (Fingar et al., 2004). Dowling 
and  colleagues  (2010)  group  recently  studied  the  roles  of  4E-BPs  in  mTORC1 
signalling. When mTORC1 activity was blocked by Raptor depletion in MEFs, the 
cells  proliferated  more  slowly  than  control  ones.  However,  knockout  of  4E-BPs 
rescued the inhibition of cell proliferation caused by Raptor silencing. When Rictor 
was depleted, knockout of 4E-BPs had no effect on the inhibition of cell proliferation. 
Their data demonstrate that 4E-BPs mediate cell proliferation through their effects on 
mTORC1, but not mTORC2.   
 
S6 Kinases 
Humans express two similar S6K proteins, which are S6K1, encoded by RPS6KB1, 
and S6K2, encoded by RPS6KB2 (Gout et al., 1998, Grove et al., 1991, Koh et al., 
1999) (Fig. 1.4). Alternative splicing of S6K1 generates two isoforms, a long one, 
containing 525 amino acids (p85 S6K1) and a short one containing 316 amino acids 
(p31 S6K1). An alternative translation start site in the N-terminus of p85 S6K1 results 
in the generation of another protein, the p70 S6K1, which lacks the first 23 amino 
acids compared to p85 S6K1 and, comprises 502 amino acids (Grove et al., 1991). The 
amino acid sequence of p85 S6K1 and p70 S6K1 is almost identical except that p70- 
S6K1 lacks the first N-terminal 23 amino acids which contain an important signal 
called nuclear localization-signal (NLS). p31 S6K1 is much shorter, only containing 
the  same  amino  acids  from  1-195  but  different  in  the  adjacent  121  amino  acids. 
Alternative translation start sites also give rise to two isoforms of S6K2, a long form 
p56 S6K2 and a short form p54 S6K2 (Fig. 1.4). The long one differs from the short 
one due to a 13 amino acid extension at its N-terminus (Gout et al., 1998).  
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ribosomal protein S6 kianses
(S6Ks)
S6K1                           S6K2
p85 S6K1                p31 S6K1
different translation start sites
p85 S6K1            p70 S6K1
p56 S6K2                p54 S6K2
different translation start sites
 
Figure 1.4. The family of S6 kinases.  
Humans express S6K1 and S6K2, which are encoded by  RPS6KB1 and RPS6KB2, 
respectively.  Alternative  splicing  of  the  primary  transcript  of  S6K1  generates  two 
isoforms,  p85  S6K1  and  p31  S6K1.  An  alternative  translation  start  site  in  the  N-
terminus of P85 S6K1 gives rise to p70 S6K1. S6K2 also has two isoforms, p56 S6K2 
and p54 S6K2, due to the alternative translation start sites. Diagram is adapted from an 
original prepared by Ronser et al. (2011a). 
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Although S6K1 has been widely studied, the nucleocytoplasmic localisation of its 
isoforms has not been completely clarified. Since p85S6K1 contains a NLS at its N-
terminus, it has long been thought of as a nuclear protein. However, using primary 
non-immortalized, non-transformed human fibroblasts, it has been recently found that 
p85S6K1 is only present in the cytoplasm (Rosner and Hengstschlager, 2011b). p70-
S6K1 was detected in both the cytoplasm and nucleus while p31S6K1 was shown to be 
nuclear (Rosner and Hengstschlager, 2011a). Both isoforms of S6K2 demonstrate a 
constitutive nuclear localization (Koh et al., 1999). 
S6Ks belong to the AGC family and perform phosphorylation at a series of serine 
and threonine residues located in different domains. In the case of S6K1, these sites 
include Thr229, Ser371, Thr389, Ser411, Ser418, Thr421 and Ser424. Among them, 
Thr229, Ser371, and Thr389 are equivalent to the conserved phosphorylation sites for 
the AGC family members. T229 is the activation loop (T loop) site and was found to 
be phosphorylated by PDK1 (Alessi et al., 1997a, Pullen et al., 1998). Ser371 is the 
turn motif site and Thr389 is the HM (hydrophobic motif) site (Hauge et al., 2007, 
Davis,  1993).  It  has  been  generally  accepted  that  phosphorylation  of  the  HM  site 
primes  S6K1  for  the  phosphorylation  of  the  activation  loop,  although  some  data 
suggest otherwise (Keshwani et al., 2011). As mentioned before, S6Ks also contain a 
TOS  motif  (FDIDL  in  S6K1)  like  several  other  mTOR  substrates.  Raptor  binds 
directly to this motif and mediates the interaction between S6Ks and mTORC1. It is 
clear that only the HM site of S6Ks (Thr389 in the case of S6K1) is highly sensitive to 
rapamycin and mTORC1 is responsible for its phosphorylation (Burnett et al., 1998, 
Isotani et al., 1999).  
 Many S6K substrates have been reported, such as rpS6, eIF4B, eEF2K, IRS1, 
Pdcd4 and BAD1 (Raught et al., 2004, Wang et al., 2001, Harrington et al., 2004, Shah 
et al., 2004, Dorrello et al., 2006, Harada et al., 2001, Ferrari et al., 1991). The best 
known  one  is  rpS6.  There  are  5  inducible  phosphorylation  sites  located  in  the  C-
terminus of rpS6, which are Ser235, Ser236, Ser240, Ser244 and Ser247 (Bandi et al., 
1993, Krieg et al., 1988). While all 5 sites are able to be phosphorylated by p70 S6Ks, 
Ser235 and Ser236 can also be phosphorylated by p90 RSK (Ferrari et al., 1991, Pende 
et al., 2004).  
The importance of S6Ks in protein synthesis was revealed from genetic studies in 
mice. The disruption of S6Ks in mice does not affect their viability or fertility, but it 
significantly slows animal growth and produces a small size phenotype (Shima et al., 39 
 
1998,  Kawasome  et  al., 1998). The generation of rpS6
P-/- mice  (in which all five 
phosphorylation sites in S6 were mutated into alanine residues) has provided valuable 
insight into the physiological roles of S6 phosphorylation. Like S6K knockout mice, 
rpS6
P-/- mice display a small cell size phenotype, although they are viable and fertile 
(Ruvinsky et al., 2005, Ruvinsky et al., 2009). These mice also show a reduction in β-
cells and impaired glucose tolerance, suggesting a role for rpS6 in β-cell function and 
glucose homeostasis. For a long period, the phosphorylation of rpS6 was connected 
with the translation of a class of mRNA that contain a terminal oligopyrimidine (TOP) 
stretch at the 5‘-end. It was thought that S6 phosphorylation was required to recruit 5‘-
TOP  mRNAs  and  therefore  enhanced  a  process  called  ―ribosome  biogenesis‖. 
However, genetic studies demonstrate the lack of  association between these events 
(Tang et al., 2001). More details will be discussed later. 
     A negative role of S6Ks in insulin signalling was revealed by the finding that mice 
lacking S6K1 have enhanced insulin sensitivity (Um et al., 2004). Cells with high 
basal  levels  of  mTOR/S6K  activity  showed  a  strong  repression  of  the  PI3K/Akt 
pathway  (Shah  et  al.,  2004).  It  is  now  known  that  S6K1  inhibits  IRS1  by 
phosphorylating it (Harrington et al., 2004, Um et al., 2004). Therefore, S6Ks exert a 
negative  feedback  loop  through  IRS1,  downregulating  the  activity  of  downstream 
components of the insulin/PI3K/Akt pathway.    
 
1.1.2.1.5.2 Ribosome Biogenesis 
Ribosome biogenesis is a complex process that consumes a large proportion of energy 
within the cell. Research in yeast and mammalian cells demonstrated that ribosome 
biogenesis is rapamycin-sensitive and thus controlled by TOR (Schmelzle and Hall, 
2000). All three nuclear RNA polymerases, Pol I, Pol II and Pol III are required for the 
synthesis of ribosomes. TOR signalling regulates ribosome biogenesis at several levels, 
including transcription by Pol I, II and III, pre-rRNA processing and translation. For 
example,  mTOR  controls  Pol  I  transcription  via  TIF-IA.  As  one  of  the  basal 
transcription factor, TIF-IA recruits Pol I to rDNA promoter and thereby facilitates the 
formation of transcription initiation complex (Miller et al., 2001, Yuan et al., 2002). 
The activity of TIF-IA is modulated by its phosphorylation at two residues, Ser44 and 
Ser199  in  opposite  ways.  For  example,  phosphorylation  of  Ser44  activates  while 
Ser199  inactivates  TIF-IA.  Inhibition  of  mTOR  signalling  inactivates  TIF-IA  by 40 
 
regulating the phosphorylation at these sites (Mayer et al., 2004). Furthermore, TIF-IA 
translocates from the nucleus to the cytoplasm following rapamycin treatment (Mayer 
et  al.,  2004).  Another  basal  transcription  factor,  UBF  has  also  been  found  to  be 
regulated  by  mTOR  via  the  involvement  of  S6K1  (Hannan  et  al.,  2003).  S6K1 
stimulates the phosphorylation of UBF in its C-terminal region, thus promoting its 
interaction with the TBP-containing factor TIF-IB. Therefore, mTOR is a key event in 
the modulation of Pol I activity and the assembly of the transcription complex.  
Pol II is responsible for the transcription of ribosomal protein (RP) genes. Studies 
in yeast have found that TOR controls the expression of RP genes via two factors, 
SFP1 and FHL1 (Marion et al., 2004, Martin et al., 2004). SFP1 was found to help 
promote RP gene transcription by binding to the promoters of RP genes. Rapamycin 
treatment caused the inactivation of SFP1, leading to the downregulation of RP gene 
transcription (Jorgensen et al., 2004). The forkhead transcription factor, FHL1, has 
also been identified as a critical regulator of RP gene transcription. FHL1 is regulated 
by  its  co-activator,  IFH1,  and  its  co-repressor,  CRF1  (Martin  et  al.,  2004).  TOR 
maintains the co-repressor CRF1 in the cytoplasm under favourable conditions. If TOR 
is  inactivated  due  to  unfavourable  growth  conditions,  CRF1  translocates  into  the 
nucleus and competes with IFH1 to bind to FHL1, inhibiting RP gene transcription 
(Martin et al., 2004). In addition, histone modifying enzymes are implicated in the 
control  of RP gene transcription and are regulated by  TOR  signalling  (Rohde and 
Cardenas, 2003, Humphrey et al., 2004). The expression of RPs is also controlled at 
the translational level via the 5‘-TOP sequence. However, the mechanism by which it 
is regulated directly or indirectly by TOR remains unclear.  
Much  less  is  known  about  the  role  of  TOR  in  Pol  III-dependent  transcription 
(transcription of tRNA and 5S genes) than that in Pol I and Pol II. Studies in yeast 
show that TOR regulates Pol III transcription by modulating the activity of Pol III and 
the  TBP-containing  transcription  initiation  factor  TFIIIB.  In  mammalian  cells, 
inhibition of mTOR causes repression of Pol III transcription (White, 2005).  
 
1.1.2.1.5.3 Transcription  
Besides the role of TOR signalling in the control of transcription by Pol I, Pol II and 
Pol III, many other genes involved in metabolic and biosynthetic are known to be 
regulated    by  mTORC1  at  the  transcriptional  level  (Peng  et  al.,  2002).  URI 41 
 
(unconventional prefolding RPB interactor 5) may be involved in the regulation of 
TOR-dependent transcription programs (Gstaiger et al., 2003). It interacts with Pol I, 
Pol II and Pol III and is phosphorylated in a TOR-dependent manner. The role of TOR 
in transcription is further demonstrated by their ability to phosphorylate STAT1 and 
STAT3 (signal transducer and activator of transcription; Kristof et al., 2003).  
 
1.1.2.1.5.4 Autophagy 
Autophagy  is  the  process  of  degradation  of  a  cell's  own  components  and  thereby 
ensures cell to survival under unfavourable conditions like nutrient starvation, stress, 
or reduced availability of growth factors. Among numerous regulators, TOR plays a 
key role in the regulation of this catabolic process.  
In yeast, TOR controls autophagy through its effects on autophagy-related (ATG) 
genes  ATG1.  ATG1  is  perhaps  the  first  component  downstream  of  TOR  in  the 
autophagy signalling pathway. It mediates the initial stages in the autophagic process 
(Noda and Ohsumi, 1998, Kamada et al., 2000). TOR decreases the affinity between 
ATG1 and its binding proteins, resulting in inhibition of autophagy (Kamada et al., 
2000, Kawamata et al., 2008, Kabeya et al., 2009). ATG1 is named ULK1 (UNC-51 
like kinase) in mammals. At least three other isoforms of ULK1 have been identified in 
human cells, which are ULK2, ULK3 and ULK4 (Yan et al., 1999). Following the 
discovery of ULKs, extensive evidence has shown that mTORC1 negatively regulates 
autophagy, although the mechanism remains to be established.  mTORC1 was reported 
as the kinase phosphorylating ULK1/2 and ATG13 (Jung et al., 2010, Jung et al., 2009, 
Ganley et al., 2009). When cells are starved, the phosphorylation of ULK complex by 
mTORC1  is  suppressed.  Under  this  condition,  ULK1  may  take  a  ‗‗closed‖ 
conformation and trigger downstream events for autophagosome formation (Jung et al., 
2010). TORC1 has also been implicated in the regulation of Tap42-associated protein 
phosphatase type 2A (PP2A) induction of autophagy in yeast (Yorimitsu et al., 2009). 
 
1.1.2.2 Signalling through mTORC2 
As  mentioned  earlier,  two  TOR  complexes  have  been  identified,  mTORC1  and 
mTORC2.  Due  to  the  lack  of  a  specific  inhibitor  for  mTORC2,  knowledge  of 
mTORC2,  especially  concerning  its  regulation,  is  very  limited.  In  recent  years, 42 
 
exciting  progress  towards  understanding  mTORC2  has  been  made.  One  promising 
discovery was made by Zinzalla et al. (2011) which established a missing link in the 
activation of TORC2. Their genetic studies showed that ribosomes are essential for the 
activation of TORC2 in yeast. In  experiments performed in mammalian cells, they 
further  demonstrated  the  role  of  ribosome  proteins  in  mTORC2  activation. 
Knockdown of ribosome subunits decreased the phosphorylation of mTORC2 targets, 
while inhibition of protein synthesis had no effect on mTORC2 activation. Prior to this 
report, Oh et al. (2010) found that mTORC2 can associate with ribosomes and that this 
association is important for mTORC2 to phsophorylate Akt.  
With  respect  to  the  functions  of  mTORC2,  it  was  suggested  as  an  important 
regulator  of  cytoskeleton  dynamics  (Jacinto  et  al.,  2004).  Using  small-interfering 
RNAs for mTOR, mLST8, Sin1 or Raptor in NIH 3T3 cells, Jacinto and colleagues 
(2004) demonstrated a role for mTORC2 in the regulation of the actin cytoskeleton. As 
mentioned earlier, mTORC2 phosphorylates Akt on the hydrophobic motif (HM) site 
Ser473  (Bayascas  and  Alessi,  2005).  Akt  is  also  constitutively  phosphorylated  at 
Thr450, which is the TM site (Facchinetti et al., 2008, Ikenoue et al., 2008). Several 
lines of evidence have established a role for mTORC2 in TM phosphorylation of Akt 
(Ikenoue et al., 2008, Jacinto and Lorberg, 2008). For example, genetic ablation of 
components of mTORC2 or inhibition of mTORC2 kinase activity strongly inhibits 
TM site phosphorylation in Akt. 
mTORC2  has  also  been  shown  to  catalyse  the  phosphorylation  of  other  AGC 
kinases, including PKC and SGK. Similarly to Akt, the activity of PKC is controlled 
by phosphorylation in the T loop, the turn motif (TM) and hydrophobic motif (HM). 
The  importance  of  mTORC2  in  the  TM  and  HM  phosphorylation  of  some  PKC 
isoforms has been demonstrated (Facchinetti et al., 2008, Ikenoue et al., 2008). For 
PKCʱ, it seems that mTORC2 is more important for TM phosphorylation than HM 
phosphorylation, since inactivation of mTORC2 does not abolish HM phosphorylation 
in PKCʱ. TM site phosphorylation is responsible for proper C-terminal folding and 
stability of Akt and PKCs, suggesting a role of mTORC2 in these events (Facchinetti 
et al., 2008, Bornancin and Parker, 1996). SGK is well known for its ability to regulate 
diverse cellular processes, one of which is stimulating sodium transport into epithelial 
cells (Loffing et al., 2006). Like Akt and PKCs, activation of SGKs is under control of 
its  phosphorylation  at  the  T  loop  and  HM  site  (Ser422  in  SGK1).  PDK1 
phosphorylates SGK1 on its T loop (Kobayashi and Cohen, 1999, Biondi et al., 2001). 43 
 
Although it was initially thought that mTORC1 was the kinase for the HM site in 
SGK1, Alessi et al. (2008) have provided strong evidence in support of mTORC2 as 
the  HM  kinase  for  SGK1.  Loss  of  mTORC2  components  Rictor,  Sin1  or  mLST8 
eliminates  Ser422  phosphorylation  in  SGK1,  even  though  mTORC1  activity  is 
maintained.  In  various  mammalian  cells  (like  HEK293,  HeLa  or  MCF7  cells), 
rapamycin  strongly suppresses the phosphorylation  of S6K1 (also  an AGC  kinase) 
without affecting SGK1 phosphorylation. The importance of TORC2 in regulating the 
activity of AGC family members is evident in yeast as well. For instance, YPK (yeast 
protein  kinase)  shares  the  highest  homology  with  SGK  and  Akt  and  TORC2  was 
reported to directly phosphorylate YPK in vitro (Kamada et al., 2005). For PKC1 in 
the budding  yeast,  phosphorylation  of its  TM site  is regulated by  TORC2 as  well 
(Jacinto and Lorberg, 2008). 
 
1.2  Eukaryotic translation factors and regulators. 
1.2.1 Overview 
Protein synthesis in eukaryotes is a complex process. Over the last few decades, there 
has been an explosion in the study of eukaryotic post-transcriptional control of gene 
expression, and in particular of messenger RNA (mRNA) translation. In general, the 
process  of  the  positioning  of  aminoacyl-transfer  RNAs  (tRNAs)  with  their 
corresponding  amino  acids  on  the  mRNAs  and  ribosomes,  and  the  synthesis  of 
polypeptides is termed mRNA translation. Translation can be divided into three stages: 
initiation, elongation and termination. In the stage of initiation, the small ribosomal 
subunit  40S  (based  on  its  sedimentation  upon  centrifugation  on  density  gradients) 
binds to the 5' end of the mRNA and scans it in a 5‘→3‘ direction until the start codon 
is  identified  with  the  help  of  initiation  factors.  The  elongation  phase  involves  the 
delivery of the correct tRNAs to ribosomes, the formation of peptide bonds and the 
translocation  of  the  ribosomes.  The  termination  of  translation  occurs  when  the 
ribosomes reach one or more STOP codons (UAA, UAG, and UGA). A simplified 
schematic diagram of the three stages of translation is given below (Fig. 1.5). 
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Figure 1.5. A simplified schematic diagram of the three stages of mRNA translation, 
initiation, elongation and termination. 
In the stage of initiation, the small ribosomal subunit 40S, together with other initation 
factors (eIFs; not shown here, see Fig. 1.6 for more details) binds to the 5‘end of the 
mRNA and begins scanning until it reaches the strat codon. With the release of eIFs, 
the large ribosomal subunit 60S joins to form an 80S initiation complex, which is 
ready to accept the correct aminoacyl-tRNA and synthesize the first peptide bond. The 
elongation  stage  involves  the  delivery  of  the  appropriate  tRNAs  to  ribosomes,  the 
formation  of  peptide  bonds  and  the  translocation  of  the  ribosomes.  Translation  is 
terminated  when  ribosomes  reach  the  stop  codon.  The  ribosome  complex  is 
disassembled after the release of the peptide chain. 
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1.2.2 Translation initiation 
In eukaryotes, two modes of translation initiation have been found, which are termed 
as cap-dependent and cap-independent translation. While translation is usually initiated 
at the 5' end of the mRNA molecule in eukaryotes, a subset of mRNA can circumvent 
this region by way of specialized sequences, which are called internal ribosome entry 
sites (IRESs). These sequences were first reported in 1988 (Pelletier and Sonenberg, 
1988) and they were described as special regions in RNA that can recruit the ribosome 
subunits to the mRNA start codon. The use of IRES sequences is more common in 
viral mRNAs to allow its translation in a cap-independent manner, especially when 
host translation is  inhibited  (Kieft, 2008),  but  some mammals  are  thought  to have 
IRESs. For example, some cellular IRES elements are located in eukaryotic mRNAs 
encoding genes involved in stress survival or other key processes (Mokrejs et al., 2006, 
Komar and Hatzoglou,  2005). Strikingly,  some  cellular mRNAs  that contain  IRES 
elements may promote translation of certain proteins during mitosis and programmed 
cell death (Komar and Hatzoglou, 2011). Actually, more than 70 eukaryotic mRNAs 
with IRES elements have been reported in yeast, the fruit fly, and mammals during the 
past few years, and the number keeps growing (Mokrejs et al., 2006). 
     The initiation stage of cap-dependent mRNA translation in eukaryotes requires a 
number of trans-acting protein factors called eukaryotic initiation factors (eIFs). It has 
been accepted that eIF3 is the first factor to bind to the 40S ribosomal subunit followed 
by eIF2. When bound to GDP, eIF2 is  inactive. The guanine nucleotide exchange 
factor  (GEF)  eIF2B  can  facilitate  the  exchange  of  GDP  to  GTP,  resulting  in  the 
formation  of  an active  ternary  complex of eIF2-GTP-Met-tRNAi (Fig.  1.7). The ʱ 
subunit of eIF2 can be phosphorylated at Ser51 by a number of related protein kinases, 
called  eIF2  ʱ  kinases,  which  are  activated  in  response  to  cellular  stresses.  In 
mammalian  cells,  there  are  four  different  eIF2ʱ  kinases,  including  general  control 
nonderepressible-2 (GCN2), haem-regulated inhibitor kinase (HRI), RNA-dependent 
protein  kinase  (PKR),  and  PKR-like  endoplasmic  reticulum  kinase  (PERK).  These 
kinases possess a similar catalytic domain allowing them to phosphorylate a common 
substrate, but  some of them  may exert additional effects, due to  having  additional 
substrates  (reviewed  in  Proud,  2005).  The  phosphorylation  of  eIF2ʱ  prevents  the 
recycling of inactive eIF2-GDP to active eIF2-GTP by inhibiting the activity of the 
guanine nucleotide exchange factor, eIF2B (Sudhakar et al., 2000; Fig. 1.7). Since the 46 
 
ternary complex cannot form, extensive phosphorylation of eIF2ʱ can result in the 
global translation repression. 
   Other eIFs bound to 40S include eIF1, eIF1A and eIF5. Once these factors, and Met-
tRNAs,  are  placed  on  the  40S  subunit,  a  43S  pre-initiation  complex  is  formed. 
Formation of the 48S pre-initiation complex occurs after the recruitment of mRNA to 
the 43S complex, which is facilitated by the cap-binding factor eIF4E and its partners, 
eIF4G and eIF4A, the so called eIF4F complex. eIF4F is thought to be the key factor 
in mRNA translation and its activity therefore is regulated by several effectors. 4E-
BP1 is the best understood as it competes with eIF4G to bind to eIF4E (Fig. 1.6). The 
nucleocytoplasmic shuttling protein 4E-T (eIF4E-Transporter) has been identified as 
another partner for eIF4E (Dostie et al., 2000; Fig. 1.6).  In fact, over the past decade, 
the  number  of  identified  eIF4E  binding  partners  has  grown  rapidly.  These  novel 
proteins include cup, bicoid, Vpg and CYFIP1 (Cho et al., 2005, Leonard et al., 2000, 
Napoli et al., 2008). Via the identification of these new partners, many new roles of 
eIF4E have been revealed. It is worth noting that mammals express multiple versions 
of eIF4E and their binding capabilities are different. For example, eIF4E-1 binds both 
eIF4G and 4E-BP1, but eIF4E-2 binds only 4E-BP1, and eIF4E-3 binds only eIF4G 
(Joshi et al., 2004). Mammalian eIF4G is also present in various versions, eIF4GI and 
eIF4GII, which share 46% amino acid identity (Imataka et al., 1998). Although it has 
been thought that these two paralogs have similar activities and functions, the cleavage 
of each of them by specific viral proteases reveals distinct effects of their integrity on 
ongoing translation (Castello et al., 2006). Moreover,  Caron et al. (2004) reported that 
eIF4GII is selectively recruited to the cap structure and this event does not correlate 
with the changes in the phosphorylation status of 4E-BP1 (unlike eIF4GI; Fig. 1.7). 
Both of eIF4Gs are phospho-proteins, and phosphorylation of eIF4GI is induced by 
serum stimulation while eIF4GII is phosphorylated at the onset of mitosis (Raught et 
al., 2000, Pyronnet et al., 2001). It has also been shown that the activities of eIF4GI/II 
are under differential regulation by cytokines (Caron et al., 2004). Therefore, eIF4GI 
and eIF4GII are likely differentially regulated and they may play selective roles in 
mammalian translation. 
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Figure 1.6. Regulation of eIF4F formation. 
When  cells  are  stimulated  by  amino  acids  or  insulin,  4E-BP1  becomes 
hyperphosphorylated, which decreases the affinity for eIF4E and induces its release 
from eIF4E. Free eIF4E can then interact with  eIF4G, forming a functional eIF4F 
complex which also contains eIF4A. eIF4E can also bind to 4E-T which is involved in 
transferring  eIF4E  to  the  nucleus.  The  Mnks  (mitogen-activated  protein  kinase-
interacting kinase), which are activated by Erk and p38 MAPK ʱ/β, need to bind to 
eIF4G  to  phosphorylate  eIF4E.  More  details  about  the  Mnks  will  be  discussed  in 
Chapter 5 section 5.1.  
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    In the eIF4F complex, the subunit eIF4A is an ATP-dependent RNA helicase, which 
can  catalyse  RNA  unwinding  and  melt  out  certain  secondary  structures  in  the  5‘-
proximal region of mRNA to facilitate ribosome binding (Rogers et al., 1999). These 
base-paired structures can present difficulties to ribosome entry and scanning. It has 
been found that the translational activities of mRNAs that possess a 5‘-UTR with high 
G-C content  are  often  reliant  upon eIF4F  (Svitkin  et  al., 2001). Programmed Cell 
Death 4 (Pdcd4) is a protein known to bind to eIF4A and eIF4G and inhibit translation 
initiation (Goke et al., 2002, Yang et al., 2003). That Pdcd4 inhibits translation is 
likely  achieved  by  preventing  the  helicase  activity  of  eIF4A  and  interference  with 
eIF4A binding to eIF4G (Yang et al., 2003). Mitogens stimulate the phosphorylation 
of Pdcd4 by S6K1 and subsequent degradation by the ubiquitin ligase SCF (Dorrello et 
al., 2006). As the co-factor of eIF4A, eIF4B interacts with eIF4A and stimulates the 
ATPase and helicase activities of eIF4A (Rozen et al., 1990, Rogers et al., 1999, Grifo 
et al., 1984, Rozovsky et al., 2008). eIF4B has also been found to interact with eIF3 
subunit and 18S rRNA (Methot et al., 1996b, Methot et al., 1996a). Thus, it has been 
proposed that eIF4B forms auxiliary bridges between the mRNA and the 40S subunit. 
In  addition,  eIF4B  is  believed  important  in  the  assembly  of  the  48S  pre-initiation 
complex (Dmitriev et al., 2003). eIF4B activity depends on its phosphorylation status, 
and  S6K1  and  RSK  have  been  implicated  in  eIF4B  Ser422  phosphorylation 
(Shahbazian et al., 2006).  
Therefore,  eIF4F,  together  with  many  other  initiation  factors,  mediate  the 
recruitment of the 43S pre-initiation complex (which already contains eIF1, eIF1A, 
eIF2, eIF3, eIF5 and Met-tRNAs) to the mRNA. There is another protein associated 
with eIF4G called the poly (A)-binding protein (PABP), which binds the poly-A tail 
and brings the 3‘UTR in close proximity to the 5‘end of the mRNA (Wells et al., 
1998).  Besides  eIF4G,  PABP  also  interacts  with  several  other  proteins,  including 
eIF4B (Bushell et al., 2001), the termination factor eRF3 (Hoshino et al., 1999) and 
Paip (poly (A)-binding protein-interacting protein) 1/2 (Craig et al., 1998). The mRNA 
circulation  brought  about  by  the  PABP-eIF4G  interaction  is  proposed  to  promote 
translation  initiation.  Take  eRF3  for  instance,  the  interaction  of  eRF3  with  the  C- 
terminus of PABP was shown to promote translation by delivering the terminating 
ribosomes to the 5‘end of the mRNA (Sonenberg and Dever, 2003). Recently, it has 
been  reported  that  Paip1  stabilizes  the  interaction  between  PABP  and  eIF4F 
(Martineau et al., 2008).  49 
 
 The 43S pre-initiation complex, accompanied by many protein factors, scans along 
the mRNA towards its 3‘ end until it reaches the start codon, AUG. When the 43S pre-
complex is bound to the start codon, a stable complex called the 48S pre-initiation 
complex  is  formed.  The  start  codon  selection  is  critically  modulated  by  eIF1  and 
eIF1A (Pestova and Kolupaeva, 2002, Pestova et al., 1998). The initiator tRNA is 
brought to the P site of the small ribosomal subunit by eIF2 and a perfect match with 
an  AUG  start  codon  triggers  the  hydrolysis  of  GTP  in  the  eIF2-GTP-Met-tRNA 
complex and the dissociation of Pi and eIF2-GDP from the small ribosomal subunit. 
The joining of 60S and release of other initiation factors are catalysed by eIF5B-GTP 
(Lee et al., 2002). The second GTP hydrolysis reaction causes the release of eIF5B and 
eIF1A from the initiation complex (Shin et al., 2002), and the 80S initiation complex 
is finally formed and translation elongation is commenced. A summary of the process 
of the eukaryotic translation initiation is represented in Fig. 1.7.  
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Figure 1.7. Translation initiation. 
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eIF 1, 1A, and 3, together with eIF5 and the ternary complex (eIF2-GTP-Met-tRNA), 
bind to the 40S ribosomal subunit and assemble the 43S preinitiation complex (PIC). 
mRNA is activated by binding of eIF4F (eIF4E, eIF4G and eIF4A) to the m
7GTP cap 
and PABP to the poly(A) tail, circularizing the mRNA. The 43S PIC, accomplanied by 
many other protein factors, scans along the mRNA for the start codon (AUG) in an 
ATP-dependent reaction. When the 43S PIC is bound to the start codon, the 48S PIC is 
formed. AUG recognition triggers the hydrolysis of GTP in the ternary complex and 
the dissociation of eIF2-GDP and Pi from 40S. Joining of the 60S subunit and release 
of other eIFs are catalyzed by eIF5B-GTP. The second GTP hydrolysis triggers release 
of  eIF5B-GDP  and  eIF1A  to  form  the  final  80S  initiation  complex.  The  ternary 
complex formation is inhibited by eIF2ʱ phosphorylation (through inhibition of eIF2B 
activity), and eIF4F assembly is blocked by 4E-BP1. Phosphorylation of 4E-BP1 by 
mTOR (not depicted here) induces its release from eIF4E. MAPK signalling promotes 
phosphorylation of eIF4E by Mnk1/2, which are recruited to eIF4G. 1, 1A, 2, 2B, 3, 
and 5 represent eIF1, eIF1A, eIF2, eIF2B, eIF3 and eIF5 respectively; 4E, 4G, 4A, 4B, 
and 5B indicate eIF4E, eIF4G, eIF4A, eIF4B and eIF5B, respectively;  PABP: poly 
(A)-binding protein.  
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1.2.3 Translation elongation 
Peptide chain elongation is the process of polymerizing amino acids into a polypeptide, 
which is dependent on eukaryotic elongation factors. The amino acid is added to the 
nascent  polypeptide  chain  in  a  three-step  microcycle:  (1)  locating  the  correct 
aminoacyl-tRNA  in  the  A  site  of  the  ribosome,  (2)  forming  the  peptide  bond,  (3) 
moving  the  ribosome  by  one  codon  forward  on  the  mRNA  and  translocating  the 
peptidyl-tRNA from the A site to the P site of the ribosome. Three elongation factors 
are involved in mammals:  eEF1A, eEF1B and eEF2.  
    eEF1A mediates the entry of the aminoacyl-tRNA into a free site (A site) of the 
ribosome. eEF1A binds to GTP prior to binding the aminoacyl-tRNA. Once activated, 
a ternary complex (eEF1A-aminoacyl-tRNA-GTP) is formed to deliver the aminoacyl-
tRNA into the A site on the ribosome. After the binding of the aminoacyl-tRNA to the 
A  site,  the  GTP  is  hydrolysed  and  inactive  eEF1A  dissociates  from  the  ribosome. 
Reactivation  of  eEF1A  requires  eEF1B,  which  serves  as  the  guanine  nucleotide 
exchange factor for eEF1A, catalysing the release of GDP from eEF1A. A peptide 
bond is formed between the aminoacyl  group and the peptidyl group in the P site 
(catalysis of peptide bond formation is performed by the peptidyl-transferase centre of 
the 60S subunit). Following the formation of the peptide bond, the polypeptide chain 
from the tRNA in the P site is released and thus a longer peptidyl-tRNA is formed in 
the A site (reviewed in Browne and Proud, 2002).  
    eEF2 catalyses the translocation of the ribosome along the mRNA during the end of 
each round of polypeptide elongation. Translocation leads to the movement of new 
peptidyl-tRNA from the A site to the P site and the uncharged tRNA from the P site to 
the E-site, resulting in  an empty A site for the entry of the next aminoacyl-tRNA 
(reviwed in Browne and Proud, 2002).  
 
1.2.4 Translation termination 
Termination of elongation is dependent on eukaryotic release factors. The process is 
similar to that of prokaryotic termination. This process is initiated when the ribosome 
encounters a stop codon (UGA, UAG, or UAA). The release factor, eRF1, is involved 
in the recognition of these codons. Another release factor, eRF3, has been implicated 
in enhancing this process by acting as a GTPase for eRF1. The ribosome complex is 
disassembled after the release of the peptide chain. 53 
 
1.3 mTOR and TOP mRNAs 
1.3.1 What are TOP mRNAs?  
An important fraction of vertebrate transcripts contain a characteristic 5‘UTR, which 
starts  with  a  uninterrupted  sequence  of  6-12  pyrimidines  (Meyuhas,  2000).  
Consequently,  these  mRNAs  are  referred  to  as  TOP  (terminal  oligopyrimidine) 
mRNAs and the genes encoding them are called TOP genes. Since the first discovery 
in  vertebrate  genes  encoding  ribosomal  proteins  (RPs)  in  the  1970s  by  Schibler‘s 
group  (1977),  TOP  mRNA  expression  has  acquired  increasing  attention  due  to  its 
unique structure and mode of regulation.  
There are two essential features for identifying a TOP mRNA: (1) the presence of a 
5‘-TOP  tract  and  (2)  a  growth-rate  associated  regulation  at  the  translational  level. 
According to this definition, it appears that all messengers that encode proteins which 
are involved in ribosome biogenesis, most notably the RPs (ribosomal proteins), are 
TOP mRNAs. Among the non-RP TOP mRNAs, the encoded proteins are typically 
involved in translation, such as some eukaryotic initiation and elongation factors and 
PABP. Iadevaia et al. (2008) reported a systematic analysis of human genes for TOP 
motifs with a focus on the translation factors. By selecting possible TOP candidates on 
the basis of the presence of a pyrimidine stretch at their 5‘ end, they tested these genes 
by  a  polysome assay to  verify their regulation  of translation.  In a few cases,  they 
analysed the transcription start site by primer extension. All the translation elongation 
factors, together with a few translation initiation factors, were found to be encoded by 
TOP mRNAs. The following table shows the sequence near the transcription start site 
(TSS) of some known TOP mRNAs in human (Table 1.1). 
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Table 1.1. A summary of known 5‘ TOP sequences in human TOP mRNAs. From 
(Meyuhas, 2000, Iadevaia et al., 2010) 
Protein  5‘ TOP sequence with preferred tss 
 
 
 
 
RPs 
rpS4Y  CUCUUCC 
rpS4X  CCUCUUUCCUU 
rpS6  CCUCUUUUCC 
rpS8  CUCUUUCC 
rpS11  CUUUUUUUC 
rpS14  CUCUUUCC 
rpS17  CCUCUUUU 
rpS24  CUUUUCCUCCUU 
rpL7a  CUCUCUCCUCCC 
rpL13a  CUUUUCC 
 
 
Initiation 
factors 
eIF3e  CUUUUCUUU 
eIF3f  CUUCUUUCU 
eIF3h  CUCUUUCUUCCU 
PABP  CCCCUUCUCCCC 
 
Elongation 
factors 
 
eEF1A  CUUUUUC 
eEF1B  CUUUUUCCUCUCUUC 
eEF1D  CCCUUUC 
eEF1G  CCUUUCUUU 
eEF2  CUCUUCC 
  B23  CUUUCCCU 
  P21  CUUUUCC 
  hnRNP A1  CUCCUUUCU 
Ribosomal proteins (RPs): After more than 20 years since the initial studies on RP 
genes, it is evident that all vertebrate RP mRNAs analysed so far are encoded by TOP 
genes, although it has not been experimentally proven in all cases;  
Initiation factors: Among the initiation factors analyzed by Iadevaia et al. (2008), only 
eIF3e, eIF3f, eIF3h exhibit the features of TOP genes; 
Elongation factors: eEF1A has a typical 5‘-TOP (Uetsuki et al., 1989). The synthesis 
rate of eEF1A is increased by serum stimulation in Swiss mouse 3T3 cells without 
being affected by actinomycin D (which is commonly used to inhibit transcription) 55 
 
(Thomas and Luther, 1981). Subsequently, it was demonstrated that the amount eEF-
1A mRNA remained constant while the transcripts shifted between mRNA protein 
particles and polysomes (Jefferies and Thomas, 1994). eEF2 is also encoded by a TOP 
mRNA (Terada et al., 1994, Avni et al., 1997). Iadevaia et al. (2008) reported that all 
five translation elongation factors are encoded by typical TOP mRNAs. 
Poly (A)-binding protein (PABP): PABP plays a key role in translation initiation. In 
addition, it has been implicated in mRNA stability (Coller et al., 1998, Amrani et al., 
1997, Minvielle-Sebastia et al., 1997), and regulation of poly (A) tail length. Various 
studies  examining  its  expression  have  demonstrated  that  PABP  exhibits  ―TOP‖ 
characteristics (Hornstein et al., 1999). 
B23 (also called nucleophosmin): B23 is a major phosphoprotein in the interphasic 
nucleolus and is involved in the pre-ribosome assembly (Zatsepina et al., 1999). As 
shown  in  Table  1.1,  B23  contains  a  TOP  sequence  in  its  5‘  end.  Moreover,  the 
translation  of  this  mRNA  is  repressed  in  serum-starved  cells  (Zong  et  al.,  1999).  
However, during mitosis when cap-dependent protein synthesis is compromised, the 
synthesis of B23 can be maintained since its 5‘ UTR contains an IRES element which 
can recruit  ribosomes,  and  bypass  the  cap structure (Qin and Sarnow,  2004). This 
suggests  that  some  TOP  mRNAs  may  be  subject  to  more  than  one  mode  of 
translational regulation. 
P21  (also  known  as  TCTP):  The  growth-related  P21  has  been  shown  to  possess 
properties  of  a  tubulin  binding  protein  and  contains  a  typical  5‘-TOP  (Table  1.1) 
(Gachet et al., 1999). 
hnRNP A1 (Heterogeneous nuclear ribonucleoprotein A1): hnRNP A1 belongs to the 
A/B  subfamily  of  ubiquitously  expressed  heterogeneous  nuclear  ribonucleoproteins 
(hnRNPs). The hnRNP A1 transcript was shown to start with a pyrimidine tract (Table 
1.1)  similar  to  TOP  mRNAs.  Moreover,  the  hnRNPA1  mRNA  is  more  efficiently 
loaded  onto  polysomes  in  growing  than  in  resting  cells  (Camacho-Vanegas  et  al., 
1997). Thus, hnRNP A1 mRNA is included in the class of TOP genes. 
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1.3.2 Regulation of TOP mRNA translation 
Translational  repression  of  TOP  mRNAs  occurs  when  proliferation  of  mammalian 
cells is blocked, as reflected by their shift from polysomes into subpolysomal fractions. 
It appears that TOP mRNAs exist in two states: repressed and active states. A vast 
majority of TOP mRNAs remain in the translationally inactive state in quiescent cells. 
In  growing  cells,  the  translationally  active  population  increases  and  they  can  be 
translated at maximum efficiency (Meyuhas, 2000). This ―all-or-none‖ phenomenon 
indicates that the repression likely results from a blockage of the translation initiation. 
 
1.3.2.1 The possible roles of S6 phosphorylation and the PI3K pathway in the 
activation of TOP mRNA translation 
Phosphorylation of ribosome protein S6 is one of the earliest events detected following 
mitogenic stimulation. The concomitant translational activation of TOP mRNAs under 
these  circumstances  led  many  investigators  to  propose  a  link  between  rpS6 
phosphorylation  and  TOP  gene  expression.  Multiple  lines  of  evidence  support  this 
hypothesis, one of which is that the treatment of mammalian cells with rapamycin 
suppressed translation of TOP mRNAs, an effect thought to be mediated by blocking 
rpS6 phosphorylation and activation (Jefferies et al., 1997). Nevertheless, subsequent 
studies  have  disagreed  with  this  model.  During  differentiation  of  murine 
erythroleukemia  (MEL)  cells,  translation  of  TOP  mRNAs  is  repressed  despite  the 
absence of changes in rpS6 phosphorylation (Barth-Baus et al., 2002). Stolovich and 
colleague (2002) found that when the phosphorylation of S6 was completely abolished 
by rapamycin, there was little effect on rpL32 translation in PC12 cells. Furthermore, 
the mutation of all five phosphorylatable serine residues of rpS6 into alanine does not 
affect the translational control of TOP mRNAs (Ruvinsky et al., 2005). Also, a mutant 
possessing a high basal S6K1 activity failed to relieve the translational repression of 
eEF1A  mRNA  in  serum-starved  HEK293  cells  (Jefferies  et  al.,  1997).  More 
convincingly,  despite  the  impairment  of  S6  phosphorylation  in  cells  derived  from 
S6K1 and S6K2 null mice, the translation of 5‘-TOP mRNAs were still modulated by 
mitogens in a rapamycin-dependent manner (Pende et al., 2004). Collectively, S6 and 
its phosphorylation are unexpectedly dispensable for translational control of mRNAs 
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A number of studies have demonstrated a role of PI3K in the translational activation 
of TOP mRNAs. For example, the inhibition of PI3K by LY294002 (a PI3K inhibitor) 
or overexpression of a dominant-negative mutant of PI3K can block the translation 
activation of TOP mRNAs. Furthermore, the translational repression of TOP mRNAs 
in  quiescent  cells  can  be  relieved  by  overexpression  of  constitutively  active  PI3K 
(Stolovich et al., 2002).  
 
1.3.2.2 Trans-acting factors 
It  has  been  hypothesised  that  the  oligopyrimidine  tract  in  TOP  mRNAs  can  be 
recognized by  specific translational  trans-acting  factors  which  may be  involved in 
their  translational  regulation.  Indeed,  the  Xenopus  homologue  of  the  human  La 
autoantigen has been demonstrated to interact with the 5‘-TOP motifs of human and 
Xenopus laevis TOP mRNAs in vitro (Pellizzoni et al., 1996, Crosio et al., 2000). 
However, whether the specific binding promotes or represses the translation of TOP 
mRNAs remains to be investigated. The results from Xenopus cell lines support the 
idea that La protein positively regulates the translation of TOP mRNAs (Crosio et al., 
2000).  In  contrast,  phosphorylation  of  human  La  at  Ser366  limits  5‘-TOP  mRNA 
binding,  and  increasing  non-phosphorylated  La  leads  to  greater  association  with 
potentially negative effects on translation of TOP mRNA (Schwartz et al., 2004). 
    Several other trans-acting effectors, which may interact with 5‘-TOP mRNAs and 
thus  mediate  its  translation,  have  also  been  reported  including  ZNF9,  AUF1  and 
miRNA-10a (Pellizzoni et al., 1997, Pellizzoni et al., 1998, Kakegawa et al., 2007). 
miRNA-10a was shown to bind immediately downstream of the 5‘-TOP motif and 
enhance TOP mRNA translation (Orom et al., 2008). More recently, the stress granule 
(SG)-associated TIA-1 and TIAR proteins have been identified as key regulators of 5‘-
TOP mRNA translation initiation upon amino acid starvation (Damgaard and Lykke-
Andersen, 2011). Therefore, these trans-acting factors represent an important group of 
regulators which are implicated in the control of TOP mRNA translation. 
 
1.4 mTOR and human diseases 
mTOR is located in a key position of the crossroads of various signalling pathways 
that modulate mRNA, ribosome and protein synthesis, which may modulate tumour 58 
 
proliferation  and  growth.  It  has  been  known  that  mTOR  signalling  pathway  is 
frequently  activated  in  many  human  cancers.  Dysregulation  in  both  upstream  and 
downstream effectors of mTOR can lead to activation of mTOR signalling. In fact, 
abnormal  activation  of  the  PI3K-Akt  pathway  has  been  widely  observed  in  many 
cancers. Overexpression and activation of IGF-1R (insulin-like growth factor receptor) 
frequently occurs in many types of human sarcomas (Baserga, 2005). Amplification of 
genes which encode subunits of PI3K and Akt occurs in many cases of human cancers, 
including  ovarian,  breast,  and  colon  cancer  (Vivanco  and  Sawyers,  2002).  As  an 
important  upstream  regulator  of  mTOR,  PTEN  inactivation  leads  to  constitutive 
activation  of  PI3K/Akt  and  thus  mTOR.  PTEN  has  been  identified  as  a  tumour 
suppressor, since many human cancers have been found to be accompanied by genetic 
mutation or loss of PTEN function (Steelman et al., 2004). Furthermore, dysregulation 
of other upstream effectors of mTOR have also been implicated in cancer genesis. For 
example,  Jones  et  al.  (1999)  observed  that  somatic  loss  of  TSC1/2  or  intragenic 
mutation  of  the  corresponding  wild-type  allele  is  seen  in  hamartomas  following  a 
comprehensive mutation analysis of TSC1 and TSC2 in a cohort of 150 unrelated TSC 
patients and their families, and Im et al. (2002) found that Rheb is highly activated in 
several  cancer cell lines. Additionally, a  high proportion of  breast  tumours  exhibit 
constitutive  activation  of  mTOR  (Perez-Tenorio  and  Stal,  2002).  Various  mTOR 
downstream targets are known to be activated in many human cancers, such as S6K1, 
which has been linked to  the genesis of breast and ovarian cancers (Mamane et al., 
2006). Hence, the mTOR signalling pathway has received considerable attention as an 
important target for cancer therapy and for anticancer drug development.    
In  addition  to  its  well  characterized  inhibitory  effects  on  mTORC1,  rapamycin 
inhibits  translation  of  several  critical  mRNA  involved  in  cell  cycle  progression, 
resulting in cell cycle arrest (Hidalgo and Rowinsky, 2000). Hence, rapamycin and its 
analogues (rapalogs; rapalogs inhibit mTORC1 by forming a complex with FKBP12 
and  are  synthesised  with  more  favourable  pharmaceutical  characteristics)  were 
expected to exert outstanding effects on many types of cancer. Consistent with this, the 
rapalog temsirolimus has been approved as a first-line treatment of renal cell cancer 
(RCC) (Yuan et al., 2009, Wan and Helman, 2007). However, due to their allosteric 
mode of binding with mTOR, rapamycin and rapalogs only partially inhibit mTORC1 
activity and leave mTORC2 unaffected. What is more, the incomplete inhibition of 
mTORC1 by rapamycin leads to a negative feedback through IRS1, causing increased 59 
 
Akt  signalling  and  cell  survival,  which  may  help  explain  the  resistance  of  some 
cancers  to  rapamycin  treatment  (O'Reilly  et  al.,  2006).  The  limited  success  of 
rapamycin led to the development of mTOR-KIs which more effectively inhibit mTOR 
kinase activity (see below). 
    Besides cancer, mTORC1 is also implicated in many other human diseases, such as 
cardiac  hypertrophy,  type  II  diabetes  and  obesity  (Inoki  et  al.,  2005).  Cardiac 
hypertrophy is one of the main risk factors for heart failure. Strong evidence has shown 
that  hyperactivation  of  the  PI3K-Akt-mTOR  pathway  is  correlated  with  cardiac 
hypertrophy (Shioi et al., 2002, Crackower et al., 2002). In type II diabetes, activation 
of  mTORC1  negatively  regulates  the  activity  of  IRS-1  via  the  S6K1-dependent 
feedback  loop,  resulting  in  insulin  resistance.  Activation  of  mTORC1  is  also 
implicated in obesity. Um et al. (2004) have shown that S6K1 null mice exhibit a 
reduction in adipose tissue mass. Thus, dysregulated mTOR signalling is implicated in 
many important human diseases, making it an exciting therapeutic target. 
 
1.5 Recent advances in the discovery of small molecule ATP-competitive mTOR-KIs  
Compared with rapalogs, mTOR-KIs may have some advantages for cancer therapies. 
In the past few years, this field has made several breakthroughs with the first sets of 
compounds  now  in  early  clinical  development  [e.g.  AZD8055  (developed  by 
AstraZeneca), OSI-027, and INK128 (Chresta et al., 2010, Bhagwat and Crew, 2010, 
Zask et al., 2011)]. Other compounds including PP242, Ku-0063794 and Torin-1 are 
currently used in preclinical research (Feldman et al., 2009, Garcia-Martinez et al., 
2009, Thoreen et al., 2009). As PP242 and AZD8055 are the compounds mainly used 
in  this  study,  and  Ku-0063794  is  structurally  similar  to  AZD8055,  they  will  be 
discussed below (Fig. 1.8). 
     PP242 was first developed and reported as an active-site inhibitor of mTOR by 
Feldman  et  al.  (2009).  It  inhibited  mTOR  in  vitro  with  an  IC50  (50%  inhibitory 
concentration)  value  of  8  nM.  It  strongly  inhibited  Akt  phosphorylation  but  only 
modestly inhibited many  Akt substrates (e.g. GSK3, TSC2 and FOXO). They also 
tested the effect of PP242 on the proliferation of primary MEFs and found that PP242 
inhibited the proliferation without affecting actins  stress  fibres, suggesting  that the 
pharmacological  inhibition  of  mTORC2  caused  by  PP242  did  not  affect  the 60 
 
morphology or the abundance of these fibres. PP242 was also found to inhibit cap-
dependent translation. 
        Ku-0063794 inhibits both mTORC1 and mTORC2 with an IC50 of around 10 nM 
in vitro, but does not suppress the activity of 76 other protein kinases or seven lipid 
kinases (even at high concentrations). It can also suppress cell growth and induce G1-
cell cycle arrest (Garcia-Martinez et al., 2009).  
       AZD8055 was developed by AstraZeneca and first described by Chresta et al. 
(2010),  and  is  currently  in  Phase  2  clinical  trials.  It  was  identified  through  the 
screening of a small library of compounds based around a pyridopyrimidine scaffold. 
The  IC50  of  AZD8055  against  native  mTOR  complex  was  approximately  0.8  nM 
(which is much lower than PP242, suggesting improved potency). AZD8055 binds 
competitively  with  ATP  and  results  in  significant  inhibition  of  tumour  growth  in 
breast, lung and colon xenograft models at a dose of 20mg/kg/day (Chresta et al., 
2010). 
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Figure 1.8. Chemical  structures of (A) PP242, (B) Ku-0063794 and (C) AZD8055 
(Feldman et al., 2009, Garcia-Martinez et al., 2009, Chresta et al., 2010).  
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1.6 Aims of this study 
The  mTOR  signalling  pathway  is  an  exciting  target  for  the  development  of 
pharmaceuticals to treat cancer and other diseases. However, rapalogs, due to their 
allosteric mode of interaction with mTOR, inhibit some functions of mTORC1, but not 
all.  They  also  leave  mTORC2  unaffected  (in  the  short  term).  This  has  led  to  the 
development  of  various  new  inhibitors  which  can  inhibit  both  mTORC1  and 
mTORC2.  The  recently  available  inhibitors,  PP242  and  AZD8055,  have  been 
identified as potential mTOR inhibitors with high selectivity. By exploring the distinct 
effects  of  rapamycin  and  these  new  inhibitors  (PP242  and  AZD8055),  I  mainly 
focused on the role of mTOR signalling pathway in the control of  general protein 
synthesis  and  particularly  the  synthesis  of  specific  proteins.  I  also  studied  the 
involvement of eIF4E phosphorylation in its sumoylation, TNFʱ biosynthesis and the 
interaction with specific mRNAs using a novel Mnk inhibitor, AZ‘9224. 
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CHAPTER 2                                                       
MATERIALS AND METHODS 
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2.1 Chemicals, biochemicals and other materials 
All  laboratory  reagents  were  purchased  from  Sigma-Aldrich  and  Fisher  Scientific, 
unless specified below. 
 
Agilent Technologies  Prime-It II Random Primer Labeling kit  
AstraZeneca, UK  AZD8055 and AZ‘9224 
Bio-Rad  Protein assay dye (Bradford) 
Reagents for SDS-PAGE gel                                          
PVDF (0.45 μm) and nitrocellulose membranes (0.45 
μm) for western blot 
Cell Signaling Technology  All the antibodies,  unless otherwise stated: 4E-BP1 
(raised in rabbit; Wang et al., 1998a), eIF4GII and 
eIF4A (kind gift from Prof. Simon Morley, University 
of Sussex), ʱ-tubulin (TU-02) (Santa Cruz 
Biotechnology), anti-HA high affinity (Roche Applied 
Science) and anti-SUMO-1 (Sigma-Aldrich) 
Calbiochem  Rapamycin 
GE Healthcare Life 
Sciences 
m
7GTP Sepharose™ 4B                                              
Protein G Sepharose 
Illustra ProbeQuant™ G-50 Micro Columns 
Invitrogen  Tissue culture reagents 
Macherey-Nagel  PCR clean up Gel extraction kit                                   
Plasmid mini, midi, maxi prep kit 
Perkin Elmer  [
35S]methionine 
GreenScreen Plus membrane 
Primerdesign  Precision Mastermix with SYBRgreen 
Promega  100bp DNA Ladder  
GoTaq DNA polymerase                                           
ImProm-II™ Reverse Transcription System                 
pGEM-T vector 
RNase inhibitor 
 
Roche Applied Science  Protease inhibitor cocktail 
Thermo Scientific  SILAC DMEM Media  
PageRuler™ Prestained Protein Ladder 
Whatman  3 MM filter paper 
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2.2 Buffers and solutions  
Buffers and solutions used in this thesis are listed in alphabetical order below. 
 
Cell freezing medium 
40% (v/v) Dulbecco‘s modified Eagle‘s medium (DMEM) 
50% (v/v) fetal bovine serum (FBS) 
10% (v/v) dimethyl sulphoxide (DMSO) 
 
Cell lysis buffer 
50 mM Tris-HCl 
50 mM β-glycerophosphate (β-GP) 
1 mM Ethylenediaminetetraacetic acid (EGTA) 
1 mM Ethylene glycol tetraacetic acid (EDTA)  
1% (v/v) Triton X-100 
β-mercaptoethanol (β-ME), Na3VO4 and protease inhibitor cocktail were added to the 
lysis buffer just before use. 
 
Formaldehyde-agarose gel (1%)           100ml                                        
1% (w/v) Ultra agarose                          1g 
10% (v/v) 10 x MOPS [3-(N-morpholino) propanesulfonic acid] buffer             
 10ml              
6% (v/v) formaldehyde                          16.4ml of 36.5% formaldehyde   
 
MOPS buffer (10x) 
200 mM MOPS 
25 mM NaAc 
10 mM EDTA 
adjust pH to 7.0 
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Northern mix buffer 
18% (v/v) formaldehyde  
30% (v/v) 20x saline-sodium citrate (SSC) buffer 
1% (w/v) SDS  
0.1 mg/ml salmon sperm DNA  
 
Phosphate-buffered saline (PBS) (10x) 
1.7 M NaCl 
40 mM KCl 
100 mM Na2HPO4 
22 mM KH2PO4 
 
Phosphate buffer (20x) 
127 mM Na2HPO4 
428 mM NaH2PO4 
 
Polysome gradient buffer 
30 mM Tris-HCl pH 7.5 
100 mM NaCl 
10 mM MgCl2 
 
RNP immunoprecipitation assay (RIPA) buffer 1 for RIP assay 
50 mM Tris-HCl, pH7.5 
1% (w/v) NP-40 
0.5% (w/v) sodium deoxycholate 
0.05% (w/v) SDS 
1 mM EDTA 
150 mM NaCl 
Protease inhibitor cocktail tablet (Roche) is added before use 
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RIPA buffer 2 (high-stringency) for RIP assay 
50 mM Tris–HCl, pH7.5 
1% (w/v) NP-40 
1% (v/v) sodium deoxycholate 
0.1% (v/v) SDS 
1 mM EDTA 
1 M NaCl 
3 M urea, 
0.2 mM phenylmethylsulfonyl fluoride (PMSF) 
 
RIPA buffer 3 for RIP assay 
50 mM Tris–HCl, pH7.0 
5 mM EDTA 
10 mM dithiothreitol (DTT) 
1% (w/v) SDS 
 
SDS-PAGE sample buffer 
62.5 mM Tris-HCl 
7% (w/v) SDS 
20% (w/v) sucrose  
0.01% (w/v) bromophenol blue 
 
SDS-PAGE running buffer (1x) 
(Diluted from 10x Tris/Glycine/SDS buffer from Bio-Rad) 
25 mM Tris-HCl, pH 8.3 
192 mM glycine 
 0.1% SDS 
 
SSC buffer (20x) 
3 M NaCl 
0.3 M Sodium Citrate Dihydrate 
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TAE buffer (50x) 
2 M Tris-base 
1 M Acetic acid 
50 mM EDTA 
adjust pH to 8.4 
 
TNM lysis buffer 
10 mM Tris-HCl pH7.5 
10 mM NaCl 
10 mM MgCl2 
 
Western blot transfer buffer (1x) 
(Diluted from 10x Tris/Glycine buffer from Bio-Rad) 
25 mM Tris-HCl, pH 8.3 
192 mM glycine 
Methanol was added at a final concentration at 15% (v/v).  
SDS was added at a final concentration at 0.2% (w/v).  
2.3 Cell Biology and Protein biochemistry  
2.3.1 Cell lines 
All the cell lines used in this thesis were from the stock in Prof. Chris Proud‘s lab, 
otherwise  stated:  PC3  (human  prostate  cancer  cell  line)  and  ZR75  (human  breast 
carcinoma cell line cell) cell lines were kind gift from Dr. Jeremy Blaydes, School of 
Medicine, University of Southampton; RAW cell line was kind gift from Dr. Malcolm 
East, Centre for Biological Sciences, University of Southampton. 
2.3.2 Culture and treatment of adherent cell line  
Cells were grown in DMEM (high glucose, GlutaMAX
TM, HEPES) supplemented with 
10% (v/v) FBS and 1% penicillin/streptomycin, and cultured in 5% CO2 incubator at 
37°C. When cells reached approximately 80% confluence, they were passaged. To do 
this, the culture medium was aspirated and the cells were rinsed with sterile PBS. One 
ml trypsin was added into the flask/dish and the cells were incubated at 37°C for 3 
min. Then the detached cells were resuspended in complete medium and seeded in new 
sterile vessels to the desired density. For long-term storage, the cells were digested 69 
 
with trypsin, resuspended in cell freezing medium and aliquoted into storage vials. 
After freezing at -80°C overnight, the cells were moved to liquid nitrogen for long-
term storage.  
2.3.3 Transient transfection of cells 
Lipofectamine
TM 2000 (Invitrogen) was used for plasmid DNA transfection according 
to  the  manufacturer‘s  protocol.  Typically,  one  day  before  transfection,  cells  were 
plated in DMEM without antibiotics to achieve a 70%-80% confluence at the time of 
transfection. On the day of transfection, plasmid DNA and Lipofectamine
TM 2000 were 
each diluted with DMEM. After 5 min incubation at room temperature, diluted plasmid 
DNA was gently mixed with diluted Lipofectamine
TM 2000 and incubated for 20 min 
at  room  temperature.  The  mixture  was  then  added  to  the  cells.  The  cells  were 
incubated at 37°C for 4-6 h before the medium was changed. Transgene expression can 
be tested after 48-98 h incubation.  
 
Amounts of reagents used for the transfection: 
Culture vessel  Vol. of dilution medium
2  DNA  Lipofectamine
™ 2000 
6-well  2 x 100 μl  1 μg  4 μl 
6-cm  2 x 250 μl  2 μg  8 μl 
 
2.3.4 Gene silencing 
The gene expression of 4E-BP1 was transiently knocked down with Stealth RNAi in 
HeLa  cells.  Stealth  RNAi  (Invitrogen)  directed  against  4E-BP1  (sequence  5′-
UCUAUGACCGGAAAUUCCUGAUGGA)  was  transfected  into  the  cells  using 
Lipofectamine
TM 2000 as the methods described in section 2.3.3. A Stealth RNAi with 
the  same  nucleotide  composition  was  used  as  negative  control  (sequence  5′-
UCUCCAGAAGGCUUAAGUCUUAGGA) (Averous et al., 2008).  
 
2.3.5 Protein extraction 
After various treatments, the cells were moved out from the incubator and placed on 
ice. The culture medium was aspirated and the cells were washed once with ice-cold 
PBS. The cells were lysed with cell lysis buffer by thorough scraping. The lysates were 
transferred to microfuge tubes and cleared by centrifugation at 20,000g for 10 min at 70 
 
4°C. Potein concentration was determined using the Bio-Rad Bradford reagent. Each 
serial  dilution  of  standard  (BSA)  and  unknown  protein  sample  was  pipetted  into 
separate disposable cuvettes in triplicate. 1 x Bradford dye reagent was added to each 
cuvette and mix. The solution was incubated at room temperature for at least 5 min. 
The spectrophotometer  was set to 595 nm  and zeroed with the blank sample. The 
absorbance  of  the  standards  and  unknown  samples  was  measured.  Protein 
concentration  of  each  unknown  sample  was  determined  using  the  standard  curve 
derived from the absorbance of the standards. 
2.3.6 Pull-down assays 
For anti-HA immunoprecipitations, 10 μl of protein G beads were added to cell lysis 
buffer and washed once. 1 g of anti-HA high affinity was then added and mixed with 
the beads for 1 h at 4°C. Subsequently, total cell lysates were added and mixed with 
the beads for 1-2 h at 4°C. The beads were then washed twice with cell lysis buffer and 
absorbed proteins were eluted in SDS-PAGE sample buffer at 95°C for 5 min. To pull 
down  eIF4E  and  associated  proteins,  cell  extracts  were  incubated  with  m
7GTP-
Sepharose 4B beads which were diluted with two volumes of Sepharose CL-4B for 1.5 
h at 4°C under constant shaking. Beads were washed twice with cell lysis buffer and 
absorbed proteins were eluted in SDS-PAGE sample buffer at 95°C for 5 min. 
 
2.3.7 Evaluation of in vivo eIF4E sumoylation 
Sumoylation of total cellular eIF4E was evaluated by m
7GTP pull down assay and 
subsequent  immunoblotting  with  anti-SUMO1  or  anti-eIF4E.  20  mM  SUMO 
isopeptidase inhibitor NEM (N-ethylmaleimide; Sigma-Aldrich) was added to the lysis 
buffer.  
 
2.3.8 SDS-PAGE electrophoresis and electrotransfer 
Cell lysates or immunoprecipitated samples were heated at 95°C for 5-7 min in SDS-
PAGE  sample  buffer.  Typically,  protein  samples  are  subjected  to  12.5%  (w/v) 
acrylamide  gel  and  run  using  Bio-Rad  electrophoresis  system.  Proteins  of  high 
molecular weight (more than 150 kDa) were analysed by resolving samples on a 10% 
acrylamide gel. Proteins of low molecular weight (less than 20 kDa; such as 4E-BP1) 71 
 
were  studied  on  a  13.5%  (w/v)  acrylamide  gel  with  high  concentration  of  2% 
bisacrylamide [0.36% (v/v)]. Gels were run in SDS-PAGE running buffer at constant 
voltage (180 V)  until  the bromophenol blue dye  was  approximately  1cm  from  the 
bottom  of  the  gel.  Samples  separated  by  SDS-PAGE  were  transferred  to 
nitrocellulose/PVDF  membranes  using  Bio-Rad  Electrotransfer  system  for  1  h  at 
100V.  PVDF  membranes  were  activated  with  methanol  for  15  sec  to  reduce  its 
hydrophobicity. To prevent the non-specific binding, membranes were then blocked in 
PBS-0.05%  (v/v)  Tween  20  containing  5%  (w/v)  skimmed  milk  for  1  h  at  room 
temperature. The membranes were probed with the indicated primary antibody diluted 
in 2% BSA overnight at 4°C. Excess antibody was removed by washing the membrane 
3  times,  5  min  each,  in  PBS-0.05  %  (v/v)  Tween  20.  After  incubation  with 
fluorescently-tagged  secondary  antibody,  the  signals  were  scanned  and  quantified 
using a Licor Odyssey imaging system (LI-COR Bioscience). 
 
Composition of separation gel and stacking gel (0.75 mm) 
Separation gel  12.5%  10%  13.5% 
H2O (ml)  1.3  2.12  0.76 
1.5 M Tris-HCl pH8.8 
(ml) 
0.88  1.25  0.88 
40%  acrylamide (ml)  1.11  1.26  1.18 
2%  bisacrylamide (ml)  0.18  0.2  0.63 
10%  (w/v) SDS (μl)  35  50  35 
10%  (w/v) APS (μl)  17.5  25  17.5 
TEMED (μl)  1.75  2.5  1.75 
Total volume (ml)  3.5  4.9  3.5 
 
Stacking gel   
H2O (ml)  1 
1.0 M Tris-HCl  pH6.8 
(ml) 
0.19 
40%  acrylamide (ml)  0.19 
2%  bisacrylamide (ml)  0.1 
10%  (w/v) SDS (μl)  15 
10%  (w/v) APS (μl)  7.5 
TEMED (μl)  1.5 72 
 
2.3.9 Measurements of protein synthesis rates 
Cells were incubated in the presence of inhibitors for the indicated time at 37°C. For 
the final 60 min, [
35S]methionine was added to a final concentration of 10 μCi/ml. 
After incubation, the medium was removed completely; the cells were washed with 
ice-cold  PBS and  then  lysed.  The protein  concentrations  in  the  extracts  were then 
quantified  using  the  Bradford  method  as  described  in  section  2.3.5.  Lysates  were 
applied to 3 MM filter papers and allowed to dry at room temperature. After two brief 
washes with 5% (w/v) trichloracetic acid (once at 100C) and one in acetone, filters 
were  then  dried.  The  incorporated  radioactivity  was  measured  by  scintillation 
counting. 
 
2.3.10 Pulsed SILAC, SILAC labelling and mass spectrometry 
For pulsed SILAC experiments, HeLa cells growing in SILAC medium (and treated as 
described in the legends) were incubated with the medium containing 154 mg/L L-
[
13C]6,[
15N]2-Lys and 89 mg/L L-[
13C]6,[
15N]4-Arg for 2-6 h at 37C. Where serum was 
used, only serum dialysed against PBS was used to decrease the levels of free Arg and 
Lys. After incubation, the cells were washed twice and then harvested in PBS. After a 
short centrifugation at 600g, the pellets were resuspended in buffer containing 50 mM 
ammonium bicarbonate, 1% sodium deoxycholate and immediately heated to 95˚C. 
   For degradation analysis, two sets of HeLa cells were grown in the medium either 
containing 77  mg/L  L-[
13C]6,[
15N]2-Lys  and  44.5  mg/L  L-[
13C]6,[
15N]4-Arg (heavy-
labelled)  or  75  mg/L  L-[
2H]4-Lys  and  43.5  mg/L  L-[
13C]6-Arg  (medium-labelled). 
Cells were passaged five times in the above medium. Then the heavy-labelled cells 
were moved into DMEM containing normal Lys/Arg and treated with the indicated 
inhibitors. After incubation, the cells were lysed as the methods described for pSILAC. 
Equal amounts of proteins from heavy-labelled and untreated medium-labelled cells 
were mixed prior to trypsin digestion. The medium-labelled samples act as an internal 
control for the heavy-labelled one. 
After  cooling,  the  protein  concentration  of  the  lysates  was  measured  using  the 
bicinchoninic  acid  (BCA)  assay  kit  according  to  the  manufacturer‘s  instructions 
(Thermo Scientific). The kit came with two reagents, reagent A and reagent B, which 
needed to be mixed at 50:1 ratio to prepare the working reagent. The unknown sample 
replicate and a serial dilution of standard protein (BSA) are incubated with the working 73 
 
reagent at 37°C for 30 min. After cooling to room temperature, the average 562 nm 
absorbance measurement of the blank replicates was subtracted from that of all other 
individual standard and unknown sample replicates. The protein concentration of each 
unknown sample was determined with a standard curve by plotting the average blank-
corrected 562 nm measurement for each BSA standard. 
25 µg of total protein was aliquoted, reduced, alkylated  and digested as described 
by Rogers and Foster (2007). After digestion, the resulting deoxycholate precipitate 
was  pelleted  by  centrifugation.  The  supernatant  containing  the  peptides  was  then 
desalted, concentrated, filtered on C18 STop and Go Extraction tips (Rappsilber et al., 
2003), and eluted into a 96-well plate. Peptide mixtures were analyzed on a linear 
trapping quadrupole-Orbitrap (ThermoFisher Scientific) tandem mass spectrometer as 
described (Chan et al., 2006).  
 
2.4 Molecular Biology 
2.4.1 Vectors  
Vectors for rat 4E-BP1 and HA-tagged eIF4E were taken from the stock in Prof. Chris 
Proud‘s lab and have been described (Waskiewicz et al., 1999, Tee and Proud, 2002). 
The vector for HA-eIF4E-Ser209Ala was generated using Quick-Change site-directed 
mutagenesis kit. 
The mutagenic primer 
for generate 
HA-eIF4E-Ser209Ala 
(sense primer 5‘-> 3‘) 
 
 
CAGCTACTAAGAGCGGCGCCACCACTAAAAATAGG 
  
2.4.2 Reverse Transcription (for real-time PCR)  
Reverse  Transcription  was  performed  using  ImProm-II™  Reverse  Transcription 
System (Promega) according to the manufacturer‘s protocol. Briefly, the experiments 
were  performed  in  20  μl  reactions  comprised  of  components  of  the  ImProm-II™ 
Reverse  Transcription  System.  Experimental  RNA  was  combined  with  the  cDNA 
primer  in  RNAse/DNAse  free  water  for  a  final  volume  of  5  μl  reaction.  The 
RNA/primer mix was thermally denatured at 70°C for 5 min and chilled on ice for at 
least 5 min. A reverse transcription reaction mix was prepared containing nuclease-free 74 
 
water,  reaction  buffer,  reverse  transcriptase,  magnesium  chloride,  dNTPs  and 
ribonuclease inhibitor on ice. As a final step, the RNA/primer combination was added 
to  the  reaction  mix  on  ice.  Following  an  initial  annealing  at  25°C  for  5  min,  the 
reaction  was  incubated  at  42°C  for  1  h.  Finally,  the  reverse  transcriptase  was 
inactivated by incubation of 15 min at 70 °C.  
 
2.4.3 Real-time RT-PCR  
A. Bench-side protocol 
1. Tubes containing lyophilised primer mix were pulse-spun before opening, and the 
lyophilised primer mix was then resuspended in RNAse/DNAse free water. 
2. When using PrimerDesign 2 x Precision
TM Mastermix with SYBR green, a mix 
containing  all  real-time  RT-PCR  reagents  was  made  up  according  to  the  protocol 
below. 
Component  Each  reaction 
Resuspended primer 
mix 
1 μl 
PrimerDesign 2X 
Precision
TM 
Mastermix* 
10 μl 
RNAse/DNAse free 
water 
4 μl 
Final volume  15 μl 
*working concentration of primers = 300 nM in a 20 μl reaction 
4. 15 μl of this mix was added into each well according to the experimental plate set 
up. 
5. cDNA was prepared using ImProm-II™ Reverse Transcription System (Promega) as 
described above, and diluted in RNAse/DNAse free water  at 1:10.  
6. 5 μl of diluted cDNA was added into each well, according to the experimental plate 
set up. The final volume in each well was 20 μl. 
7. Wells where the cDNA was replaced with RNAse/DNAse free water was included. 
Any amplification in this sample was indicative of cDNA cross contamination between 
wells, or contamination of one or more reagents. 
B. Amplification protocol 
Amplification was performed on Applied Biosystems StepOnePlus™ Real-Time RT-
PCR instrument using the following conditions.  75 
 
 
 
Stage  Time  Temperature 
 
Cycle 
Enzyme activation  10 min  95ºC  1x 
Denaturation  15 sec  95ºC   
40-50x 
Data collection  60 sec  60ºC 
Melt Curve Stage  1x 
 
                              
2.4.4 Microarray Analysis 
A. Sucrose gradient density centrifugation and RNA detection 
Briefly,  HeLa  cells  were  lysed  and  post-nuclear  lysates  were  applied  to  sucrose 
gradients (10% to 60%) which were then centrifuged at 16, 0000 g for 2 h at 4 °C. 
Gradients were fractionated with continuous monitoring the absorbance at 254 nm. 
Eleven 1 ml fractions were collected into guanidine-HCl, and followed by precipitation 
with ethanol. The RNA was then resuspended in water and further purified by sodium 
acetate/ethanol precipitation.    
B. Microarray hybridisation 
The human cDNA microarrays were kindly obtained from Dr Paddy McTighe at the 
University  of  Nottingham  Genomics  Facility.  RNA  from  sucrose  density  gradient 
fractionation  was  pooled  into  subpolysomal  or  polysomal  fractions  based  on  the 
polysome profile, precipitated first with 2.5 M LiCl and then with sodium acetate and 
ethanol. Fluorescently labelled DNA probes were generated using equal proportions of 
RNAs of pooled subpolysomal fractions (Cy3) and pooled polysomal fractions (Cy5) 
and  hybridised  to  the  microarrays  as  described  previously  (Bushell  et  al.,  2006). 
Microarray  slides  were  scanned  using  a  GenePix  4200B  microarray  scanner  and 
GenePix Pro 6.0 software (Axon Instruments). 
C. Analysis of Microarray Data 
Fluorescence intensities for individual spots on the microarray were quantified using 
GenePix  Pro  6.0.  All  statistical  analysis  was  performed  by  Dr.  Lindsay  Wilson, 76 
 
University of Leicester.  
 
2.4.5 Polysome analysis and Northern blot analyses 
A. To prepare cell lysates 
HeLa cells that had been washed three times with ice-cold PBS buffer were lysed 
directly on the plate with 300 μL of lysis buffer (268 μL TNM lysis buffer, 1% Triton 
X-100, 10 mM DTT, 40 U RNase inhibitor) and transferred into a microcentrifuge 
tube. The lysates were centrifuged for 5 min at 17,000 g at 4°C. The supernatant was 
transferred to a new tube in the presence of 3 μL heparin (10 μg/μL) and stored at -
80°C after freezing in liquid nitrogen.  
B. To prepare the density gradients 
The polyallomer centrifuge tube was placed in dry ice, and 1.5 ml of 50% sucrose 
solution was carefully added in the bottom of the tube. After the first layer was frozen, 
the next lighter sucrose solution was added, and so on until all six layers were frozen 
well. The gradients were stored at -80°C until required. The day before the sample 
centrifugation, the gradients were taken out into 4°C overnight to allow them to thaw 
slowly. 
C. Sample centrifugation and fraction collection 
The lysates were carefully applied onto the top of the gradient and the gradient was 
inserted into the pre-cold bucket. The metal cup was screwed onto the bucket and 
placed in the rotor. The samples were centrifuged at 160000 g for 110 min at 4°C. 
Immediately  after  the  centrifugation,  the  fractions  were  collected  into  9 
microcentrifuge  tubes  using  the  fraction  collectors  (Gilson  FC  203B/FC  204)  with 
continuous monitoring the absorbance at 254 nm. 
D. RNA extraction and Northern analysis  
RNA from each fraction was extracted using the Proteinase K method and precipitated 
by isopropanol. For Northern blot analysis, RNA was separated on 1% formaldehyde-
agarose  gels  and  transferred  to  GreenScreen  Plus  membrane  (Perkin  Elmer)  as 
recommended by the manufacturer. Typically, samples were loaded on 1% agarose-
formaldehyde gel and run in 1x MOPS buffer at 150 V for 20 min. After running, the 
gel was placed in an RNase-free dish and rinsed twice with sufficient deionized water. 
The transfer was performed in 20x phosphate buffer overnight at 4°C. After transfer, 
the membrane was washed in pre-warmed Northern mix buffer at 42°C for at least 20 77 
 
min.  The  purified  radioactive  probe  was  added  and  incubated  with  the  membrane 
overnight  at  42°C.  The  radioactive  probes  were  prepared  by  the  random  primer 
technique (Prime-It II Random Primer Labeling kit, Agilent Technologies) using DNA 
fragments isolated from plasmids containing PCR-amplified cDNA sequences.  
 
Primers for cloning DNA fragments used in generating the radioactive probes 
(sense primer 5’-> 3’) 
HNRNPA3  tgagaaatgg ggcacactcacaga 
NAP1L1  gacttgatggtctggtagaaacacc 
PRDX6  ctggtgctgt gagccagaggat 
(For  RPL11,  RPS19  and  β-actin,  plasmids  containing  these  PCR-amplified  cDNA 
sequences were kind gifts from Professor Fabrizio Loreni‘s lab, University of Rome, 
Italy) 
 
First, DNA fragments and random primers were added into a microcentrifuge tube 
and heated in a boiling water bath for 5 min. 5x dATP buffer, labelled nucleotide (ʱ-
32P –dATP; Perkin Elmer) and Exo(-) Klenow enzyme were then added to the reaction 
tube and incubated at 37°C for 10 min. Finally, the reaction was stopped by adding 
stop mix buffer following the incubation period. Before applied to the hybridisation, 
the  probes  were  purified  using  illustra  ProbeQuant™  G-50  Micro  Columns  (GE 
healthcare). Primers for amplification were designed according to sequences present in 
the GenBank/EBI Data Bank. After hybridisation, the membrane was washed in 2x 
SSC plus 1% SDS buffer twice (1
st wash at room temprature for 10 min, and 2
nd wash 
at 65°C for 20-30 min). Northern blots were then visualised and quantified using a 
phosphorimager and the Image-Quant software (Amersham Biosciences).  
 
2.4.6 RNA-protein interaction assay (Niranjanakumari et al., 2002) 
A. In vivo formaldehyde fixation of HeLa cells. 
HeLa cells transfected with HA-eIF4E, HA-eIF4E-S209A or the corresponding empty 
vector were collected with trypsin digestion. After washed once with DMEM, twice 
with ice-cold PBS, the cells were resuspended in 10 ml of ice-cold PBS. Formaldehyde 
(36.5% HCHO/10% methanol) was added to a final concentration of 1% (v/v) and 
incubated with  slow shaking for 10 min at  room  temperature, followed by further 78 
 
incubation with glycine (pH7.0, 0.25 M) for 5 min at room temperature (to quench the 
crosslinking reaction). The cells were harvested by centrifugation at 200 g for 4 min 
followed by two washes with ice-cold PBS. The cell pellets were frozen in dry ice and 
stored at -80°C for subsequent analysis. 
B.Solubilization of crosslinked complexes by sonication.  
Fixed cell pellets were resuspended in 2 ml of RIPA buffer 1 and lysed by three rounds 
of sonication, 20 s each. Between each cycle, the samples were kept in ice-water bath 
for 2 min. Insoluble material was removed by centrifugation at 16,000 g for 10 min at 
4°C. 
C. Preclearing lysates 
An aliquot of the above lysate (500 µl) was mixed with 30 µl (packed volume) protein 
G-Sepharose  beads  in  the  presence  of  nonspecific  competitor  tRNA  (final 
concentration of 100 µg/ml). The mixture was rotated for 1 h at 4°C. The precleared 
supernatant was collected by centrifugation. 
D. Immumoprecipitation of crossslinked RNP (Ribonucleoprotrein) complexes. 
Protein G-Sepharose beads (30 µl, packed volume) were coated with anti-HA (1.5 µg) 
for  2  h  at  4°C  followed  by  extensive  washing  with  RIPA  buffer  1.  Before 
immunoprecipitation, the beads were incubated for 10 min with 0.5 µl of RNasin (40 
U/µl, Promega). The precleared lysate (500 µl) was mixed with the anti-HA–coated 
beads, and incubated with rotation at 4°C for 90 min. The beads were collected using a 
minicentrifuge at 6000 rpm for 45 s and the supernatant was saved for RNA extraction. 
The beads were then washed six times with 1 ml of RIPA buffer 2 by 10 min rotation 
at  room  temperature.  The  beads  containing  the  immunoprecipitated  samples  were 
collected and resuspended in 100 µl of RIPA buffer 3. 
E. Reversal of crosslinks and RNA purification 
Samples  (resuspended  beads)  were  incubated  at  70°C  for  45  min  to  reverse  the 
crosslinks.  The  RNA  was  extracted  from  these  samples  using  Trizol  (Invitrogen) 
according  to  the  manufacturer‘s  protocol.  RNA  precipitates  were  collected  by 
microcentrifugation at 16,000 g for 10 min, washed with 70% ethanol, air-dried, and 
resuspended in 10 µl of RNase-free water. 
F. Analysis of immunoprecipitated RNA by RT-PCR 
The RNA (3/10th of the total sample) purified from the previous step was used as a 
template  to  synthesize  cDNA  using  the  method  as  described  before.  PCR  was 
performed  in  a  50-µl  volume  using  GoTaq  DNA  polymerase  (Promega).  After  an 79 
 
initial incubation at 95°C for 2 min, the reaction mixtures were subjected to 25–35 
cycles of amplification using the following sequence: 95°C for 30 s, 46-51°C for 30 s, 
and 72°C for 30 s, followed by a final extension step at 72°C for 5 min. 25 μl of each 
reaction mixture was run on a 2% agarose gel for analysis. 
 
G. Details of primers used in the RIP assay [primers were designed by PrimerDesign; 
they  used  a  modified  version  of  Beacon  Designer  and  the  industries  finest  DNA 
analysis software (visual OMP) to model in silico the thermodynamic properties of 
each real-time PCR probe they designed]. 
 
Gene symbol  Sense Primer 
5’-> 3’ 
Product length  (bp) 
BIRC2  GTGGGTCGCAATGATGATGT  115 
CCL7  TGTAAAAACTGTGGGATGCTC  114 
MMP3  ATGATGAACAATGGACAAAGGATAC  101 
VEGFC  CCCCAAACCAGTAACAATCAGT  96 
RBMX  GTGGAGGAAGCCGATCTGA  92 
MCL1  CTGATTGTTCTGCTGCCTCTAC  104 
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CHAPTER 3                                                                           
THE DISTINCT EFFECTS OF RAPAMYCIN AND mTOR 
KINASE INHIBITORS ON mTOR DOWNSTREAM 
SIGNALLING AND PROTEIN SYNTHESIS 
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3.1 Introduction 
As already discussed, mTOR forms two types of multiprotein complex with distinct 
components and functions, mTORC1 and mTORC2. mTORC1 controls many essential 
functions in cells, such as mRNA translation, cell growth and cell proliferation, while 
mTORC2 is thought to promote cell survival (reviewed in Corradetti and Guan, 2006). 
mTORC1  is  sensitive  to  rapamycin  inhibition,  whereas  mTORC2  is  considered 
rapamycin-insensitive in the short-term treatment (Rosner and Hengstschlager, 2008). 
Rapamycin does not directly inhibit mTOR kinase activity; rather, it works through an 
unusual  allosteric  mechanism  which  requires  interaction  with  the  immunophilin 
FKBP12 and binding to a domain far from the kinase‘s active site. Since rapamycin 
does not inhibit mTORC2, it is less well studied than mTORC1. Recently, many new 
mTOR-KIs have been developed as possible anti-cancer agents. These new compounds 
are  reported  to  be  highly-selective  and  ATP-competitive,  and  some  can  induce 
significant inhibition of tumour cell line growth both in vitro and in vivo (reviewed in 
Zask  et  al.,  2011).  Because  these  novel  mTOR-KIs  affect  both  mTORC1  and 
mTORC2,  they  would  be  very  useful  to  identify  many  mTOR  functions  that  are 
resistant  to  inhibition  by  rapamycin.  In  this  chapter,  I  have  studied  the  effects  of 
rapamycin and two mTOR-KIs (PP242, AZD8055) on a number of aspects of mTOR 
signalling and protein synthesis, in order to identify differences in their effects. 
 
3.2 Results 
3.2.1 The mTOR-KI AZD8055 strongly inhibits insulin-induced phosphorylation of 
targets of mTORC1 and mTORC2. 
Insulin and insulin-like growth factors (IGFs) initiate the PI3K-Akt-mTOR signalling 
pathway at the plasma membrane, resulting in the phosphorylation of a number of 
targets, such as S6K1 and 4E-BP1 (reviewed in Hay and Sonenberg, 2004). In order to 
examine  the  effects  of  mTOR-KIs  on  the  ability  of  insulin  to  induce  the 
phosphorylation of mTOR signalling downstream effectors, HeLa cells were starved of 
serum for at least 16 h and then treated with insulin. In the presence or absence of 
rapamycin  or  AZD8055,  the  phosphorylation  of  different  targets  of  mTORC1  and 
mTORC2 was studied using phosphospecific antibodies.  
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Figure 3.1. AZD8055 inhibits insulin-induced phosphorylation of 4E-BP1 at different 
sites in serum-starved HeLa cells. 
HeLa cells were starved of serum (16 h) and then treated with AZD8055 (100 nM) for 
1 h prior to stimulation with insulin. Lysates were analyzed by western blot using the 
indicated antibodies. The arrows indicate different species of 4E-BP1 ʱ, β and γ.         
* indicates nonspecific bands. 
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As  an  important  downstream  target  of  mTORC1,  phosphorylation  of  4E-BP1  is 
often used as readout of mTORC1 activity. Although rapamycin inhibits mTORC1, it 
does so incompletely. For example, phosphorylation at Thr37/46 and Thr70 of 4E-BP1 
is not blocked by rapamycin in various cell lines (Thoreen et al., 2009). As expected, 
insulin increased the phosphorylation of 4E-BP1 at all the sites, even though 4E-BP1 
was already substantially phosphorylated at Thr37/46 (Fig. 3.1). This is consistent with 
the  previous  findings,  suggesting  that  the  phosphorylation  at  the  N-terminal  sites 
(Thr37/46) of 4E-BP1 is not sensitive to serum deprivation but is maintained by the 
amino acids in the medium (Wang et al., 2005, Thoreen et al., 2009). Moreover, the 
phosphorylation  of  Ser65  and  Thr70  gradually  increased  along  the  time  course  of 
insulin treatment. The increase in Ser65 phosphorylation was probably more rapid than 
that in Thr70, as it was already dramatically enhanced after 5 min incubation with 
insulin. AZD8055 had a strikingly strong effect on the phosphorylation of 4E-BP1. It 
completely  blocked  Ser65  phosphorylation  and  substantially  decreased  Thr70 
phosphorylation  induced  by  insulin  (Fig.  3.1).  The  basal  level  of  Thr37/46 
phosphorylation  was  already  considerably  high,  resulting  in  saturated  signal  when 
stimulated  by  insulin.  However,  AZD8055  still  reduced  insulin-induced 
phosphorylation at these sites. 
    Ribosomal  protein  S6K  is  another  well-characterized  downstream  target  of 
mTORC1.  S6Ks  have  many  substrates,  including  rpS6  which  has  several 
phosphorylation  sites  (Ferrari  et  al.,  1991).  Since  Ser240/244  of  rpS6  is  not 
phosphorylated by p90 RSK (it phosphorylates Ser235/236; Pende et al., 2004) and is, 
therefore, more specific to mTOR regulation, it was chosen to test the effect of the 
inhibitors. The basal level of phosphorylation of rpS6 at Ser240/244 was very low (in 
serum-starved  HeLa  cells),  demonstrating  that  S6K  was  not  activated  (Fig.  3.2). 
Insulin  induced  rapid  phosphorylation  of  rpS6  at  Ser240/244.  The  phosphorylation 
level  was  stronger  after  10  min  incubation  with  insulin.  Rapamycin  decreased  the 
phosphorylation induced by insulin to the basal level, consistent with this site being 
regulated by mTORC1 and S6Ks. AZD8055 also showed a strong inhibition at this site 
and completely blocked the insulin-induced phosphorylation of rpS6 at these sites. 
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Figure 3.2. Rapamycin and AZD8055 strongly inhibit the phosphorylation of rpS6 at 
Ser240/244 in response to insulin in HeLa cells. 
HeLa cells were starved of serum (16 h) and then treated with rapamycin (100 nM) or 
AZD8055 (100 nM) for 1 h prior to stimulation with insulin. Lysates were analyzed by 
western blot using a S6-pSer240/244 antibody. The same blot was reprobed with a 
tubulin antibody as a loading control.   
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The phosphorylation of Akt at Thr308 and Ser473 was also examined in serum-
depleted HeLa cells (Fig, 3.3). Of the two sites, Thr308 is located in the T loop and 
phosphorylated by PDK1 (Alessi et al., 1997b, Stokoe et al., 1997), whereas Ser473 is 
in the hydrophobic motif and is considered as mTORC2 site (Sarbassov et al., 2005). 
The interplay between these two sites is ambiguous, but it has been reported both of 
them are required for Akt to achieve its optimal activity (Andjelkovic et al., 1997, 
Alessi et al., 1996).  
Insulin rapidly increased the phosphorylation of Akt at Thr308 and Ser473 and its 
substrate, FOXO after 2 min (Fig. 3.3). However, the phosphorylation of Akt at Ser473 
(and  its  substrate  FOXO)  was  reduced  after  30  min  of  stimulation  by  insulin. 
AZD8055  abolished  the  phosphorylation  of  Akt  at  Ser473  and  also  remarkably 
reduced its phosphorylation at Thr308. The phosphorylation of FOXO was partially 
inhibited by AZD8055, suggesting that phosphorylation of this site is only modestly 
affected  by  loss  of  phosphorylation  of  Akt  at  Ser473.  The  mechanism  by  which 
AZD8055 inhibits phosphorylation of Akt at Thr308 is unclear. Feldman et al. (2009) 
found that another mTOR kinase inhibitor PP242 also inhibited Akt phosphorylation at 
both Ser473 and Thr308 in WT MEFs. By contrast, when phosphorylation of Akt at 
Ser473 was abolished by genetic approaches (either by loss of SIN1 or transfecting 
cells with a Ser473Ala mutant of Akt), Thr308 remained phosphorylated even in the 
presence  of  PP242.  Their  findings  support  the  idea  that  the  inhibition  of 
phosphorylation  of  Thr308  by  PP242  is  dependent  on  its  inhibition  of  Ser473 
(Feldman et al., 2009). In a very recent report on AZD8055 by Chresta et al. (2010), 
the authors found that the inhibition of phosphorylation of Akt at Thr308 by AZD8055 
is not as potent as Ser473 and generally requires higher doses of this compound. They 
hypothesised that  the inhibition of Thr308  by  mTOR-KIs  is  probably  caused by  a 
reduction  in  the  ability  of  PDK1  to  phosphorylate  Akt  on  Thr308  when  Ser473 
phosphorylation is transiently but fully inhibited, rather than the ability of mTOR-KIs 
to directly inhibit PDK1. 
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Figure 3.3. Effects of AZD8055 on the phosphorylation of Akt, Akt substrates, eEF2 
and rpS6 in response to insulin. 
HeLa cells were starved of serum (16 h) and then treated with AZD8055 (100 nM) for 
1 h prior to stimulation with insulin. Lysates were analyzed by western blot using the 
indicated antibodies. The multiple bands of FOXO are due to the antibody detecting 
the phosphorylation of different isoforms of FOXO: FOXO1, FOXO3a and FOXO4.  
* indicates nonspecific bands. 
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The effect of AZD8055 on phosphorylation of rpS6 at Ser235/236 and eEF2 at 
Thr56  was  also  examined  (Fig.  3.3).  Similarly  to  Ser240/244  (Fig.  3.2),  insulin 
induced  the  phosphorylation  of  Ser235/236  very  quickly.  AZD8055  substantially 
decreased the phosphorylation of this site. The remaining signal might be due to a 
small contribution from p90 RSK. It has been previously shown that phosphorylation 
of  eEF2  at  Thr56  by  eEF2  kinase  inhibits  its  activity,  and  eEF2  kinase  is 
phosphorylated by p70 S6K at Ser366 (Ryazanov and Davydova, 1989, Redpath et al., 
1993, Wang et al., 2001). Insulin caused the dephosphorylation of eEF2 after 5 min, 
resulting in its activation, whereas AZD8055 increased the phosphorylation of eEF2, 
leading to its inactivation (Fig 3.3).  
To confirm that the above effects of AZD8055 on Akt and its substrate were not 
confined to HeLa cells, two other cell lines were chosen: the breast cancer cell line 
MCF7 and the human embryonic kidney cells HEK293. As seen in Fig. 3.4, AZD8055 
inhibited both basal and insulin-induced Akt phosphorylation at Thr308 and Ser473 in 
the two cell lines. The phosphorylation of GSK3 was also reduced by treatment with 
AZD8055. In agreement with the effects observed in HeLa cells (Fig. 3.3), AZD8055 
only slightly decreased the phosphorylation of FOXO. However, it also blocked its 
basal phosphorylation in MCF7 cells (Fig. 3.4).  
 Akt can directly phosphorylate TSC2 at two sites, Ser939 and Thr1462 on the full-
length human protein (Dan et al., 2002). Phosphorylation of TSC2 inhibits its activity 
as  a  GTPase-activating  protein  for  Rheb,  thereby  allowing  Rheb-GTP  to  activate 
mTORC1 signalling (reviewed in Manning and Cantley, 2003). As shown in Fig. 3.4, 
AZD8055 strongly inhibited insulin-induced phosphorylation of TSC2 at Thr1462.  
Collectively, AZD8055 suppressed the insulin-induced activation of various targets 
of mTORC1 and mTORC2, showing its strong effects on both complexes. 
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Figure 3.4. Effects of AZD8055 on the phosphorylation of Akt and its substrates in 
MCF7 and HEK293 cells. 
Cells were starved of serum (16 h) and then treated with AZD8055 (100 nM) for 1 h 
prior to  stimulation with insulin.  Lysates  were analyzed by western blot using the 
indicated antibodies.  * indicates unspecific bands. 
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3.2.2 The mTOR-KIs PP242 and AZD8055 inhibit the phosphorylation of targets of 
mTORC1 and mTORC2 in serum-fed cells.  
The above data demonstrated the effects of AZD8055 on mTOR signalling in response 
to insulin. These data are obviously very useful and valuable for understanding the 
effects of mTOR-KIs. However, for cancer therapy, examining these compounds in 
serum-replete culture cells may provide more useful insights.     
To  compare  the  different  effects  between  rapamycin  and  AZD8055  in  serum-
maintained  cells,  HeLa  cells  growing  in  serum-replete  medium  were  treated  with 
rapamycin and AZD8055 over a range of times up to 60 min. The phosphorylation of 
4E-BP1 at different sites was tested. As seen in Fig. 3.5, in the presence of serum, the 
basal level of phosphorylation of 4E-BP1 was already high. Rapamycin did not lead to 
a  significant  change  in  the  phosphorylation  of  these  sites.  In  contrast,  AZD8055 
substantially suppressed phosphorylation of Thr37/46 and Ser65. For Thr37/46, the 
phosphorylation of all three isoforms (ʱ, β, γ) was inhibited by AZD8055 even as early 
as  10  min  of  treatment.  For  Ser65  and  Thr70,  clear  band  shifts  were  observed 
following treatment with AZD8055. The insensitivity of phosphorylation of Thr37/46 
and Thr70 to rapamycin in HeLa cells has been reported before (Thoreen et al., 2009), 
but the lack of effect of rapamycin on Ser65 appears surprising. This might be due to 
the cross-reaction of the antibody with another site in human 4E-BP1. More details 
will be discussed below.  
The effect of rapamycin and AZD8055 on the phosphorylation of translation factors, 
eEF2  and  eIF2Bε,  was  also  studied  (Fig.  3.5).  Both  rapamycin  and  AZD8055 
inactivated eEF2 through increasing its phosphorylation at Thr56. The phosphorylation 
of GSK3 leads to its inactivation and loss of function in phosphorylating eIF2B, thus 
facilitating mRNA translation (Rayasam et al., 2009). Rapamycin slightly increased 
the phosphorylation of GSK3, whereas AZD8055 decreased it (Fig. 3.5). The distinct 
effects of rapamycin and AZD8055 on GSK3 were further reflected by the behaviour 
of eIF2Bε-Ser535 caused by these compounds (Fig. 3.5). Rapamycin also caused the 
enhancement  of  Akt-pThr308  and  a  minimal  change  of  PRAS40-pThr246  whereas 
AZD8055  inhibited  both  of  them.  The  finding  that  rapamycin  increased  the 
phosphorylation  of  Akt  and  its  substrates  probably  provides  new  insights  into  its 
limited success towards some tumour types.  
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Figure 3.5.  Effects of differing periods of treatment with rapamycin or AZD8055 on 
selected proteins in serum-fed HeLa cells. 
(A, B) HeLa cells growing in serum were treated with rapamycin (rapa; 100 nM) or 
AZD8055  (AZD;  100nM)  for  the  indicated  times,  and  then  lysed.  Lysates  were 
analyzed by western blot using the indicated antibodies. The signal for tubulin in A 
also serves as a loading control for B. Three isoforms (ʱ, β, γ) of 4E-BP1 are indicated; 
* denotes nonspecific bands. 
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To have a better understanding of the distinct effects of rapamycin and mTOR-KIs, 
another mTOR kinase inhibitor PP242 was included for analysis (Fig. 3.6). PP242 was 
developed by Feldman et al. (2009) and showed profound effects on both mTORC1 
and mTORC2 in L6 myotubes and HEK293 cells. Therefore, I examined its effects in 
HeLa cells, the main cell type used in this study. HeLa cells growing in serum-fed 
medium were treated with PP242 at different concentration, rapamycin at 100nM or 
AZD8055 at 100nM for 60 min. As shown in Fig. 3.6, rapamycin completely inhibited 
the  phosphorylation  of  rpS6  at  Ser235/236  and  decreased  the  signal  seen  with  an 
antibody that recognises the Ser240/244, specific sites for S6Ks (Ferrari et al., 1991, 
Pende et al., 2004). The residual signal of pSer240/244 may be due to an ability of this 
batch  of  antibody  to  detect  non-phosphorylated  rpS6.  Similar  effects  on  rpS6 
phosphorylation were seen with PP242 and AZD8055 (even the lowest concentration 
used  here  had  a  substantial  inhibition).  PP242  also  increased  the  level  of 
phosphorylation of eEF2 at Thr56 (Fig. 3.6 A). 
In  addition,  PP242  also  exhibited  similar  effects  on  4E-BP1  to  AZD8055.  No 
obvious effects of rapamycin were observed on these sites. As mentioned before, the 
finding that rapamycin failed to inhibit Ser65 may reflect the recognition by some 
batches of this antibody of another site in human 4E-BP1. Indeed, the cross-reaction of 
the antibody  with  Ser101 may  account  for the  remaining signal  for  Ser65 in  cells 
treated with rapamycin. Since the corresponding residue in rat or mouse 4E-BP1 lies in 
a different sequence context (Wang et al., 2003), HeLa cells were transfected with a 
vector encoding rat 4E-BP1, where the corresponding site is S64, not 65. The data in 
Fig.  3.6C  clearly  showed  that  rapamycin  partially  inhibited  and  PP242 completely 
blocked the signal seen with this antibody for rat 4E-BP1. Phosphorylation of Akt at 
Ser473 was diminished by PP242, as seen in Fig. 3.6D, while that of Akt-Thr308, 
GSK3 and PRAS40 was not completely inhibited by PP242. Rapamycin again slightly 
increased the phosphorylation of all these sites (Fig. 3.6D).  
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Figure 3.6. Effects of rapamycin, PP242 and AZD8055 on downstream signalling 
targets of mTORC1 and mTORC2 in serum-fed HeLa cells. 
(A), (B) and (D): serum-fed HeLa cells were treated with the PP242 at the indicated 
concentrations, rapamycin (rapa; 100 nM) or AZD8055 (100 nM) for 60 min. Cell 
lysates were analyzed by western blot using the indicated antibodies. (C) HeLa cells 
were transfected with an empty vector (pcDNA 3.1) or a vector encoding rat 4E-BP1 
(containing C-terminal Myc and His tags). Where indicated, cells were treated with 
rapamycin or PP242 for 60 min. Lysates were analysed by western blot using the 
indicated antibodies. * denotes nonspecific bands; arrows indicate the species under 
study. 93 
 
In order to have a complete understanding of the distinct effects of rapamycin and 
mTOR-KIs on mTOR signalling, a summary of all the targets tested is given in Table 
3.1.  Although  rapamycin  induced  an  inhibition  of  rpS6  phosphorylation  at  both 
Ser235/236  and  Ser240/244,  it  had  limited  effect  on  4E-BP1  phosphorylation, 
suggesting  its  incomplete  inhibition  of  mTORC1  activity.  In  contrast,  mTOR-KIs 
(PP242 and AZD8055) significantly inhibited the phosphorylation of these rapamycin-
insensitive  sites.  Both  rapamycin  and  mTOR-KIs  caused  inactivation  of  eEF2  by 
increasing  its  phosphorylation  at  Thr56.  Rapamycin  treatment  increased 
phosphorylation of Akt at Ser473 as well as its substrates GSK3 and PRAS40, whereas 
mTOR-KIs inhibited the phosphorylation of those targets, revealing a lack of function 
of  rapamycin  on  mTORC2.  Rapamcyin  also  increased  phosphorylation  of  Akt  at 
Thr308, which might be mediated by the feedback loop via S6Ks (Harrington et al., 
2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
 
 
 
 
 
Table 3.1. Summary of effects of rapamycin and mTOR-KIs (PP242 and AZD8055) 
on the phosphorylation of mTORC1 and mTORC2 targets in serum-fed cells.  
         Compound 
Target 
Rapamycin 
 
mTOR kinase   
inhibitors 
Functions 
 
 
Serum-fed 
Cells 
4E-BP1-
Thr37/46 
             /     
 
mTORC1 sites  4E-BP1-Ser65     
4E-BP1-Thr70                /   
rpS6-
Ser235/236 
   
rpS6-
Ser240/244 
   
eEF2-Thr56      S6K substrate 
Akt-Thr308      PDK1       site 
Akt-Ser473      mTORC2 site 
GSK3ʱ/β-
Ser21/9 
     
Akt Substrates 
PRAS40-
Thr246 
   
 : Increase;  
 : Decrease; 
/: No effect;    
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3.2.3 mTOR-KIs, but not rapamycin, decrease the binding of eIF4G to eIF4E in HeLa 
cells.  
Activation  of  mTORC1  stimulates  cap-dependent  translation  via  its  downstream 
substrates. It is well understood that the hypophosphorylated 4E-BP1 interacts strongly 
with the cap-binding factor eIF4E, inhibiting the formation of the translation initiation 
complex  eIF4F  and,  therefore  acting  as  a  negative  regulator  of  cap-dependent 
translation  (Pause  et  al.,  1994).  Identification  of  the  strong  effects  of  PP242  and 
AZD8055  on  mTOR  signalling,  especially  on  the  phosphorylation  of  4E-BP1, 
suggested  it  would  be  very  interesting  to  assess  the  effects  of  mTOR-KIs  on  the 
formation of eIF4F. 
To  assess  the  binding  between  eIF4E  and  4E-BPs/eIF4G  (i.e.  the  formation  of 
eIF4F), m
7GTP Sepharose beads, which mimic the mRNA 5‘cap to precipitate cap-
interacting  proteins,  were  used  to  perform  a  pull  down  assay.  Firstly,  effect  of 
AZD8055 on the formation of eIF4F in response to insulin was examined in serum-
starved HeLa cells (Fig 3.7). 
Insulin rapidly promoted the binding of eIF4GI to eIF4E after 2 min. Surprisingly, 
increasing  the  length  of  insulin  treatment  did  not  further  enhance  the  interaction 
between eIF4GI and eIF4E. AZD8055 substantially inhibited the amount of eIF4GI 
bound to eIF4E when it caused a large increase of bound 4E-BP1 (Fig. 3.7).  
PMA  (phorbol  myristate  acetate)  can  also  activate  mTOR  independently  of  Akt 
through  inhibition  of  TSC2  (Roux  et  al.,  2004).  Therefore  effect  of  AZD8055  on 
PMA-induced eIF4F formation was studied as well (Fig. 3.8). PMA induced eIF4GI 
binding to  eIF4E in  serum-starved HeLa cells.  This  effect was  blocked by  adding 
AZD8055  in  a  dose-dependent  manner.  Rapamycin  however  did  not  inhibit  the 
binding  of  eIF4GI  to  eIF4E.  The  data  in  Fig.  3.7  and  Fig.  3.8  demonstrate  that 
AZD8055 blocks both insulin and PMA-induced eIF4GI binding to eIF4E in HeLa 
cells.  
 
 
 
 
 
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Effects of AZD8055 on the insulin-induced formation of eIF4F in HeLa 
cells. 
HeLa cells were serum-starved for 16 h, then treated with AZD8055 at 100 nM for 60 
min, and then incubated with insulin for the indicated time. Equal amounts of lysates 
were subjected to affinity chromatography on m
7GTP-Sepharose. Bound proteins were 
analysed  by  western  blot  using  the  indicated  antibodies.  Note:  samples  were  also 
applied to CL4B sepharose in order to test any nonspecific binding (one typical data 
will be shown later). 
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Figure 3.8. AZD8055 inhibits PMA-induced eIF4F formation in HeLa cells. 
HeLa  cells  were  serum-starved  for  16  h,  treated  with  rapamycin  at  100  nM  or 
AZD8055 at the indicated concentrations for 60 min, and then incubated with PMA for 
30  min.  Equal  amounts  of  lysates  were  subjected  to  affinity  chromatography  on 
m
7GTP-Sepharose. Bound proteins were analysed by western blot using the indicated 
antibodies.  
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Due to the promising results of AZD8055 on the formation of eIF4F, it would be 
interesting to compare its effects with rapamycin in serum-fed cells. Differing times of 
treatment with rapamycin and AZD8055 was carried out to compare their effects (Fig. 
3.9). Rapamycin and AZD8055 had significantly different effects on the association of 
the translation initiation factors in serum-replete HeLa cells. Treatment with AZD8055 
resulted in a large increase of bound 4E-BP1, raising the level of 4E-BP1 on the beads 
above that seen in untreated cells. Because the binding of 4E-BP1 and eIF4G to eIF4E 
are mutually exclusive (Haghighat et al., 1995), it appears logical that the increase of 
bound  4E-BP1  was  accompanied  by  a  significant  loss  of  eIF4GI  (as  observed  for 
AZD8055 treatment). Treatment with rapamycin only caused a slight increase in the 
amount of 4E-BP1 bound to eIF4E, consistent with its limited inhibition of 4E-BP1 
phosphorylation.  Surprisingly,  but  reproducibly,  rapamycin  enhanced  the  scaffold 
protein  eIF4GI  bound  to  eIF4E,  rather  than  reducing  it,  which  is  very  difficult  to 
explain based on the current knowledge. 
To further clarify this finding, prolonged treatment with the compounds was carried 
out and another important component of eIF4F, eIF4A was included in the analysis 
(Fig. 3.10).  
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Figure 3.9. Effect of short time treatment with rapamycin or AZD8055 on eIF4F 
formation in serum-fed HeLa cells. 
HeLa cells growing in serum-maintained medium were treated with rapamycin (rapa; 
100 nM) or AZD8055 (AZD; 100 nM) for the indicated times (up to 60 min). Equal 
amounts of lysates were subjected to affinity chromatography on m
7GTP-Sepharose. 
Bound proteins were analysed by western blot using the indicated antibodies.  
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Figure 3.10. Effect of prolonged treatment with rapamycin or AZD8055 on eIF4F 
formation in serum-fed HeLa cells. 
HeLa cells growing in serum-maintained medium were treated with rapamycin (rapa; 
100  nM) or AZD8055  (AZD; 100 nM) for the indicated times (up to 3 h). Equal 
amounts of lysates were subjected to affinity chromatography on (A) and (C) m
7GTP-
Sepharose or (C) CL4B Sepharose.  Bound proteins were analysed by western blot 
using the indicated antibodies. (B) Quantification of (A) for eIF4GI/eIF4E and 4E-
BP1/eIF4E binding. The bottom blot of eIF4E from whole cell lysate in (C) indicates 
input control.  
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Increasing the time (3 h) of AZD8055 treatment inhibited the association of eIF4GI 
with  eIF4E,  and  strongly  increased  the  binding  of  4E-BP1  to  eIF4E  (Fig.  3.10A). 
Additionally, eIF4A, which unwinds the secondary structure of the mRNA 5‘ UTR to 
render it more conducive to ribosomal binding and subsequent translation (Rogers et 
al.,  1999),  also  dissociated  from  eIF4E  upon  AZD8055  treatment  up  to  3  h  (Fig. 
3.10C). The presence of all the components of eIF4F (eIF4A, eIF4G and 4E-BP1) in 
the m
7-GTP bound material shows the integrity of this complex. Thus, treatment with 
AZD8055 causes the dissociation of both eIF4GI and eIF4A from eIF4E, showing its 
strong inhibitory effect on the assembly of eIF4F. The enhanced binding of eIF4GI to 
eIF4E also occurred following the prolonged treatment with rapamycin (Fig. 3.10A 
and C), which clearly shows the amount of bound eIF4GI was further increased by 
long  time  treatment  with  rapamycin.  Similar  results  were  observed  for  eIF4A 
following rapamycin treatment (Fig. 3.10C). As seen in the right lane of Fig. 3.10C, 
there was no nonspecific binding to the CL4B beads.  
eIF4G and 4E-BP have been reported to have other paralogs (Imataka et al., 1998, 
Poulin et al., 1998, Lin et al., 1994, Pause et al., 1994), therefore, I examined whether 
rapamycin and mTOR-KIs have differing effects on those isoforms.  
Treatment with AZD8055 caused a substantial decrease in the amount of eIF4GII 
bound to eIF4E, as seen for eIF4GI (Fig. 3.11A). Rapamycin induced a small increase 
of the amount of bound eIF4GI and apparently had little effect on eIF4GII (it was 
difficult to determine change of eIF4GII exactly, due to the weak detection by the 
antibody for eIF4GII). Both PP242 and AZD8055 elicited a large retention of 4E-BP1 
and 4E-BP2, accompanied by a loss of eIF4GI (Fig. 3.11B). The increase in binding of 
4E-BP1 and 4E-BP2 induced by rapamycin was very slight, as observed in Fig. 3.11B. 
The finding that rapamycin had similar effects on 4E-BP1 and 4E-BP2 excluded the 
possibility  that  4E-BP2  was  the  second  factor  which  dissociated  with  eIF4E  upon 
rapamycin treatment. To summarise, rapamycin and mTOR-KIs have differing effects 
on the assembly of eIF4F. 
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Figure 3.11. Effects of rapamycin and mTOR-KIs (PP242 and AZD8055) on the 
binding of different paralogs of eIF4G and 4E-BPs. 
(A)  and  (B)  HeLa  cells  growing  in  serum-maintained  medium  were  treated  with 
rapamycin (rapa; 100 nM) , PP242 (PP; 1 μM) or AZD8055 (AZD; 100 nM) for 60 
min. Equal amounts of lysates were subjected to affinity chromatography on m
7GTP-
Sepharose.  Bound  proteins  were  analysed  by  western  blot  using  the  indicated 
antibodies.  
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3.2.4 mTOR-KIs inhibit protein synthesis more strongly than rapamycin. 
Given the contrasting effects of rapamycin and the mTOR-KIs, their effects on the rate 
of protein synthesis were examined. HeLa cells maintained in serum were treated with 
rapamycin  or  mTOR-KIs  for  2  h.  Short  times  were  first  chosen  to  minimise  the 
influence  of  the  effects  of  the  compounds  on  ribosome  biosynthesis  (Mayer  and 
Grummt,  2006).  The  rate  of  protein  synthesis  was  assessed  by  measuring  the 
incorporation of [
35S]methionine into TCA-insoluble material. This method is able to 
estimate the amount of protein synthesized in a population of cells. 
The data in Fig. 3.12 show that rapamycin only had a small inhibitory effect on the 
protein  synthesis  whereas  AZD8055  had  a  much  stronger  one  by  around  30%. 
Therefore, what accounts for the greater effect of mTOR-KIs on total protein synthesis? 
Thoreen et al. (2009) found similar effects in MEFs when treated with Torin 1 (another 
ATP-competitive mTOR inhibitor) and that this pattern was maintained in Rictor null 
MEFs. This indicates that the greater effect of mTOR-KIs on protein synthesis is not 
due to effects mediated through mTORC2, but rather through rapamycin-insensitive 
effects of mTORC1, for example, 4E-BP1 phosphorylation.  
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Figure 3.12. Effects of rapamycin and AZD8055 on protein synthesis rates in HeLa 
cells growing in serum. 
Serum-fed HeLa cells were treated with rapamycin (100 nM) or AZD8055 (100 nM) 
for 1 h and then incubated with [
35S]methionine (10 μCi/ml) for 1 h. 30 μg of Lysates 
were added to 3 MM filter paper and the incorporated radioactivity was measured as 
described in Materials and Methods section 2.3.9. Data are given ± SEM, n = 3.  
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3.2.5 Role of 4E-BP1 in the effects of rapamycin and mTOR-KIs on protein synthesis.  
To assess whether the stronger inhibition of protein synthesis by mTOR-KIs is due to 
their  effects  on  4E-BP1,  I  first  attempted  to  eliminate  mTOR  inhibition  of 
eIF4G/eIF4E binding by knocking down expression of 4E-BP1 using siRNA (Averous 
et al., 2008). To achieve a good knockdown efficiency, various incubation times (from 
48 h to 96 h) after transfection with siRNA were tested. Expression of 4E-BP1 in the 
samples transfected with 4E-BP1 siRNA was greatly diminished after 96 h incubation 
compared to the samples transfected with control siRNA (Fig. 3.13A). Therefore, 96 h 
was chosen for the subsequent experiments. As shown in Fig 3.13B, compared with 
control siRNA, transfection with 4E-BP1 siRNA caused a recovery of eIF4GI bound 
to  eIF4E  in  cells  treated  with  AZD8055.  However,  AZD8055  can  still  induce  an 
increase of the amount of 4E-BP1 bound to eIF4E in 4E-BP1 siRNA-transfected cells, 
revealing  an  incomplete  knockdown  of  4E-BP1  expression.  More  importantly, 
AZD8055 still decreased eIF4GI binding (Fig. 3.13B). In total, since knocking down 
4E-BP1  could  not  eliminate  the  inhibitory  effects  of  AZD8055  on  eIF4GI/eIF4E 
binding,  this  approach  is  not  suitable  for  studying  the  contribution  of  4E-BP1  to 
overall protein synthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 106 
 
 
 
 
Figure 3.13. Knocking down 4E-BP1 diminishes the inhibition of eIF4GI/eIF4E 
binding by AZD8055. 
(A) and (B) Serum-fed HeLa cells were transfected with siRNA targeted to the 4E-BP1 
mRNA (BP1) or, as a negative control, scrambled siRNA (ctrl). (A) After indicated 
times (up to 96 h), cell lysates were analysed by western blotting using the indicated 
antibodies. (B) After 96 h incubation, cells were treated with mTOR inhibitors where 
indicated.  Cell  lysates  were  then  subjected  to  affinity  chromatography  on  m
7GTP 
Sepharose and the bound material was analyzed by western blot using the indicated 
antibodies. The graphic below represents the ratio of bound eIF4GI/eIF4E under each 
condition. 107 
 
Therefore extra eIF4E was introduced into the cells, arguing that these eIF4E could 
bind to increased amounts of non-phosphorylated, active 4E-BPs induced by mTOR 
inhibitors. First, HeLa cells were transfected with untagged eIF4E vectors (Fig. 3.14). 
Treatment with AZD8055 caused a dissociation of eIF4GI with eIF4E when cells were 
transfected  with  empty  vector,  eIF4E  mutant  vector  (4E-W73A)  or  without 
transfection. This dissociation was recovered by overexpression of wild type eIF4E, 
accompanied by the retention of 4E-BP1, suggesting more free eIF4E bound to eIF4GI 
as well as to dephosphorylated 4E-BP1. Interestingly, expression of 4E mutant form 
(4E-W73A) failed to recover the loss of eIF4GI caused by AZD8055, which agrees 
with earlier finding that when Tryptophan at position 73 in eIF4E was mutated into 
alanine, eIF4E was incapable of interacting with eIF4G in vivo (Marcotrigiano et al., 
1997). However, no significant increase in levels of eIF4E was observed in total cell 
lysates (Fig. 3.14). Since this untagged eIF4E comigrates with endogenous eIF4E, it 
was not easy to assess its overexpression level. 
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Figure 3.14. Overexpression of untagged eIF4E wild type (4E-WT) and eIF4E mutant 
form (4E-W73A) in serum-fed HeLa cells. 
HeLa cells growing in serum were transfected with a vector encoding wild type eIF4E 
or a vector encoding mutant eIF4E (or the corresponding empty vector, EV). The cells 
were then treated with AZD8055 (100 nM) for 1 h. The lysates were directly analyzed 
by  western  blot  (the  bottom  two  blots)  or  were  first  subjected  to  affinity 
chromatography  on  m
7GTP-Sepharose  and  the  bound  material  was  analyzed  by 
western blot.  
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Therefore  an  N-terminal  HA-tagged  eIF4E  was  used.  A  number  of  different 
conditions were tested to achieve a good expression level (data not shown). To verify 
that the HA-tag did not interfere with the binding of eIF4E to its partners, this HA-
tagged eIF4E was immunoprecipitated and the immunoprecipitates were analysed for 
eIF4GI, eIF4GII and 4E-BP1 (Fig. 3.15). The data in Fig. 3.15 show that HA-eIF4E 
bound to each of these three partners. Moreover, treatment with PP242 and AZD8055 
did  not  cause  a  reduction  of  the  amount  of  eIF4GI  and  eIF4GII  bound  to  eIF4E, 
suggesting that sufficient amount of eIF4E was introduced to moderate the effects of 
the dephosphorylated, and active 4E-BPs.  
Given  that  HA-eIF4E  is  able  to  bind  these  partners  in  a  similar  manner  to 
endogenous  eIF4E,  HeLa  cells  were  transfected  with  this  vector  as  well  as  a 
corresponding  empty  vector  as  the  control.  After  48  h,  rapamycin  and  mTOR-KIs 
(PP242 and AZD8055) were added to the cells for 60 min prior to lysis. The lysates 
were then applied to m
7-GTP sepharose to analyse the effect of these compounds on 
cap-bound proteins following eIF4E overexpression. In contrast to control cells (which 
received the empty vector), cells expressing HA-eIF4E showed similar levels of bound 
eIF4GI  compared to untreated cells  even when exposed to mTOR-KIs (Fig. 3.16). 
Thus, overexpressing HA-eIF4E is able to remove the inhibitory effect of mTOR-KIs 
on binding of eIF4GI to eIF4E.  
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Figure 3.15. The interaction of HA-eIF4E with eIF4Gs and 4E-BP1. 
HeLa cells were transfected with a vector encoding HA-tagged eIF4E. After 48 h, the 
cells were treated with rapamycin (100 nM), PP242 (1 μM) and AZD8055 (100 nM) 
for 60 min and then lysed. The lysates were subjected to immunoprecipitation using 
HA  antibodies;  the  immunoprecipitates  were  analyzed  by  western  blot  using  the 
indicated antibodies. The positions of the HA-tagged eIF4E and the light chain of the 
HA antibody are shown. 
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Figure 3.16. The effects of overexpressing HA-eIF4E on eIF4GI/eIF4E binding.  
Serum-fed HeLa cells were transfected with HA-tagged eIF4E (or the corresponding 
empty vector, EV). After 48 h, the cells were treated with rapamycin (100 nM), PP242 
(1 μM) and AZD8055 (100 nM) for 60 min. The lysates were subjected to m
7GTP-
Sepharose affinity assay and the bound material was analyzed by western blot using 
the indicated antibodies. 
 
 
 
 
 
 
 
 
 112 
 
Since  the  inhibition  of  eIF4F  formation  by  mTOR-KIs  was  eliminated  by 
introducing exogenous eIF4E, it was logical to compare the effects of rapamycin and 
mTOR-KIs  on  protein  synthesis  under  this  condition,  i.e.  whether  eliminating  the 
inhibitory  effects  of  mTOR-KIs  could  rescue  their  inhibition  to  protein  synthesis. 
[
35S]methionine incorporation experiments performed in HeLa cells transfected with 
HA-eIF4E or a corresponding empty vector showed that overexpressing HA-eIF4E 
significantly attenuated the small inhibitory effect of rapamycin on protein synthesis in 
control HeLa cells (-eIF4E; Fig. 3.17). In contrast, overexpressing HA-eIF4E did not 
significantly reduce the inhibition of protein synthesis caused by PP242 or AZD8055 
(Fig. 3.17). This suggests that the level of eIF4G/eIF4E binding in HeLa cells does not 
primarily account for the inhibition of protein synthesis caused by these inhibitors. 
Since rapamycin and mTOR-KIs completely block S6 phosphorylation (Fig. 3.6), the 
distinct effects of rapamycin and mTOR-KIs on protein synthesis are not due to this 
event.  As  discussed  above,  neither  is  the  difference  due  to  mTORC2  because  the 
effects of another mTOR kinase inhibitor, Torin 1, were nearly equivalent in wild-type 
and Rictor-null MEFs (Thoreen et al., 2009).  
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Figure 3.17. Effects of eIF4E overexpression on the inhibition of protein synthesis by 
mTOR inhibitors. 
HeLa cells transfected with a vector encoding HA-eIF4E (or the corresponding empty 
vector) were treated with rapamycin (100 nM), PP242 (1 μM) and AZD8055 (100 nM) 
for 60 min. [
35S]methionine was then added into the medium for labelling (60 min) and 
the incorporation of [
35S]methionine was determined as described in Materials and 
Methods  section  2.3.9.  The  data  are  derived  from  at  least  three  independent 
experiments in each case; bars indicate the standard deviation. P values between the 
two groups (-/+ eIF4E) were calculated using individual t test. Data are given ± SEM, 
n>= 4. 
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3.3 Discussion 
In this chapter, I have carried out a detailed study comparing the effects of rapamycin 
and the recently developed mTOR-KIs (AZD8055 and PP242) on mTOR signalling 
pathways. Consistent with earlier reports (Garcia-Martinez et al., 2009, Feldman et al., 
2009, Thoreen et al., 2009), mTOR-KIs exhibit a much stronger effect than rapamycin 
on  both  mTOR  complexes.  More  importantly,  they  inhibit  protein  synthesis  to  a 
substantial extent where rapamycin has almost no effect. Therefore, what is the main 
mechanism accounting for the distinct effects of rapamycin and mTOR-KIs on protein 
synthesis? Given that mTOR-KIs inhibit the rapamycin-insensitive mTORC2 (shown 
by effect on Akt phosphorylation at Ser473), the difference might be a reflection of 
mTORC2  function.  However,  the  studies  of  Thoreen  et  al.  using  another  ATP-
competitive mTOR inhibitor Torin 1 excluded this possibility, since they found that 
the effects of Torin 1 on protein synthesis were similar in wild type and Rictor null 
MEFs  which  lack  functions  of  mTORC2  (Thoreen  et  al.,  2009).  In  addition,  both 
rapamycin  and  mTOR-KIs  blocked  the  activation  of  S6Ks,  indicating  the  stronger 
effects of mTOR-KIs on protein synthesis were not due to S6Ks either.  
My  results  clearly  show  that  while  mTOR-KIs  were  effective  at  blocking  the 
phosphorylation  of  4E-BP1  on  multiple  sites,  rapamycin  did  not  block  4EBP1 
phosphorylation as completely as mTOR-KIs. Indeed, only the phosphorylation of rat-
4E-BP1  on  Ser64  was  shown  to  be  suppressed  by  rapamycin  (Fig.  3.6),  which  is 
consistent with earlier findings (Feldman et al., 2009, Garcia-Martinez et al., 2009, 
Wang et al., 2005). With respect to the activation of Akt, my data show that rapamycin 
always  stimulated  the  phosphorylation  of  Akt  on  both  Ser473  and  Thr308.  This 
reflects its lack of effect on mTORC2 and may be due to the relief of the feedback loop 
from  S6K  to  IRS1,  a  key  signalling  molecule  that  links  activation  of  the  insulin 
receptor to PI3K (Harrington et al., 2004, Um et al., 2004). In contrast to rapamycin, 
inhibition  of  both  mTORC1  and  mTORC2  by  mTOR-KIs  suppresses  rather  than 
facilitates Akt activation.  
      Consistent with the dramatic impact of mTOR-KIs on 4E-BP1 phosphorylation, 
these compounds increased the association of eIF4E and 4E-BP1 to a much greater 
extent than rapamycin. Unexpectedly, while mTOR-KIs always decreased the binding 
of  eIF4G  to  eIF4E  (i.e.  the  assembly  of  eIF4F  complex),  rapamycin  consistently 115 
 
caused a modest increase in eIF4G binding. I attempted to address this by comparing 
the effects of these inhibitors on other isoforms such as 4E-BP2 or eIF4GII. However, 
the  impact  of  these  inhibitors  remained  similar  to  that  observed  for  4E-BP1  and 
eIF4GII.  Nevertheless,  these  observations  together  with  the  activation  of  Akt  by 
rapamycin are potentially important for explaining the limited value of rapamycin as 
an effective anti-cancer drug. Therefore, it would be very important to study the effects 
of these compounds on the synthesis of specific proteins on a proteome-wide scale. I 
first  attempted  to  perform  the  isobaric  tags  for  relative  and  absolute  quantitation 
(iTRAQ) experiment to address the differences of eIF4E-bound proteins caused by the 
inhibitors. However, I did not successfully identify any new regulator which might be 
involved in the control of eIF4F assembly.      
PP242 and AZD8055, like other newly-developed mTOR-KIs (Zask et al., 2011, 
Feldman et al., 2009), exhibit strong inhibition of protein synthesis whereas rapamycin 
does not. Given the marked differences between rapamycin and mTOR-KIs on the 
formation  of  the  cap-dependent  translation  initiation  complex  eIF4F,  I  examined 
whether this difference resulted in distinct effects on protein synthesis. Introducing 
wild-type eIF4E allows the increased levels of hypophosphorylated 4E-BP1 to bind to 
extra eIF4E, thus removing the inhibition of the association between eIF4G and eIF4E 
caused  by  mTOR-KIs.  However,  in  cells  overexpressing  eIF4E,  mTOR-KIs  again 
greatly reduced the rate of general protein synthesis, indicating decreased levels of 
eIF4G/eIF4E  are  not  responsible  for  the  impact  of  these  compounds  on  protein 
synthesis. Puzzlingly, although rapamycin did not decrease the binding of eIF4G to 
eIF4E, overexpressing eIF4E recovered the modest inhibition of rapamycin on protein 
synthesis.  
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CHAPTER 4                                                    
DISTINCT EFFECTS OF RAPAMYCIN AND mTOR 
KINASE INHIBITORS ON PROTEIN SYNTHESIS 
REVEALED BY pSILAC METHOD 
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4.1 Introduction  
The experiments described in Chapter 3 addressed the different effects of rapamycin 
and  mTOR-KIs  on  mTOR  signalling  pathways  and  general  protein  synthesis.  Key 
questions remain unanswered, including whether the greater effects of mTOR-KIs on 
overall  protein  synthesis  reflect  their  bigger  effect  on  the  synthesis  of  proteins  in 
general or on the synthesis of specific proteins. Therefore, it would be very important 
to study the effects of these compounds on the synthesis of specific proteins on a 
proteome-wide scale. 
Since its invention (O'Farrell, 1975), two-dimensional (2D) gel electrophoresis has 
been  widely  used  for  differential  expression  proteomics.  This  method  separates 
proteins  through  two  systems,  isoelectric  focusing  and  polyacrylamide  gel 
electrophoresis. Coupled with staining techniques, 2D gel electrophoresis can visualize 
a large number of protein spots. However, 2D gel electrophoresis does have several 
challenges, including that some of very acidic and basic proteins will fall outside of the 
pI  (isoelectric  point)  range,  or  that  low  abundance  proteins  are  poorly  covered. 
Microarray and other current methods for analysis of system-wide gene expression 
only  detect  changes  in  mRNA  abundance  (Hoheisel,  2006).  Therefore  more 
quantitative and powerful tools on a proteome-wide scale are needed.  
    Ong et al. (2002) reported a simple, inexpensive yet accurate MS-based approach to 
expression proteomics, which is named stable isotope labelling by amino acids in cell 
culture (SILAC). SILAC utilizes stable isotope-labelled amino acids in cell medium to 
investigate cellular proteomes quantitatively. Compared to classical approaches like 
microarray,  SILAC  is  able  to  provide  new  insights  into  bioanalytical  problems 
quantitively. This approach was originally performed in mammalian cell line NIH 3T3 
and  C2C12  (Ong  et  al.,  2002),  which  were  grown  in  medium  lacking  a  standard 
essential amino acid but supplemented with a non-radioactive, isotopically labelled 
amino acid. Ong et al. (2002) found no difference between growth of these cells and 
those in normal medium (as proved by doubling time, ability to differentiate and cell 
morphology).  More  importantly,  the  complete  incorporation  of  the  isotopically 
labelled amino acid into the cells can be achieved after 5 rounds of cell divisions (Ong 
et al., 2002). Using this strategy, Ong et al. (2002) studied the process of muscle cell 
differentiation and found that glyceraldehyde-3-phosphate dehydrogenase, fibronectin, 
and pyruvate kinase M2 were up-regulated in this process. After that, SILAC has been 118 
 
diversely  used  in  other  systems  such  as  yeast  (Jiang  and  English,  2002),  bacteria 
(Kerner et al., 2005) and plants (Gruhler et al., 2005). A schematic of typical SILAC 
protocol is presented in Fig. 4.1.  
As shown in Fig. 4.1, cells growing in normal DMEM are split into two culture 
dishes, each containing light (L) or heavy (H) SILAC medium respectively. Cells are 
subcultured in their respective SILAC medium 5-6 times until full incorporation has 
been  achieved.  Treatments  are  added  to  one  cell  population  to  induce  a  different 
response between the control and experimental cell populations. Cells are then lysed 
and equal amounts of proteins from heavy-labelled and light-labelled cells are mixed. 
Subsequent fraction procedure is performed to produce peptide mixtures which are 
suitable for MS analysis. 
The SILAC method has also been applied to measure protein turnover (Doherty et 
al., 2005, Pratt et al., 2002, Milner et al., 2006). However, as we known, the rates of 
protein turnover is a reflection of both synthesis and degradation. So a high H/L ratio 
could be either due to the high translation rate of a stable protein or the low translation 
rate  of  a  rapidly  degraded  protein.  To  directly  compare  translation  rates  without 
interference  from  degradation,  Selbach  and  colleagues  developed  a  new  pulsed 
labelling strategy, pSILAC  (Schwanhausser  et  al., 2009).  Instead of labelling cells 
with several rounds of doubling for a few days, they only cultivated the cells in the 
SILAC  medium  with  isotopically  labelled  amino  acids  for  a  few  hours  and  then 
subjected the cell lysates to MS analysis.  Fig. 4.2 describes the workflow of their 
pSILAC approach. Based on this pulsed-labelling method, the differences in protein 
stability could be ignored since pre-existing proteins remain labelled with the ―L‖ form 
of amino acids. It is likely that newly synthesized proteins could also be affected by 
degradation. However, this can be ignored because this degradation will occur equally 
in both the ―M‖ and ―H‖ labelled proteins (Fig. 4.2). Therefore H/M ratios in this 
method can provide accurate information about the synthesis rate of a specific protein.  
In summary, SILAC provides relative quantification in proteomics while pSILAC 
directly  detects  changes  at  the  translation  level  without  interference  from  protein 
degradation. Given the increasing interest in the regulation of translation, SILAC and 
pSILAC can be diversely applied to a wide range of biological questions.  
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Figure 4.1. An overview of a typical SILAC protocol. 
Cells are first grown in normal DMEM and then transferred into light (L) or heavy (H) 
SILAC  medium  until  cells  have  fully  incorporated  the  isotoplabelled  amino  acids. 
After the adaptation, the two cell populations are differentially treated and mixed. A 
subproteome can be digested to peptides with trypsin and then analyzed by MS for 
protein identification and quantification. m/z: the mass to charge ratio. 
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Figure 4.2. The pSILAC approach (Schwanhausser et al., 2009). 
Cells  growing  in  ―light‖  (L)  medium  are  either  transferred  into  ―heavy‖  (H)  or 
―medium heavy‖ (M) SILAC medium. From this time point on, cells are pulse-labelled 
because all newly synthesized proteins incorporate either the ―H‖ or the ―M‖ amino 
acids, and pre-existing proteins remain labelled in the ―L‖ amino acids. After this short 
labelling phase (a few hours), the two cell populations are equally mixed and analyzed 
by MS. The ratio of peak intensities of H versus M peptides is a direct reflection of 
differences in synthesis rates of the corresponding protein. m/z: the mass to charge 
ratio 
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4.2 Results 
4.2.1 Polysome-microarray analyses 
DNA microarray is the most classical and useful way to measure the level of mRNAs 
and investigate the translation regulation. Therefore, I first applied this approach to 
study the distinct effects of mTOR inhibitors.  HeLa cells were treated with rapamycin, 
PP242 and AZD8055 for 2 h (as used in [
35S] methionine incorporation experiments) 
and were subjected to sucrose gradients and polysome profile analyses in School of 
Pharmacy, University of Nottingham (with the kind help from Dr. Lindsay Wilson, Dr. 
Martin  Bushell  and  Professor  Anne  Willis,  University  of  Leicester,  UK).  The 
polysome profiles are presented in Fig. 4.3. In these profiles, a substantial proportion 
of the total mRNA was located in the polysomes in HeLa cells growing in serum (Fig. 
4.3,  control).  Rapamycin  only  caused  a  slight  shift  of  the  polysomes  into 
subpolysomes compared to the control (Fig. 4.3, rapamycin). In contrast, PP242 and 
AZD8055 strongly decreased the size of the peaks of polysomes (Fig. 4.3, PP242, 
AZD8055),  implying  that  mTOR-KIs  have  much  greater  inhibitory  effects  on 
translation than rapamycin. This finding is consistent with the general protein synthesis 
data (Fig. 3.12), which is that rapamycin only decreased protein synthesis by around 
10% after 2 h treatment, while mTOR-KIs have a much stronger effect (around 30%). 
RNA was then extracted from sucrose gradients and pooled into subpolysomal or 
polysomal  fractions.  Fluorescently  labelled  DNA  probes  were  generated  and 
hybridised to the human cDNA microarrays (with the help of Dr. Lindsay Wilson, 
University of Leicester, UK). Surprisingly, after the initial data analysis, a number of 
mRNAs encoding ribosomal proteins such as rpLP1, rpLS2L1, rpL39L1, rpL17 and 
rpL2L3 whose translation are known to be suppressed by rapamycin (Jefferies et al., 
1994, Jefferies et al., 1997, Terada et al., 1994, Grolleau et al., 2002), were found to 
be more loaded onto polysomes after 2 h treatment by rapamycin. In order to confirm 
this  and  also  obtain  more  information,  further  analysis  of  the  microarray  data  is 
currently being performed by Dr. Lindsay Wilson. However, for the studies performed 
in this thesis, another approach was required to further study the effects of mTOR 
inhibition  on  the  synthesis  of  specific  proteins,  especially  ribosomal  proteins  on  a 
proteome-wide scale. 
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Figure 4.3. Polysome profiles. 
HeLa cells growing in serum were treated by rapamycin (100 nM), PP242 (1 μM) and 
AZD8055  (100  nM)  for  2  h  before  harvesting.  Cell  lysates  were  then  centrifuged 
through sucrose gradients. Eleven fractions were collected from each gradient while 
recording the absorbance profile. More details and subsequent microarray analysis are 
described in Materials and Methods section 2.4.4. 
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4.2.2  pSILAC analysis reveals qualitative differences in the effects of mTOR-KIs and 
rapamycin on the synthesis of specific proteins.  
As described earlier, SILAC is a simple but powerful approach for the accurate relative 
quantification by proteomics. It has been recently adapted to measure protein synthesis 
rates in response to iron (Schwanhausser et al., 2009). In this case, the proteins in 
experimental samples are pulsed labelled with heavy amino acids with simultaneous 
addition of irons. Control cells are pulsed labelled with medium amino acids in parallel 
without addition of iron. We therefore applied this method to tag newly-synthesized 
proteins and identify their changes in the rates of synthesis which may be affected by 
mTOR inhibitors. However, this method reported by (Schwanhausser et al., 2009) was 
not designed for examining the effects of different inhibitors on protein synthesis. As 
the aim was to investigate the difference between rapamycin and mTOR-KIs, it was 
necessary to combine treatments of these compounds with different forms of amino 
acids labelling. Thus, a modified protocol was applied in the experiments (Fig. 4.4).   
As shown in this protocol, HeLa cells are first incubated in normal DMEM and then 
transferred to the SILAC medium containing heavy lysine and arginine isotopologs 
together with the relevant compounds for short periods of time (a few hours). Control 
HeLa cells are also transferred to heavy SILAC medium but without the addition of the 
compounds. This short labelling time allows the tagging of only newly-synthesized 
proteins by the heavy isotopes of the amino acids, as the pre-existing proteins remain 
in the light form. After the labelling phase, cells are lysed and proteins are digested 
with trypsin which cleaves after arginine and lysine. Peptides are analysed by mass 
spectrometry. As shown in Fig. 4.4B, the proportions of the two variants (heavy/light) 
provide  information  about  the  relative  rates  of  synthesis  of  the  specific  protein. 
Multiple peptides from the same protein are analysed to derive accurate information 
about their rates of accumulation. 
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Figure 4.4. Cartoon of the pSILAC method applied in this thesis. 
(A)  HeLa  cells  previously  maintained  in  normal  medium  are  placed  in  medium 
containing stable isotope-labelled arginine and lysine. After a pulse labelling period of, 
e.g., 2-6 h, cells are lysed, proteins are subjected to tryptic digestion and then analysed 
by mass spectrometry. (B) Two species are observed for any given tryptic peptide, one 
with normal amino acids that are not labelled (L; ‗untagged‘), and one with heavy 
arginine and/or lysine (H; ‗tagged‘). The ratio of tagged to untagged peptides reflects 
the relative rate of synthesis of the studied protein; data from multiple peptides from 
the same protein are averaged. Triplicate experiments are performed independently for 
final data analysis. 
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Together with Dr Valentina Iadevaia, a number of different labelling times from 2 h 
to 6 h were tested. 2 h was first chosen based on the [
35S]methionine incorporation 
experiments. The longer time 6 h gave a higher proportion of labelled peptides and 
ability  to  provide  more  accurate  and  quantifiable  data  than  labelling  for  2  h. 
Importantly, treating cells with rapamcyin or mTOR-KIs for 6 h had similar effects as 
2 h treatment on general protein synthesis (Fig. 3.12 and Fig. 4.5). As seen in Fig. 4.5, 
rapamycin has almost no effect while PP242 and AZD8055 have very strong inhibitory 
effect on protein synthesis. Therefore, 6 h labelling time was chosen as the one used in 
the experiments.  
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Figure 4.5. Effect of prolonged treatment with rapamycin or mTOR-KIs on [
35S] 
methionine incorporation.  
HeLa cells were treated with rapamycin (100 nM), PP242 (1 μM) and AZD8055 (100 
nM) for 6 h. [
35S]methionine was then added into the medium for the final 1 h. Cells 
were lysed and 30 μg of lysates were added to 3 MM filter paper. The incorporation of 
[
35S]methionine was determined as described in Materials and Methods section 2.3.9. 
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Together with Dr Valentina Iadevaia, we labelled and treated serum-fed HeLa cells 
with  rapamycin  and  mTOR-KIs  based  on  the  protocol  shown  in  Fig.  4.4.  After 
denatured at 95°C, the lysates were sent to University of British Columbia, Canada and 
analysed by MS by Dr Leonard J. Foster‘s group. Generally, our pSILAC data reveal 
that  mTOR-KIs  had  a  particularly  striking  effect  on  the  synthesis  of  a  number  of 
proteins. Among this set of proteins, those encoded by 5‘-TOP mRNAs are prominent. 
The  pie  chart  data  presented  in  Fig.  4.6  show  that  PP242  and  AZD8055  strongly 
inhibited the synthesis of proteins encoded by 5‘-TOP mRNAs in serum-fed HeLa 
cells. As seen in this figure, the synthesis of the great majority of this set of proteins 
was inhibited by more than 50% by PP242 and AZD8055. Similarly, the majority of 
the  most  inhibited  proteins  by  mTOR-KIs  were  those  encoded  by  known  5‘-TOP 
mRNAs, except NAP1L1 which will be discussed later (Table 4.1).  
In  contrast  to  the  profound  effects  of  mTOR-KIs,  rapamycin  inhibited  their 
synthesis much more weakly. In fact, inhibition by more than 50% by rapamycin was 
only observed for a small proportion of the 5‘-TOP mRNA-encoded proteins (Fig. 
4.6). The inhibitory effects of rapamycin on more than half of the 5‘-TOP mRNA-
encoded proteins analysed were less than 50%, while the translation of a significant 
proportion  of  such  proteins  only  decreased  by  less  than  20%.  The  most  inhibited 
protein by rapamycin is rpS3A (60%), which is much more inhibited by PP242 (89%). 
With respect to those proteins that are not encoded by 5‘-TOP mRNAs, PP242 and 
AZD8055 had a much smaller effect in general. As shown in Fig. 4.6, the synthesis of 
the  majority  of  this  type  of  mRNAs  (non-TOPs)  was  inhibited  by  less  than  50%. 
Rapamycin also had less effect on this set of proteins. In line with this, the ten least 
inhibited proteins by each compound were those encoded by non-TOP mRNAs (Table 
4.1).  Table  4.1  also  shows  that  PP242  always  had  slightly  greater  effects  than 
AZD8055 on the synthesis of individual protein, which is consistent with its bigger 
effects  on  general  protein  synthesis.  For  example,  the  synthesis  of  RPS17  was 
decreased by PP242 by 85%, which was stronger than effect of AZD8055 (77%; Table 
4.1). The Transcription Start Site (TSS) of individual protein in Table 4.1 was also 
annotated  according  to  the  searching  results  from  the  DataBase  of  human 
Transcriptional Start Sites and full-length cDNAs (DBTSS; http://dbtss.hgc.jp) (Suzuki 
et al., 2002). It can be seen that the transcripts of ribosomal proteins and translation 
factors in Table 4.1A start with a sequence of polypyrimidines.  
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Figure 4.6. pSILAC data. 
This  figure  shows  the  degree  of  inhibition  by  the  three  different  inhibitors  used 
(rapamycin,  PP242  and  AZD8055).  5‘-TOP:  proteins  encoded  by  known  5‘-TOP 
mRNAs; non-TOP: proteins not to be encoded by known 5‘-TOP mRNAs. 
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Table 4.1 Proteins whose synthesis is most (A) or least (B) inhibited by each 
compound (PP242, AZD8055 or rapamcyin) as revealed by the pSILAC method. 
A 
Proteins whose synthesis is most inhibited by each compound (PP242, AZD8055 or rapamycin) as revealed by the pSILAC method 
PP242  AZD8055  Rapamycin 
Gene 
symbols 
Transcription 
start site
1 
(DBTSS) 
Inhibition 
by  
PP242 
Gene 
symbols 
Transcription  
start site
1 
(DBTSS) 
Inhibition 
by 
AZD8055 
Gene 
symbol-
s 
Transcription  
start site
1 
(DBTSS) 
Inhibition 
by  
rapa 
RPS3A  CCCTTTT  89%  EEF1A1  CTTTTTCG  82%  RPS3A  CCCTTTT  60% 
RPS17  CTGTTTCCTCTTTT  85%  EEF2  CTCTTCC  82%  RPS5  CTCTTCCT  59% 
EEF2  CTCTTCC  83%  RPS17  CTGTTTCCTCT
TTT 
77%  RPS9  CTCTTTCTC  55% 
RPS5  CTCTTCCT  82%  RPS5  CTCTTCCT  76%  EEF1G  CCTTTCTTT  54% 
RPS20  CTTTTT  81%  RPS19  CCTTTCCCCT  76%  RPS20  CTTTTT  52% 
RPS19  CCTTTCCCCT 
 
80%  RPLP0  CCTTCTCTC  75%  CLIC1  AGAGG  52% 
RPLP2  CCTTTTCCTC 
 
78%  RPS16  CCTTTTCC  75%  HNRP
DL 
AGAAGC  52% 
RPLP1  CCCTTTCCTC  78%  RPS9  CTCTTTCTC  75%  EEF2  CTCTTCC  51% 
RPS14  CTCTTTCC 
 
78%  RPLP2  CCTTTTCCTC  74%  RPL7A  CTCTCTCCT
CCC 
51% 
RPL6  CTCTTTCCC  77%  NAP1L1  CTTTTT  74%  RPS4X  CCTCTTTCC
TT 
51% 
B 
Proteins whose synthesis is least inhibited by each compound (PP242, AZD8055 and rapamycin) as revealed by the pSILAC method 
PP242  AZD8055  Rapamycin 
Gene 
symbols 
Transcription  
start site
1 
(DBTSS) 
Inhibition 
by  
PP242 
Gene 
symbols 
Transcription  
start site
1 
(DBTSS) 
Inhibition 
by 
AZD8055 
Gene 
symbols 
Transcription  
start site
1 
(DBTSS) 
Inhibition 
by  
rapa 
PCNA  ACTGAG  9%  BCLAF1  ATCGGA  0.1%  ARF1  AGAGCC  0.2% 
SPTAN1  gccACTACCC  11%  RBBP7  GAGAGA  6%  ALDOA  AAAAGGG  0.8% 
MYH9  AAAGTC  19%  RCN1  GACGTG  7%  UBQLN1  AATTTC  0.8% 
HIST1H1
B 
TCTTGA  20%  HMGB2  AAACCA  8%  YWHAZ  TTCCGG  0.8% 
VIM  GTCCCC  24%  TCOF1  GGGGCG  11%  HMGB2  AAACCA  1% 
HPRT1  GAACCT  26%  PARK7  GCAGTG  12%  CD44  GAATAA  2% 
ALDOA  AAAAGG  27%  CPS1  tAAAAT  15%  BCLAF1  ATCGGA  3% 
VCP  AGTCTC  29%  HIST1H1
B 
TCTTGA  15%  VCP  AGTCTC  4% 
MARCK
S 
ACTTGG  31%  FLNB  AGAGCA  17%  BASP1  AGTAGC  4% 
CPS1  tAAAAT  31%  HIST1H4
K 
GTAAAC  17%  PSME1  GCTTT  7% 
1.  TSSs are searched from DBTSS (http://dbtss.hgc.jp/).  Lower case letters indicate a less 
common reported start site 130 
 
To clearly show the distinct effects of mTOR inhibitors on the proteins encoded by 
5‘-TOP  or  non-TOP  mRNAs,  data  for  selected  proteins  from  these  two  sets  are 
presented in Fig. 4.7. The regulation of several proteins known to be encoded by TOP 
mRNAs,  such  as  ribosomal  proteins  (RPs),  elongation  factors  (eEFs)  and  the 
heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) are included in this list.  As 
seen in Fig. 4.7A, PP242 or AZD8055 caused very strong inhibition (often more than 
70%; red or black bars) whereas rapamycin always had a much smaller effect (often 
less than 50%; blue bars). For example, the accumulation of 40S ribosomal protein S3 
(rpS3) was inhibited by PP242 and AZD8055 by more than 70%. Rapamycin only 
decreased the synthesis of this protein by less than 20% (Fig. 4.7A). For non-TOP 
mRNAs,  as  illustrated  in  Fig.  4.7B,  rapamycin  typically  inhibited  their  protein 
synthesis by around 20%. The reduction caused by PP242 or AZD8055 was often less 
than 50%. These data (Fig. 4.6 and Fig. 4.7) thus define a clear difference between the 
behaviour of these two sets of proteins (TOP and non-TOP mRNAs) and between the 
effects of rapamycin and mTOR-KIs. 
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Figure 4.7.  The relative rates of synthesis of selected proteins revealed by pSILAC. 
(A) and (B) show the relative rates of synthesis (H/L ratio) of selected proteins in each 
category, 5‘-TOP and non-TOP; data are derived from three independent experiments, 
and given as mean + SEM (n = 3).  
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Unexpectedly but interestingly, mTOR-KIs and rapamycin also strongly inhibited 
the  synthesis  of  several  proteins  which  are  not  known  to  be  encoded  by  5‘-TOP 
mRNAs (Fig. 4.8 and Table 4.1). This group included nucleosome assembly protein 1-
like  1  (NAP1L1),  nascent  polypeptide-associated  complex  alpha  subunit  (NACA), 
peroxiredoxin 6 (PRDX6), transketolase (TKT), heat shock 70 kDa protein 8 (HSPA8), 
heterogeneous nuclear ribonucleoprotein C (HNRNPC) and L-lactate dehydrogenase B 
(LDHB). Actually, the behaviour of these proteins appears similar to those of known 
5‘-TOP mRNA products. It is therefore of interest to examine the transcription start 
site (TSS) of each gene in this group. Searching the data from the DataBase of human 
Transcriptional Start Sites and full-length cDNAs (DBTSS; http://dbtss.hgc.jp) (Suzuki 
et al., 2002) showed that the mRNAs for NAP1L1, NACA, PRDX6 and LDHB start 
with a sequence of at least 5 pyrimidines (Table 4.2). This structural feature is one of 
the  canonical  hallmarks  of  5‘-TOP  mRNAs,  suggesting  that  these  mRNAs  might 
belong to this subset of messages. Others in Table 4.2 including HSPA8, HNRNPC 
and TKT also start with a cytosine but this is not followed by an uninterrupted stretch 
of several pyrimidines (Table 4.2).  
Many of these proteins in Table 4.1 play roles in different aspects of cell physiology. 
For  example,  nucleosome  assembly  proteins  (NAPs)  are  initially  identified  as 
chaperones  and  nucleosome  assembly  factor  while  this  family  has  been  recently 
implicated in a large variety of other cellular functions, such as transcription, nuclear 
import and lysine biosynthesis (Laskey et al., 1978, Zlatanova et al., 2007). Another 
example,  NACA,  is  known  to  bind  newly  synthesised  peptides  emerging  from 
ribosomes  and  thus  block  their  inappropriate  interaction  with  the  endoplasmic 
reticulum (ER) (Lauring et al., 1995, Wiedmann et al., 1994). Further studies suggest 
that NACA also plays a role in cell proliferation and apoptosis (Stilo et al., 2003, 
Quelo et al., 2004). 
Our pSILAC data reveal that mTOR-KIs exhibit different effects on the synthesis of 
several  members  of  the  HnRNP  family.  They  strongly  inhibited  the  synthesis  of 
HnRNP A1 and HnRNP C whereas they only weakly or hardly affected the synthesis 
of HnRNP A3, K, M, A2/B1 (Fig, 4.7, 4.8 and 4.14). Among this family, only the 
mRNA for HnRNP A1 is a known 5‘-TOP message. However, as mentioned above, 
HnRNP  C,  whose  synthesis  is  largely  reduced  by  mTOR  inhibitors,  does  have  an 
unusual 5‘-terminal sequence (rich in pyrimidines; Table 4.2). 
 133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Selected proteins whose synthesis is particularly strongly affected by 
mTOR-KIs. 
The effects of rapamycin and mTOR-KIs on the relative rates of synthesis (H/L ratio) 
of selected proteins are displayed as mean +SEM. In each case, data are derived from 
three independent experiments. 
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Table  4.2.  Proteins  whose  synthesis  is  significantly  inhibited  by  mTOR-KIs 
(PP242 and AZD8055) or rapamycin as revealed by the pSILAC method.  
 
Gene Symbols 
 
Transcription start 
site
1 
 
 
Inhibition 
by  
PP242  
 
Inhibition 
by 
AZD8055  
 
Inhibition 
by 
Rapamycin  
 
Functions 
(provided by NCBI database) 
 
NAP1L1 
 
CTTTTT 
 
57% 
 
74% 
 
46% 
The protein encoded by this gene 
may be involved in modulating 
chromatin formation and regulating  
cell proliferation 
 
NACA 
 
tCTTTCTG 
 
75% 
 
64% 
 
32% 
NACA prevents nascent ribosome-
associated polypeptides from 
inappropriate interactions with 
cytosolic proteins. 
 
 
 
PRDX6 
 
 
 
cTTCTTC 
 
 
 
50% 
 
 
 
55% 
 
 
 
26% 
PRDX6 is involved in redox 
regulation of the cell. It may be also 
involved in the regulation of 
phospholipid turnover and in 
protection against oxidative injury. 
 
 
 
TKT 
 
 
 
CTCGGC 
 
 
 
69% 
 
 
 
64% 
 
 
 
33% 
In mammals, TKT connects the 
pentose phosphate pathway to 
glycolysis. It plays a role in the 
channeling of excess sugar 
phosphates into the main 
carbohydrate metabolic pathways 
 
 
HSPA8 
(also known as 
Hsc70) 
 
 
 
tCTCATTG 
 
 
 
53% 
 
 
 
59% 
 
 
 
42% 
HSPA8 belongs to the heat-shock 
cognate subgroup of the heat shock 
protein 70 family. It binds to 
nascent polypeptides to facilitate 
correct protein folding and  also 
functions as an ATPase 
 
 
 
HNRNPC 
 
 
 
CCATTTTGT 
 
 
 
53% 
 
 
 
38% 
 
 
 
28% 
HNRNPC belongs to the subfamily 
of heterogeneous nuclear 
ribonucleoproteins (hnRNPs). It 
binds pre-mRNA and is involved in 
the assembly of 40S hnRNP 
particles 
 
 
LDHB 
 
 
CTTGC 
 
 
61% 
 
 
42% 
 
 
27% 
The enzyme encoded by this gene 
catalyzes the reversible conversion 
of lactate and pyruvate, and NAD 
and NADH, in the 
glycolytic pathway. 
                                                 
1. Lower case letters indicate a less common reported start site.  135 
 
4.2.3 Analysis of the behaviour of specific mRNAs by real-time PCR and Northern blot 
Subsequently,  it  is  important  to  examine  the  behaviour  of  specific  mRNAs,  i.e. 
validation of the microarray and pSILAC data.  Real-time RT-PCR (also called qPCR) 
and Northern blot are the common approaches to perform gene expression analysis. 
4.2.3.1 Analysis by real-time PCR  
First, the behaviour of specific mRNAs in the microarray samples was examined using 
real-time  RT-PCR.  Relative  quantification  (Comparative  CT  Method  Quantitation) 
was used for data analysis. When using this method, the expression of a target gene 
needs to be normalised relative to the expression of an endogenous control gene, which 
should be expressed at a constant level across all sample groups in a study, and should 
not be influenced by treatments or conditions. As mentioned in Section 4.2, RNAs 
from  11  fractions  were  pooled  into  subpolysomal  (Subs)  or  polysomal  (Polys) 
fractions, based on the polysome profiles (Fig. 4.3). Several genes were tested in order 
to find a good endogenous control including 18S rRNA, GAPDH and β-actin. Fig. 4.9 
shows the amplification plots for 18S rRNA. As shown in Fig. 4.9, treatment with 
PP242 and AZD8055 strongly affected the distribution of 18S in the subpolysomal and 
polysomal samples. Similar results occurred for GAPDH and β-actin, suggesting that it 
is difficult to find an endogenous control gene whose expression is not affected by 
mTOR-KIs. 
We therefore adopted the standard curve method arguing that the relative expression 
of a specific gene can be assessed via the standard curve assay. As shown in Fig. 4.10, 
although β-actin amplified nicely against serial dilutions of cDNAs cloned from total 
RNA (Fig. 4.10B), the polysomal samples treated with AZD8055 failed to amplify 
(Fig. 4.10A). Other genes such as GAPDH were also examined using this method, but 
similar  results  occurred  (data  not  shown).  Although  real-time  RT-PCR  is  a  highly 
sensitive technique, the samples from microarray are not suitable for real-time PCR 
analysis. Hence, alternative approaches (for example, Northern blot) are required. 
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Fig. 4.9 Amplification plots of 18S against cDNAs derived from RNA from the 
microarray experiments. 
cDNAs  were  synthesized  using  RNA  samples  from  the  microarray  experiments 
described in section 4.2.1. The methods of reverse transcription and real-time RT PCR 
are described in Materials and Methods section 2.4.2 and 2.4.3. Subs: subpolysome 
fractions; Polys: polysome fractions. Arrows indicate different treatment. 137 
 
 
 
 
 
 
Fig. 4.10. Amplification of β-actin. 
Amplification of β-actin against (A) cDNAs derived from the polysome RNA from the 
microarray experiments described in section 4.2.1 or (B) serial dilutions of cDNAs 
cloned from total RNA. The methods of reverse transcription and real-time RT PCR 
are  described  in  Materials  and  Methods  section  2.4.2  and  2.4.3.  Polys:  polysome 
fractions. Arrows indicate different treatment. 138 
 
4.2.3.2  Analysis by Northern blot 
With the help of Dr. Valentina Iadevaia, Northern blot analysis was then performed to 
examine the behaviour of specific mRNAs. First, the effects of short treatment (2 h) 
with mTOR inhibitors on various mRNAs were studied. Fig. 4.11 gives a simplified 
work flow.  
DNA probes were prepared for:  (1) known TOP mRNAs (rpL11); (2)  non-TOP 
mRNAs (β-actin); (3) possible ―new-TOP‖ mRNAs (PRDX6). The blots are presented 
in Fig. 4.12. It can be observed that: (1) treatment with rapamycin and mTOR-KIs 
caused the association of most of rpL11 mRNA with subpolysomes; (2) β-actin mRNA 
is mainly associated with polysomes in control and rapamycin-treated cells. AZD8055 
and PP242 caused a partial decrease of the amount of this mRNA associated with 
polysomes;  (3)  the  polysomal  distribution  of  PRDX6  was  not  greatly  affected  by 
rapamycin but shifted strongly to the subpolysomes by treatment with AZD8055 and 
PP242.  
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Figure 4.11. Northern blot protocol. 
HeLa cells growing in serum were incubated with rapamycin (100 nM), PP242 (1 μM) 
or AZD8055 (100 nM) for 2 h and then lysed directly on the plate with 300 μL of 
TNM lysis buffer. The lysates were then centrifuged for 5 min at 16,000 g at 4°C. The 
supernatant was transferred to a new tube in the presence of 3 μL heparin (10 μg/μL), 
frozen in liquid nitrogen and stored in -80 ℃ for later analysis. Lysates were resolved 
into polysomal and non-polysomal fractions by sucrose density gradient centrifugation 
and the absorbance at 254 nm was recorded. Nine fractions were collected from each 
gradient. The extracted RNA was then analysed by Northern blot. See Materials and 
Methods section 2.4.5 for details. 
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Figure 4.12. Northern blot data (2 h treatment). 
Serum-fed HeLa cells were treated with rapamycin (100 nM), AZD8055 (100 nM) and 
PP242  (1  μM)  for  2  h.  Northern  blots  were  performed  on  RNA  extracted  from 
fractions separated by sucrose density gradients. The fractions of subpolysomes and 
polysomes are indicated on the blot. 
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  As mentioned before, a number of different labelling times from 2 h to 6 h were 
tested in pSILAC experiments. The longer time 6 h was selected since it gave a higher 
proportion of labelled peptides and ability to provide more accurate and quantifiable 
data  than  labelling  for  2h.  Therefore,  in  line  with  the  conditions  used  in  pSILAC 
experiments, prolonged treatment was then performed in Northern blot analysis. HeLa 
cells  were  treated  with  rapamycin,  PP242  or  AZD8055  for  6  h.  Judging  from  the 
polysome profile of 6 h (Fig. 4.13), treatment with rapamycin for 6 h had minor effect 
on the distribution of mRNAs in polysomes. In contrast, both AZD8055 and PP242 
caused a huge rise in the peaks of level of 80S monomers (Fig. 4.13), implying a more 
substantial inhibition of translation initiation. 
Based on the pSILAC results, it is of high interest to investigate the behaviour of 
mRNA from different groups, i.e. known 5‘-TOP, non-TOP and possible ―new TOP‖ 
mRNAs (Table 4.2). Therefore, the polysomal distribution of rpS19 was studied as a 
typical 5‘-TOP mRNA. β-actin and hnRNP A3 were selected as non-TOP mRNAs. 
More  importantly,  some  of  the  genes  in  Table  4.1  whose  translation  was  strongly 
inhibited by mTOR inhibitors contain a TOP-like stretch in their 5‘-end. Therefore, it 
is important to evaluate the effect of prolonged treatment with mTOR inhibitors on 
their polysome association using Northern blot. NAP1L1 and PRDX6 were chosen as 
possible candidates for ―TOP‖ mRNAs.   
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Figure 4.13. Polysome profiles (6 h treatment). 
Serum-fed HeLa cells were treated with rapamycin (100 nM), AZD8055 (100 nM), or 
PP242 (1 μM) for 6 h. Lysates were fractionated on sucrose density gradients. The 
positions  of  80S  ribosomal  particles  and  polysomes  are  labelled;  arbitrary  units 
represent absorbance values at 254 nm which are on the same scale for each panel.  
Detailed procedures are described in Materials and Methods section 2.4.5. 
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As seen in Fig. 4.14A and C, the distribution of the HnRNPA3 mRNA remained 
unchanged  after  treatment  of  cells  with  various  mTOR  inhibitors,  showing  that 
blocking   mTOR  activity  does  not  impair the translation of this  non-TOP  mRNA. 
mTOR inhibitors did modestly affect the polysomal distribution of the β-actin mRNA 
(Fig.  4.14A,  B).  In  contrast,  the  synthesis  of  the  known  TOP  mRNA  rpS19  was 
strongly blocked by either rapamycin or mTOR-KIs (Fig. 4.14A, D). In fact, AZD8055 
and PP242 caused a much more pronounced accumulation of the signals in the non-
polysomal fractions than rapamycin. The distinct effect of rapamycin and mTOR-KIs 
on  the  polysomal  distribution  of  5‘-TOPs  and  non-TOPs  agrees  with  the  previous 
finding that they had larger effects on the synthesis of proteins encoded by 5‘-TOP 
mRNAs revealed by pSILAC approach (Fig. 4.6), and more importantly, it suggests 
that  a  rapamycin-insensitive  component  may  be  involved  in  the  regulation  of  the 
translation of this subset of mRNA (5‘-TOP) by mTOR signalling. 
Prompted by the results in Fig. 4.8 and Table 4.1, the distribution of the mRNAs for 
PRDX6  and  NAP1L1  was  also  investigated.  Consistent  with  the  pSILAC  data, 
rapamycin caused a partial shift of the PRDX6 mRNA out of the polysomal fractions 
but mTOR-KIs had a much greater effect (Fig. 4.8; Fig. 4.14A, E). For NAP1L1 (Fig. 
4.8; Fig. 4.14A, F), its behaviour is more similar to that observed for rpS19, again 
consistent with the possibility that the mRNA for NAP1L is a new 5‘-TOP mRNA.  
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Figure 4.14. Northern blot data (6 h treatment). 
Northern blots were performed on RNA extracted from fractions shown in Fig. 4.13. 
(A) is the Northern blot data for the mRNAs indicated; (B-F) show quantitation of the 
signals as % of total of each mRNA detected on the blot (in each fraction). In (A), the 
positions of the ribosomal particles and polysomes are labelled. 
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4.2.4 Protein breakdown analysis by SILAC approach  
As we know, protein turnover is affected by both the rate of synthesis and degradation. 
Therefore,  a  modified  SILAC  approach  was  used  to  study  the  effects  of  mTOR 
inhibition by these compounds on the degradation of specific proteins. The protocol of 
this experiment is given in Fig. 4.15. 
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Figure 4.15.  A modified SILAC approach for protein breakdown analysis. 
Two sets of HeLa cells were grown in the SILAC medium either containing heavy-
labelled (H) or medium-labelled (M) Arg and Lys. Cells were passaged five to six 
times in the above medium. The heavy-labelled cells were then moved into the SILAC 
medium containing normal Lys/Arg (L) and treated with the indicated inhibitors for 6 
h. In this mode, the medium-labelled samples act as internal control for the heavy-
labelled ones; the ratio of heavy: medium (H/M) versions of given peptides  yields 
information on the relative rates of decay of the pre-existing ‗heavy‘ version of the 
specific protein.  
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The final data for analysis were obtained in triplicate for all four conditions (control, 
rapamycin, AZD8055 and PP242) from multiple peptides derived from each of more 
than 300 proteins.  Fig.  4.17 shows the H/M  ratios  for  selected proteins which are 
known to be encoded by 5‘-TOP mRNAs, including various ribosomal proteins (RPs) 
and eukaryotic elongation factors (eEFs). 
As seen in Fig. 4.16, it is clear that rapamycin and mTOR-KIs modestly increased 
the  H/M  ratios  of  these  proteins,  suggesting  that  inhibition  of  mTOR  activities 
influences  the  levels  of  proteins  via  decreasing  the  rates  of  synthesis  rather  than 
accelerating the rates of degradation. From the H/M ratios, the average half-life can be 
calculated  (Table  4.3).  The  data  for  AZD8055  are  shown,  not  PP242.  Overall, 
AZD8055  had  a  stronger  effect  than  rapamycin  on  half-life  of  proteins  from  each 
category. As seen in Table 4.2, the average protein half-life was about 19 h. AZD8055 
extended the average to 22 h while rapamycin  slightly increased it (to 19.8 h).  In 
general, proteins not encoded by known 5‘-TOP mRNAs have shorter half-lives than 
those  encoded  by  known  5‘-TOP  mRNAs  (Table  4.3).  Interestingly,  although 
rapamycin only had a small effect on overall protein stability, it substantially increased 
the half-lives of this set of proteins (encoded by known 5‘-TOP mRNAs), from 22.7 to 
27.2 h. Remarkably, AZD8055 did so to a much greater extent (from 22.7 to 32.4 h; 
Table 4.3).  
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Figure 4.16. The H/M ratio of selected 5‘-TOP mRNA encoded proteins  
Data  are  given  as  mean  SEM  (n  =  3).  In  each  case,  data  are  derived  from  three 
independent experiments. 
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Table 4.3. Effects of mTOR inhibition on protein half-lives which are converted form 
SILAC data. In each category, proteins with triplicate SILAC data were chosen and 
analysed. The data are displayed as average +SEM. 
Condition  Average t½ 
(h) 
All 
Average t½ 
(h)  
Proteins 
encoded by 
known  
5‘-TOPs 
Average t½ 
(h)  
Proteins  
not encoded by 
 known  
5‘-TOPs 
Control  18.9+ 0.33  22.7 + 1.02  18.5 + 0.45 
Rapamycin  19.8+ 0.42  27.2 + 2.08  18.8 + 0.36 
AZD8055  22.0 + 0.52  32.4 + 1.99  21.0 + 0.51 
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4.3  Discussion 
Multiple approaches were performed to assess the distinct effects of rapamycin 
and mTOR-KIs on synthesis of specific proteins. 
In this chapter, I studied the distinct effects of rapamycin and mTOR-KIs on synthesis 
of specific proteins using various methods. Microarray was first performed to study the 
gene  expression  in  cells  treated  with  different  inhibitor.  However,  the  initial 
microarray  data  analysis  showed  an  unusual  pattern  of  translation  of  ribosomal 
proteins caused by rapamycin, which led me to adopt another proteome-wide approach, 
pSILAC, to further study this. Real-time quantitative RT-PCR and Northern blot were 
used to validate the data revealed by microarray and pSILAC. The results of real-time 
PCR  showed  mTOR-KIs  strongly  affected  the  distribution  of  18S  and  β-actin  in 
sub/polysome samples, and also suggest that this method is not suitable as a validation 
method for my analysis. Northern blot was then carried out to study the behaviour of 
specific mRNAs revealed by pSILAC. In line with the real-time PCR data, it showed 
that mTOR-KIs did cause a partial decrease of the amount of β-actin mRNA associated 
with polysomes. 
mTOR-KIs strongly inhibit the synthesis of a wide range of proteins, particularly 
those encoded by TOP genes. 
mTOR-KIs (PP242 and AZD8055) suppressed general protein synthesis to a much 
stronger  extent  than  rapamycin.  The  pSILAC  data  reveal  that  mTOR-KIs  strongly 
inhibit the synthesis of a subset proteins encoded by 5‘-TOP genes, which contain an 
unusual oligopyrimidine tract (TOP) at their 5‘-end. Rapamycin is known to partially 
suppress the 5‘-TOP mRNA translation in serum-stimulated cells (Jefferies et al., 1994, 
Jefferies  et  al.,  1997,  Terada  et  al.,  1994,  Grolleau  et  al.,  2002).  However,  when 
compared with PP242 and AZD8055, the inhibition caused by rapamycin appears quite 
mild.  
Therefore, what caused the much greater inhibition by mTOR-KIs of the translation 
of 5‘-TOP mRNAs? It has been suggested that rapamycin suppresses 5‘-TOP mRNA 
translation through inhibition of p70 S6K (Jefferies et al., 1997). However, there are 
multiple  lines  of  evidence  supporting  the  idea  that  translational  activation  of  TOP 
mRNAs  requires  neither S6K1 nor  rpS6  phosphorylation (Barth-Baus  et  al., 2002, 
Pende et al., 2004, Ruvinsky et al., 2005). Furthermore, both rapamycin and mTOR-152 
 
KIs  blocked  phosphorylation  of  rpS6,  suggesting  that  this  is  not  the  main  event 
resulting in the difference between rapamycin and mTOR-KIs. 
 Rapamycin and mTOR-KIs also exerted distinct effects on eIF4G/eIF4E binding. 
My previous data already show that overexpressing eIF4E, which prevents the mTOR 
kinase  inhibitor-caused  loss  of  eIF4G/eIF4E  complexes,  could  not  eliminate  the 
mTOR  kinase  inhibitor-caused  inhibition  of  protein  synthesis.  More  importantly, 
recent work by Dr. Valentina Iadevaia in our lab has also shown that rapamycin and 
mTOR-KIs still caused substantial shifts of the rpL11, NAP1L1 and PRDX6 mRNAs 
out of polysomal fractions, demonstrating that eIF4E (and its partners) is not the main 
factor resulting in the distinct effects of rapamycin and mTOR-KIs on the translation 
of 5‘-TOP mRNAs. 
Nonetheless, mTOR must play a key role in the translational control of 5‘-TOP 
mRNAs  and the functions  of mTOR  involved in the regulation of  5‘-TOP  mRNA 
translation may not be strongly affected by rapamycin but more profoundly inhibited 
by mTOR-KIs. Interestingly, it has been recently suggested that mTOR may exert its 
effect on the translation of 5‘-TOP mRNAs through a novel, unidentified complex 
rather  than  the  canonical  mTOR  complexes  mTORC1  and  mTORC2  (Patursky-
Polischuk et al., 2009). 
Possible “New” TOP mRNAs revealed by the pSILAC data 
So far, all vertebrate genes for the 80 ribosomal proteins and some other genes which 
are  involved  in  translation  are  identified  as  TOP  mRNAs  (Iadevaia  et  al.,  2008). 
Recently all five elongation factors were found to be encoded by TOP mRNAs; among 
the  initiation  and  termination  factors,  only  eIF3e,  eIF3f,  and  eIF3h  exhibit  the 
characteristics of TOPs (Iadevaia et al., 2008). 
One important finding revealed by the pSILAC data is that the synthesis of certain 
proteins that are not encoded by known TOP mRNAs is strongly inhibited by mTOR 
inhibitors. Based on the results from DBTSS database, in several cases, the 5‘-UTR of 
these corresponding mRNAs apparently shows the features of TOP mRNA (Table 4.2), 
i.e.  their  transcription  start  site  is  a  pyrimidine  (usually  cytosine)  followed  by  an 
unbroken stretch of pyrimidines. The analysis using Northern blot shows the behaviour 
of  these  mRNAs  upon  treatment  with  mTOR  inhibitors,  particularly  one  of  the 
possible ―new‖ TOPs, NAP1L1 (Table 4.2, Fig. 4.14). Furthermore, analysis by real-
time  RT-PCR  by  Dr.  Valentina  Iadevaia  demonstrated  that  inhibition  of  mTOR 
signalling  with  these  inhibitors  did  not  affect  the  overall  levels  of  these  mRNAs 153 
 
(unpublished work). This promising finding indicates that these mRNAs are possibly 
new members of 5‘-TOP family, although further studies are required to confirm this. 
mTOR inhibition affects levels of most proteins via their rates of synthesis rather 
than degradation 
The pSILAC data show the strong inhibitory effects of mTOR-KIs on synthesis of a 
number of proteins.  
It is also interesting to determine whether the levels of specific proteins are affected 
by changes in their decay rates. Thus, the protein degradation data are very important 
for  several  reasons,  since  they  clearly  show  (1)  mTOR  inhibitors  did  not  trigger 
general protein breakdown; instead, they increased the stability of a number of proteins; 
(2) in general, mTOR kinase inhibitor AZD8055 had bigger effects than rapamycin on 
stabilising the proteins;  (3) interestingly,  the stability of  proteins encoded by TOP 
mRNAs was substantially increased by mTOR inhibitors, which agrees with the recent 
finding  that  protein  half-lives  are  affected  by  energetic  and  dynamic  constraints 
(Schwanhausser et al., 2011). This also makes good physiological sense; the improved 
stability of existing housekeeping proteins, for example, ribosomal proteins, can help 
cells to recover from stressful conditions such that caused mTOR signalling inhibition.  
 
 
 
 
 
 
 
 
 
 
 
 154 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5                                                               
THE STUDY OF THE Mnk INHIBITOR: AZ’9224 
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5.1 Introduction 
MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) are protein serine/threonine 
kinases that are activated by p44/42 MAPK (Erk1/2) or p38 MAPK (Waskiewicz et al., 
1997,  Fukunaga  and  Hunter,  1997).  The  best  understood  substrate  of  the  Mnks  is 
eIF4E (Mahalingam and Cooper, 2001, Scheper et al., 2001, Ueda et al., 2004).  
5.1.1 Discovery and protein structure of Mnks 
The  Mnks  were  first  discovered  simultaneously  by  two  teams  during  screens  for 
identification of novel Erk2 substrates and Erk1 substrates, respectively (Waskiewicz 
et al., 1997, Fukunaga and Hunter, 1997). Both Mnk1 and 2 transcripts (gene symbols: 
MKNK1 and  MKNK2) are subject  to  alternative splicing,  giving  rise to  full  length 
(Mnk1a/2a) as well as truncated versions (Mnk1b/2b) which lack C-terminal MAPK-
binding motif (Fig. 5.1). In the N-terminal region, all the Mnk isoforms contain a PBR 
(polybasic region) which is thought to be involved in the binding of eIF4G and also in 
nuclear  localisation  (Pyronnet  et  al.,  1999,  Parra-Palau  et  al.,  2003).  The  catalytic 
domains of Mnk1a/b and Mnk2a/b share several particular features: two unusual short 
inserts and a DFD (Asp-Phe-Asp) motif (where most protein kinases have DFG; Jauch 
et al., 2005, Jauch et al., 2006). The NES (nuclear export sequence) domain in Mnk1a 
is  involved  in  the  export  of  Mnk1  from  nucleus,  while  its  function  in  Mnk2a  is 
unknown due to the lack of several critical residues (Parra-Palau et al., 2003; Fig. 5.1). 
Mnk1a  contains  a  MAPK-binding  motif  in  its  C  terminus,  which  mediates  its 
interaction  with  Erk1/2  and  p38  MAPK  (Waskiewicz  et  al.,  1997,  Fukunaga  and 
Hunter, 1997). The corresponding domain in  Mnk2a shares high identity with that 
found in Rsk, leading to its preferred interaction with Erk1/2 (Waskiewicz et al., 1997). 
Mnk2a also preferably binds to phosphorylated Erk, likely making it  constitutively 
active  (Parra  et  al.,  2005).  The  short  versions  Mnk1b  and  2b  lack  the  C-terminal 
MAPK-binding motif (Fig. 5.1). No short versions have yet been identified in mice 
(Parra et al., 2005). 
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Figure 5.1. The essential structural components of the four Mnk isoforms (Mnk1a, 1b, 
2a and 2b) present in human cells. PBR, polybasic region (in green); NES, nuclear-
export sequence; X, non-functional NES; MAPK, MAPK-binding motif (in blue).  
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5.1.2 Activation mechanisms  
The  activities  and  regulation  of  Mnks  vary  between  the  isoforms.  With  respect  to 
Mnk1, the long form Mnk1a is responsive to activation of both Erk1/2 and p38, while 
the  basal  activity  of  Mnk1b  is  much  higher  than  Mnk1a  and  is  not  significantly 
affected by inhibitors of these modules, consistent with the fact that Mnk1b lacks a 
MAPK-binding motif (Fukunaga and Hunter, 1997, Wang et al., 1998, Waskiewicz et 
al., 1997, O'Loghlen et al., 2007). Mnk2a displays high levels of basal activity in cells 
which can be slightly increased by agonists of Erk1/2 but not P38 MAPK (Scheper et 
al., 2001). Mnk2b shows much lower activity than Mnk2a and it is not clear which 
circumstances  can  promote  its  activity  (Scheper  et  al.,  2003).  The  various  kinases 
involved in the activation of Mnks are displayed in Fig. 5.2.  
  The compound CGP57380 has been described as a low-molecular-weight kinase 
inhibitor of Mnk1 both in vitro and in vivo (Knauf et al., 2001). This compound was 
showed  to  inhibit  Mnk1  kinase  activity  in  vitro  with  an  IC50  of  2.2  μM  without 
inhibiting various other kinases, such as p38 MAPK, JNK1and Erk (Tschopp et al., 
2000,  Knauf  et  al., 2001). However,  a  study against  an extended panel of protein 
kinases indicated that CGP57380 is not a specific inhibitor of Mnks, since it showed 
similar inhibitory effects against several other protein kinases like MKK1, BRSK2 and 
CK1δ (Bain  et  al., 2007). There is  therefore  a clear  requirement to  identify novel 
specific Mnk inhibitors. AZ‘9224 is a compound from AstraZeneca and described as a 
Mnk inhibitor. It is the main aim of my study here to investigate its specificity and its 
effects.  
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Figure 5.2. MAPK signalling cascades leading to activation of Mnks. 
Mitogens, stresses and cytokines promote the activation of different MAPK pathways, 
which  in  turn  phosphorylate  and  activate  different  Mnk  isoforms.  Mnk1  can  be 
affected by both  Erk1/2 and p38  MAPK modules  but  Mnk2  is  only responsive to 
Erk1/2. It should be made clear that it is the ʱ and β isoforms of p38 MAPK that are 
responsible for the regulation of Mnks rather than the more-distantly related γ or δ 
ones. 
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5.1.3 Substrates 
A number of different substrates have been reported to be phosphorylated by Mnks. 
eIF4E is the best understood one. In eukaryotes, the translation initiation factor eIF4E 
binds to the mRNA cap structure and interacts with eIF4G, which serves as a scaffold 
protein for the assembly of eIF4E and eIF4A to form the eIF4F complex (Haghighat et 
al., 1995, Mader et al., 1995, Marcotrigiano et al., 1999). eIF4E is phosphorylated at 
Ser209 in response to stress and mitogen stimulation (Flynn and Proud, 1995, Minich 
et  al.,  1994).  Mnk1  was  found  to  be  associated  with  the  eIF4F  complex  via  its 
interaction with the C-terminal region of eIF4G (Pyronnet et al., 1999). Moreover, 
Mnk1 and 2 were shown to phosphorylate eIF4E at Ser209 in the presence of mitogen 
or  under  cell  stress  (Waskiewicz  et  al.,  1997,  Wang  et  al.,  1998).  In  embryonic 
fibroblasts derived from Mnk1 and Mnk2 double knockout mice, the phosphorylation 
of eIF4E at Ser209 was not detected, even in the presence of the activated Erk and/or 
p38 MAP kinases (Ueda et al., 2004). Results using cells from single knockout mice 
further  revealed  that  Mnk1  induced  the  phosphorylation  of  eIF4E  upon  MAPK 
activation, while Mnk2 was mainly responsible for the basal phosphorylation of eIF4E 
(Ueda et al., 2004). Taken together, these findings strongly suggest that the Mnk1 and 
2  are  the  only  eIF4E  kinases,  and  they  mediate  inducible  and  constitutive  eIF4E 
phosphorylation, respectively. 
   Other  identified  substrates  of  Mnks  include  the  heterogeneous  nuclear 
ribonucleoprotein  A1  (hnRNP  A1;  Buxade  et  al.,  2005),  the  PTB  (polypyrimidine 
tract-binding protein)-associated splicing factor (PSF; Buxade et al., 2008) and sprouty 
2 (Bundschu et al., 2006). The Mnks have been found to phosphorylate hnRNP A1 at 
two residues, Ser192 and Ser310 in response to T cell activation (Buxade et al., 2005). 
This phosphorylation resulted in decreased interaction of hnRNP A1 with TNF (tumor 
necrosis  factor)  ʱ-AREs  (AU-rich  elements)  in  vitro  or  TNFʱ  mRNA  in  vivo, 
suggesting that Mnks play key roles in the regulation of hnRNP A1. Together with its 
homolog  p54
nrb,  PSF  forms  a  multifunctional  heterodimer  implicated  in  diverse 
nuclear  processes  (reviewed  in  Shav-Tal  and  Zipori,  2002).  Mnks  were  found  to 
phosphorylate PSF at two sites in vitro during a proteomic approach and the Mnk-
mediated phosphorylation appears to increase the binding of PSF to the TNFʱ mRNA 
in  vivo  (Buxade  et  al.,  2008).  Mnks  are  also  able  to  phosphorylate  cytoplasmic 
phospholipase  A2  (cPLA2)  resulting  in  enzyme  activation  and  cPLA2-mediated 160 
 
arachidonate  release  (Hefner  et  al.,  2000).  Furthermore,  Mnk1  has  been  shown  to 
regulate  the  phosphorylation  of  human  Sprouty  2  (hSpry2)  at  Ser112  and  Ser121 
(Bundschu et al., 2006, DaSilva et al., 2006). Enhancement of serine phosphorylation 
of  hSpry  leads  to  the  stabilization  of  hSpry2  and  therefore  an  increased  ability  of 
hSpry2 to antagonize RTK induced Ras-Erk activation (DaSilva et al., 2006). 
 
5.2 Results 
5.2.1 AZ’9224 inhibits the phosphorylation of eIF4E in various cell lines. 
To test whether AZ‘9224 inhibits the phosphorylation of eIF4E at Ser209, MCF7 
cells were treated with different doses of this compound from 300nM to 1μM for 1 h. 
As  shown  in  Fig.  5.3,  in  serum-fed  MCF7  cells,  the  basal  level  of  eIF4E 
phosphorylation was low but was significantly enhanced by treatment with rapamycin. 
In  contrast,  AZ‘9224  showed  a  dose-dependent  inhibitory  effect  on  eIF4E 
phosphorylation. It completely abolished eIF4E phosphorylation at a concentration of 
1μM. Concomitant use of AZ‘9224 with rapamycin also substantially inhibited eIF4E 
phosphorylation in MCF7 cells (Fig. 5.3).  
In the absence of serum, the basal level of eIF4E phosphorylation is very low as 
shown in Fig. 5.4. Treatment with PMA can stimulate both Erk1/2 and p38 in a PKC 
dependent manner (Schultz et al., 1997). AZ‘9224 abolished the basal level of eIF4E 
phosphorylation  and  PMA-induced  eIF4E  phosphorylation  in  MCF7,  HEK293  and 
HeLa cell lines (Fig. 5.4). 
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Figure 5.3 Dose dependent effects of AZ‘9224 in serum-fed MCF7 cells. 
Serum-fed  MCF7  cells  were  treated  with  AZ‘9224  at  the  indicated  concentrations 
and/or rapamycin (rapa; 100 nM) for 60 min. Cell lysates were analyzed by western 
blot using the indicated antibodies. Tubulin was examined as a loading control. 
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Figure 5.4. Effects of AZ‘9224 on eIF4E phosphorylation in response to PMA in 
various cell types. 
MCF7, HEK293 and HeLa cells were starved of serum overnight and then treated with 
1 μM AZ‘9224 prior to PMA stimulation. Whole cell lysates were subjected to western 
blot analysis.  
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Subsequently,  a  wide  variety  of  cell  lines  including  MCF7,  MEFs  (mouse 
embryonic fibroblasts), PC3 (human prostate cancer cell line) and ZR75 (human breast 
carcinoma cell line cells) were tested. The effects of the mTOR inhibitors rapamycin 
and  AZD8055  on  eIF4E  phosphorylation  were  also  analysed.  AZ‘9224  strongly 
inhibited eIF4E phosphorylation at Ser209 in serum-fed MCF7, PC3 and ZR75 cells. 
Except in MEFs, either rapamycin or AZD8055 increased eIF4E phosphorylation in 
these  cell  lines  (Fig.  5.5).  As  rapamycin  and  AZD8055  possessed  contrary  effects 
towards Akt phosphorylation (shown in Chapter 3), it is unlikely that the increased 
level of eIF4E phosphorylation caused by these inhibitors was due to Akt activation. 
Akt phosphorylation at Thr308 was not significantly affected by AZ‘9224 in PC3 and 
ZR75 cells (Fig. 5.5). Other investigators reported that silencing p70 S6K had no effect 
on  rapamycin-induced  eIF4E  phosphorylation  (Wang  et  al.,  2007b).  Therefore,  it 
appears  that  inhibition  of  mTORC1  activity  increases  eIF4E  phosphorylation 
independently of Akt and p70 S6K.  
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Figure 5.5.  Effects of AZ‘9224 and mTOR inhibitors on eIF4E phosphorylation in 
various cell types. 
Serum-fed MCF7, MEFs, PC3 and ZR75 cells were treated with rapamycin (100 nM), 
AZD8055  (100  nM),  AZ‘9224  (1  μM),  or  co-treated  with  rapamycin/AZ‘9224  or 
AZD8055/AZ‘9224.  Whole  cell  lysates  were  subjected  to  western  blots  using  the 
indicated antibodies.  
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5.2.2 The inhibition by AZ’9224 of the formation of eIF4F in MCF7 and PC3 cells 
may be due to its off-target effects on other kinases.  
The effect of AZ‘9224 on eIF4E phosphorylation appears very promising. Therefore, it 
is of high importance to assess its specificity, i.e. whether AZ‘9224 shows inhibitory 
effects against other protein kinases/signalling pathways.  
Higher concentrations of the compond (up to 10 μM) were used in the following 
experiment. As shown in Fig. 5.6, AZ‘9224 at 10 μM had a mild effect on the binding 
of eIF4GI to eIF4E without inhibiting 4E-BP1 phosphorylation at Thr37/46 in MCF7 
and PC3 cells. If AZ‘9224 only inhibits Mnks without side effects on other kinases, the 
decreased amount of bound eIF4GI could suggest that phosphorylation of eIF4E at 
Ser209 has an effect on eIF4GI/eIF4E binding. 
However,  subsequent  experiments  showed  that  AZ‘9224  also  inhibited  the 
phosphorylation of Erk1/2, which is  upstream of Mnks. Fig. 5.7 demonstrated that 
AZ‘9224  at  10  μM  decreased  the  serum-induced  phosphorylation  of  Erk1/2  when 
inhibiting eIF4G binding in both MCF7 and PC3 cells. Furthermore, phosphorylation 
of the PDK1 site Thr308 in Akt was also impaired by AZ‘9224 at 10 μM. Although 
AZ‘9224 did not exhibit any inhibitory effect on the phosphorylation of 4E-BP1 in 
MCF7 and PC3 growing in serum (Fig. 5.6), it did block the phosphorylation of rpS6 
(Fig. 5.7). Serum-induced S6 phosphorylation at Ser240/244 was slightly decreased in 
MCF7 but substantially in PC3 cells.  
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Figure 5.6. Effect of AZ‘9224 on the binding of eIF4GI to eIF4E in MCF7 and PC3 
cells. 
MCF7  and  PC3  cells  growing  in  serum-maintained  medium  were  treated  with 
AZ‘9224  at  the  indicated  concentrations  for  1  h.  Equal  amounts  of  lysates  were 
subjected  to  affinity  chromatography  on  m
7GTP-Sepharose.  Bound  proteins  were 
analysed by western blot using the indicated antibodies. The bottom blot of eIF4E 
from whole cell lysate was used as an input control.  The phosphorylation of 4E-BP1 
at Thr37/46 was also examined. 
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Figure 5.7. Effect of AZ‘9224 on the serum-induced binding of eIF4GI to eIF4E in 
MCF7 and PC3 cells. 
MCF7 and PC3 cells were starved of serum overnight (>16 h) and were then treated 
with AZ‘9224 at the indicated concentrations for 1 h prior to serum stimulation for the 
indicated  times.  (A)  Equal  amounts  of  lysates  were  subjected  to  affinity 
chromatography on m
7GTP-Sepharose. Bound proteins were analysed by western blot 
using the indicated antibodies. (B) Whole lysates were examined by western blot using 
the indicated antibodies.  
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5.3 Summary and Discussion 
In  summary,  despite  the  striking  effects  of  AZ‘9224  on  eIF4E  phosphorylation  at 
Ser209 in various cell types, it unfortunately exhibits some off-target effects, i.e. it 
inhibits  protein kinases  or other effects  which  are  either upstream  of  the  Mnks  or 
up/downstream of mTOR. All these studies indicate that AZ‘9224 is not a specific 
inhibitor of Mnk isoforms and the results from this compound should be difficult to 
interpret. Therefore, the generation of a novel specific Mnk inhibitor or Mnk1/2 double 
knockout  animals  is  expected  to  provide  more  valuable  information  about  the 
mechanism of Mnks in the future (Ueda et al., 2004).   
mTOR inhibitors, particularly rapamycin, increased the phosphorylation of eIF4E 
phosphorylation on Ser209, which has been reported before (Wang et al., 2007b). The 
phosphorylation  of  eIF4E  has  been  shown  to  be  regulated  by  Mnks  through 
modulation of Mnk1-eIF4G interaction (Shveygert et al., 2010, Pyronnet et al., 1999). 
Given  that  the  distinct  effects  of  rapamycin  and  mTOR-KIs  on  the  binding  of 
eIF4GI/eIF4E (Fig. 3.9-3.10), the reason accounting for their apparently similar effects 
on  eIF4E  phosphorylation  remains  unclear.  Indeed,  my  finding  that  rapamycin 
increases the binding of eIF4G/eIF4E provides a potential explanation to its ability to 
increase eIF4E phosphorylation, since eIF4E phosphorylation is partially modulated by 
Mnk1-eIF4G interaction (it is also controlled by Mnk activity) (Shveygert et al., 2010, 
Knauf  et  al.,  2001,  Pyronnet  et  al.,  1999).    Wang  et  al.  (2007b)  concluded  that 
inhibition of mTOR by rapamycin increases eIF4E phosphorylation through a PI3K-
dependent  and  Mnk-mediated  mechanism.  However,  the  mechanism  by  which 
AZD8055  increased  eIF4E  phosphorylation  remains  unclear.  Overall,  these  data 
suggest  simultaneous  inhibition  of  mTOR  and  Mnk  may  provide  better  results  in 
tumour therapy, especially in those which are not sensitive to rapamycin (Bianchini et 
al., 2008, Wang et al., 2007b). 169 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6                                                         
STUDIES ON THE ROLE OF 
PHOSPHORYLATION OF eIF4E 
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6.1 Introduction 
The  cap-binding  protein  eIF4E  may  act  as  a  convergence  point  for  the  PI3K  and 
MAPK signalling pathways. eIF4E is partially activated via phosphorylation at Ser209 
by Mnks (eIF4E is also controlled by the interaction with 4E-BP1; Knauf et al., 2001, 
Waskiewicz  et  al.,  1997,  Wang  et  al.,  1998,  Pause  et  al.,  1994).  However,  the 
physiological significance of eIF4E phosphorylation has not been clearly defined so far.   
6.1.1 Ser209 is the only phosphorylation site on eIF4E 
Ser209 is located near the C-terminus of eIF4E (Flynn and Proud, 1995, Joshi et al., 
1995). It is now clear that eIF4E is phosphorylated by the Mnks at a single site Ser209 
in  mammals,  although  Ser53  was  initially  identified  as  the  phosphorylation  site 
(Rychlik et al., 1987). Multiple lines of evidence have shown that the Ser53Ala mutant 
still underwent phosphorylation (Flynn and Proud, 1995, Lazaris-Karatzas et al., 1990, 
Kaufman et al., 1993). It is likely that the mutation of Ser53 to Ala affects the function 
of  eIF4E  via  the  interference  with  the  structure  of  eIF4E,  rather  than  the 
phosphorylation state of eIF4E (Scheper and Proud, 2002). Ser209 was first identified 
as  the  major  phosphorylation  site  by  Joshi  et  al.  (1995)  and  Flynn  et  al.  (1995). 
Recently, Sonenberg et al. determined that Ser209 is the only phosphorylation site on 
eIF4E using an orthophosphate labelling approach (Furic et al., 2010). Using MEFs 
isolated from Wild-Type (WT) and KI (in which Ser209 was mutated to Ala) littermate 
embryos, 
32P-radiolabelled eIF4E was detected by immunoprecipitation in only WT 
MEFs, which underwent a two-fold increase by PMA treatment (Furic et al., 2010).      
 
6.1.2 Effects of phosphorylation of eIF4E on its affinity for capped mRNA 
Given the fact that phosphorylation of eIF4E is increased by extracellular stimuli that 
activate  protein  synthesis  (Wang  et  al.,  1998),  it  was  generally  thought 
phosphorylation  of  eIF4E  increased  its  affinity  to  cap  structure.  To  address  this, 
Minich  et  al.  developed  a  method  for  the  separation  of  phosphorylated  and 
nonphosphorylated  eIF4E  from  rabbit  reticulocytes  by  chromatography  on  rRNA-
Sepharose (Minich et al., 1994). Using this method, they found that phosphorylated 
eIF4E had three- to four-fold greater affinity for cap analogs and capped mRNA than 
nonphosphorylated  eIF-4E.  However,  it  is  possible  that  contamination  with  other 
proteins  such  as  4E-BP1  in  Minich  et  al.‘s  method  would  influence  their  results. 171 
 
Subsequently, with the discovery of the Mnks, other investigators raised controversial 
opinions.  For  instance,  Proud‘s  group  pointed  out  that  phosphorylation  of  eIF4E 
actually diminished its ability to bind cap analogue or capped mRNA (Scheper et al., 
2002). Using fluorescence spectroscopy and surface plasmon resonance techniques, it 
was  clear  that  phosphorylated  eIF4E  bound  with  lower  affinity  than  the 
nonphosphorylated form to cap analog and to capped RNA (Scheper et al., 2002). The 
reduction of the cap affinity for phosphorylated eIF4E was observed by Zuberek et al. 
(2003). Proud‘s group have proposed a new model of eIF4E phosphorylation during 
translation initiation. In this model, phosphorylation of eIF4E occurs immediately after 
the  formation  of  eIF4F  complex.  Reduced  affinity  of  eIF4E  for  the  cap-structure 
results in its dissociation from the cap, allowing the recruitment of a second eIF4E 
molecule  and  associated  proteins,  plus  the  40S  subunit.  Proud‘s  group  have  also 
demonstrated  that  the  phosphorylation  of  eIF4E  has  no  effect  on  its  binding  to 
eIF4G/4E-BP1, which is consistent with the 3D structure of eIF4E: the region that 
binds eIF4G/4E-BP1 is far away from the phosphorylation site Ser209 (reviewed in 
Scheper and Proud, 2002). 
 
6.1.3 Physiological role of eIF4E phosphorylation 
The biological significance of eIF4E phosphorylation remains controversial. It seems 
critical for normal development in Drosophila, since Lachance et al. (2002) found that 
transgenic Drosophila organisms expressing eIF4E-Ser251Ala (in Drosophila, Ser251 
corresponds  to  Ser209  of  mammalian  eIF4E)  in  an  eIF4E  mutant  background  had 
decreased  viability  (35%  lethality),  were  delayed  in  development  and smaller  than 
control  siblings.  When  Ser251  was  mutated  to  Asp  to  mimic  constitutive 
phosphorylation, the lethality was fully rescued in these transgenic lines. In contrast, 
mice with deletion in Mnk1/2 kinases developed normally in the absence of detectable 
phosphorylated eIF4E (Ueda et al., 2004). Wendel et al. (2004) showed that eIF4E 
was a potent oncogene in vivo using the Eμ-Myc transgenic mouse lymphoma model. 
Using the same model, they further demonstrated that the oncogenic activity of eIF4E 
was connected with its ability to activate translation and become phosphorylated on 
Ser209 (Wendel et al., 2007). In human prostate carcinomas (PCas), inactivation of 
PTEN caused an increase of basal level of PI3K and constitutive activation of the Akt 
pathway. Bianchini et al. (2008) found that the mTOR and the Mnk/eIF4E pathway 172 
 
were balanced to maintain the translation of mRNAs for proteins required for cell 
proliferation and stress response in PCas. Analysis by Wheater et al. in breast cancer 
cell lines provided evidence that the sensitivity of breast cancer cells to Mnk inhibition 
correlated  with  basal  levels  of  eIF4E  phosphorylation.  They  suggested  that  the 
presence of phosphorylated eIF4E could provide a biomarker for the identification of 
tumours which are responsive to Mnk inhibition (Wheater et al., 2010). In primary 
central  nervous  system  lymphoma  cells  (PCNSL),  Muta  et  al.  (2011)  showed  that 
eIF4E phosphorylation played an important role in proliferation and inhibition of the 
Mnk/eIF4E pathway could be a promising therapeutic target in patients with PCNSL. 
Studies  by  Furic  and  colleagues  (2010)  showed  that  knock-in  mice  expressing  a 
nonphosphorylable  form  of  eIF4E-Ser209Ala  (eIF4E-KI)  were  resistant  to 
tumourigenesis in a prostate cancer model. When they investigated the molecular basis 
that  underlies  the  eIF4E-KI  mice  to  tumourigenesis  using  polysome  profiling  and 
DNA  microarray,  a  subset  of  mRNAs  of  KI  MEFs  were  found  to  shift  to  lighter 
fractions relative to WT MEFs, such as the chemokine (C-C motif) ligand 2 and 7 
(Ccl2  and  Ccl7);  the  matrix  metalloproteinases  (MMPs)  MMP3  and  MMP9  and 
baculoviral IAP repeat-containing protein 2 (BIRC2). Their results indicated that some 
mRNAs involved in tumour progression differed in translational level between WT 
and KI MEFs. Overall, these data suggest the oncogenic activity of phospho-eIF4E and 
its potential as a target in cancer therapy. 
 
6.1.4 Sumoylation of eIF4E 
Protein  Sumoylation  which  is  mediated  by  activating  (E1),  conjugating  (E2)  and 
ligating (E3) enzymes is an important regulator of protein function in a wide range of 
cellular  processes  (Di  Bacco  and  Gill,  2006).  In  mammals,  there  are  four  SUMO 
(small  ubiquitin-like  modifier)  molecules,  designated  SUMO-1  to  SUMO-4.  These 
four  SUMO  molecules  exhibit  variable  sequence  identity  and  expression  pattern 
(Wilkinson and Henley, 2010). SUMO-1 is also known as UBL1 (Shen et al., 1996), 
PIC1 (Boddy et al., 1996), sentrin (Okura et al., 1996), GMP1 (Matunis et al., 1996) 
and Smt3c (Lapenta et al., 1997). SUMO-1 was first reported as a covalent protein 
modifier of RanGAP1 (Ran-GTPase-activating protein) (Matunis et al., 1996). The 
sequence  of  SUMO-2  is  highly  similar  to  SUMO-3.  However,  the  sequences  of 
SUMO-2/3 share only about 50% similarity with that of SUMO-1. SUMO-4 isoform 173 
 
has been predicted as a 95-residue protein, although endogenous SUMO-4 protein has 
not been detected. SUMO-1/2/3 are expressed ubiquitously (reviewed in Wilkinson 
and Henley, 2010).  
The functional outcomes of sumoylation are immensely diverse but its molecular 
consequences on the substrate protein can be summarized into three aspects. First, 
sumoylation  may  block  the  interaction  between  kinases  and  substrate  proteins  via 
―masking‖ the binding site. Secondly, after attachment to the substrate, SUMO may 
create  a  new  binding  site  and  recruit  new  binding  partners  in  a  SUMO-dependent 
pattern.  Finally,  SUMO  modification  can  lead  to  a  conformational  change  of  the 
sumoylated  protein,  regulating  its  activity  or  exposing  previously  masked  binding 
faces  (reviewed  in  Geiss-Friedlander  and  Melchior,  2007,  Wilkinson  and  Henley, 
2010). 
A study in Drosophila confirmed eIF4E as a sumoylation substrate (Nie et al., 
2009). Given the importance of SUMO modification in protein regulation, it is of high 
interest to investigate the role of mammalian eIF4E sumoylation in mRNA translation 
and protein synthesis. Recently, Xu et al. (2010) reported that eIF4E was sumoylated 
on lysines 36, 49, 162, 206 and 212 by SUMO-1 and the sumoylation promoted the 
formation of eIF4F complex. However, they only detected a very small proportion of 
eIF4E which was sumoylated both in vivo and in vitro.  
 
6.1.5 The control of TNFα biosynthesis by the Mnks. 
TNFʱ (tumour necrosis factor) is a cytokine involved in the control of inflammatory 
phenomena.  Its  synthesis  is  under  complex  regulation.  Through  AU-rich  elements 
(AREs) in the 3‘UTR of its mRNA, the expression of TNFʱ is tightly controlled at the 
posttranscriptional  level,  including  transport  (Dumitru  et  al.,  2000),  stabilization 
(Kontoyiannis  et  al.,  1999)  and  translation  (Han  et  al.,  1990).  However,  the 
mechanism remains poorly understood. Both Erk and p38 MAPK pathways are known 
to regulate the production of TNFʱ (Ballester et al., 1998, Buxade et al., 2001).  It has 
been  reported  that  MAP  kinase-activated  protein  kinase-2  (MK-2)  is  essential  for 
biosynthesis of TNFʱ without affecting its mRNA level and secretion (Kotlyarov et al., 
1999). Buxade et al. (2005) identified Mnks/eIF4E pathway as a novel player in the 
post-transcriptional regulation of TNFʱ in T cells. They showed that Mnks regulate 
TNFʱ expression in T cells via the 3‘UTR of its mRNA. A Mnk inhibitor (CGP57380) 
or  siRNA-mediated  knockdown  of  Mnk1  decreased  TNFʱ  production,  while 174 
 
overexpression  of  Mnk1  enhanced  protein  expression  of  a  reporter  containing  the 
TNFʱ 3‘UTR. Moreover, novel substrates for the Mnks that bind to the AREs of TNFʱ 
mRNA  have  been  identified,  including  hnRNP  A1  and  the  PSF-p54
nrb  complex 
(Buxade et al., 2008, Buxade et al., 2005). The phosphorylation mediated by Mnks 
reduced the binding of hnRNP A1to TNFʱ mRNA in vivo.  
 
6.2  Results 
6.2 .1 Effects of AZ’9224 on the sumoylation of eIF4E 
The report that phosphorylation of eIF4E is required for its sumoylation may provide 
new insights into the control of eIF4E translational activity (Xu et al., 2010). Thus, it 
was important to study effects of the Mnk inhibitor AZ‘9224 on eIF4E sumoylation. 
Xu et al. (2010) utilized a vector for eIF4E with mutations of all the five lysines, 
which may interfere with the phosphorylation site at Ser209, whereas the use of the 
Mnk inhibitor circumvents this issue.  
As shown in Fig. 6.1, multiple bands were detected in the m
7GTP pull down assay 
after immunoblotted with anti-SUMO-1. However, in the presence of a large amount 
of eIF4E in the bound material, only a minimal fraction (less than 1%) was apparently 
modified by SUMO-1. Adding NEM (N-ethylmaleimide; the isopeptidase inhibitor) in 
the lysis buffer did not significantly enhance the SUMO-1 signal. Unlike the dramatic 
effect of eIF4E phosphorylation on its sumoylation found by Xu et al. (2010), the 
inhibition of eIF4E phosphorylation by the Mnk inhibitor AZ‘9224 did not affect its 
sumoylation (Fig. 6.1). One reason may be that only a tiny amount of eIF4E was 
modified  by  SUMO-1,  resulting  in  the  difficulty  of  detection.  Subsequently,  the 
expression of eIF4E was increased by introducing wild type eIF4E into HeLa cells. 
Again, only a tiny proportion of eIF4E which might be modified by SUMO-1 was 
detected (data not shown). Therefore, my data using the Mnk inhibitor AZ‘9224 in 
HeLa cells did not confirm Xu et al.‘s findings. 
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Figure 6.1. Effects of AZ‘9224 on sumoylation of eIF4E. HeLa cells were cultured in 
regular complete medium and then treated with AZ‘9224 for 1 h. 
After harvesting, the cells were lysed in the presence or absence of 20 mM NEM (the 
isopeptidase inhibitor). Cell lysates were subjected to m
7GTP pull down assay and the 
bound material was analysed by western blot using anti-SUMO-1 or anti-eIF4E. A 
10% amount of input lysates was resolved by SDS-PAGE and immunoblotted with 
anti-p-eIF4E-S209. Arrows indicate possible signals for SUMO-1-eIF4E. 
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6.2.2  Studies on the role of Mnk/eIF4E on the synthesis of TNFα. 
Buxade et al. (2005) already demonstrated a role for the Mnks in the control of TNFʱ 
biosynthesis in T cells. Indeed, TNFʱ is primarily produced by activated macrophages. 
Here, I was interested in investigating the regulation of TNFʱ in mouse leukaemic 
monocyte macrophage cell line, RAW cells.  
LPS  (lipopolysaccharide)  induces  TNFʱ  biosynthesis  in  murine  macrophages 
(Kotlyarov et al., 1999, Dumitru et al., 2000). Thus, RAW cells were treated with 
various kinase inhibitors prior to LPS stimulation. As shown in Fig. 6.2, the potent 
inhibitor of p38 MAPK, SB203580 did not significantly inhibit the phosphorylation of 
p38  MAPK,  as  it  inhibits  its  catalytic  activity  (Kumar  et  al.,  1999).  However, 
SB203580 caused a reduction in eIF4E phosphorylation, suggesting that it worked (Fig. 
6.2). The LPS-stimulated expression of TNFʱ obtained from whole RAW cells lysate 
was substantially diminished by treatment with PD098059 (an inhibitor of MEK1) but 
remained unchanged by either SB203580 or AZ‘9224 (Fig. 6.2). These results show 
that TNFʱ synthesis depends much more on MEK/Erk than p38 MAPK signalling in 
RAW cells.  
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Figure 6.2. Effects of MAPK pathway on the synthesis of TNFʱ in RAW cells. 
RAW cells were treated as indicated for 1 h with 10 µM SB203580, 10 µM PD098059 
or  1  µM  AZ‘9224  prior  to  LPS  stimulation.  After  harvesting,  the  lysates  were 
subjected to western blotting using the indicated antibodies. 
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6.2.3 Studies on the role of eIF4E phosphorylation on the binding with specific mRNAs 
using RIP assay. 
Based on the results in (Furic et al., 2010), it would be interesting to examine whether 
eIF4E phosphorylation plays a role in the binding of specific mRNAs to eIF4E. The 
method RIP (RNA-protein interactions) assay, which was inspired by the chromatin 
immunoprecipitaion  (ChIP)  approach,  made  it  possible  to  study  the  interaction  of 
proteins such as eIF4E with specific messages (Niranjanakumari et al., 2002). The 
protocol for this method has been described in Materials and Methods section 2.4.6. 
Briefly, live cells were crosslinked with formaldehyde and then quenched by glycine. 
The fixed cells were sonicated and a specific antibody against the target protein was 
used  to  immunoprecipitate  crosslinked  complexes.  Following  stringent  washes,  the 
crosslinks were reversed and isolated RNA was analysed by RT-PCR using specific 
primers (Niranjanakumari et al., 2002). 
Based on the list of mRNAs which were more actively translated in WT compared 
to  KI  MEFs  (in  which  eIF4E  Ser209  was  mutated  to  Ala;  Furic  et  al.,  2010),  6 
candidates were chosen for RIP analysis, including Birc2, Ccl7, Mmp3, Vegfc, Rbmc, 
Mcl1. The functions of the proteins encoded by these messages are described in Table 
6.1. HeLa cells were transfected with HA-eIF4E, HA-eIF4E-Ser209A or the empty 
vector  (EV).  After  2  days,  cells  were  harvested  and  crosslinked  as  described  in 
Methods and Materials. The supernatant (unbound fraction after immunoprecipitation) 
and the pellet (immunoprecipitated fraction) samples were first analysed using β-actin 
primers (Fig. 6.3). β-actin was amplified in all the supernatant samples (EV, HA-eIF4E 
and  HA-eIF4E-S209A).  With  respect  to  the  pellet  samples,  unfortunately,  a  small 
amount of PCR products was still detected for the EV sample. This may be due to the 
nonspecific binding during the immunoprecipitation and/or contamination with other 
samples.  Interestingly,  β-actin  mRNA  binds  to  both  HA-eIF4E  and  HA-eIF4E  -
Ser209A (Fig. 6.3). 
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Table 6.1.  Candidates of RIP assay analysis and the brief description of their functions. 
Gene symbol  Description of Functions 
(provided by NCBI database)  
Birc2  baculoviral IAP repeat containing 2 
The protein encoded by this gene is a member of a family of 
proteins that inhibits apoptosis by binding to tumour necrosis 
factor receptor-associated factors TRaf1 and TRaf2. 
Ccl7  chemokine (C-C motif) ligand 7 
This gene encodes monocyte chemotactic protein 3, a secreted 
chemokine which attracts macrophages during inflammation 
and metastasis. 
Mmp3  matrix metallopeptidase 3 
Proteins  of  the  matrix  metalloproteinase  (MMP)  family  are 
involved in the breakdown of extracellular matrix in normal 
physiological processes. 
Vegfc  vascular endothelial growth factor C 
The protein encoded by this gene is a member of the platelet-
derived growth factor/vascular endothelial growth factor 
(PDGF/VEGF) family. 
Rbmx  RNA binding motif protein 
This  gene,  an  active  X  chromosome  homolog  of  the  Y 
chromosome RBMY gene, is widely expressed whereas the 
RBMY  gene  evolved  a  male-specific  function  in 
spermatogenesis. 
Mcl1  myeloid cell leukemia sequence 1 
This  gene  encodes  an  anti-apoptotic  protein,  which  is  a 
member of the Bcl-2 family. It has been identified as a target 
of eIF4E. In human lymphoma, enhanced translation of Mcl1 
likely contributes to eIF4E-mediated oncogenesis (Wendel et 
al., 2007).  
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Figure 6.3. RIP results for β-actin mRNA. 
Serum-replete  HeLa  cells  transfected  with  HA-eIF4E  or  HA-eIF4E-S209A  are 
crosslinked,  immunoprecipitated  and  analysed  by  RT-PCR  using  β-actin  primers 
(length of amplification product, ~100bp). 
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The interaction of eIF4E with other mRNAs was then examined using RIP assay 
(Fig. 6.4). No PCR products were visible for Mmp3 either in the supernatant or the 
pellet samples (Fig. 6.4, Mmp3). According to studies from (2008), MMP3 mRNA 
expression was deficient in HeLa cells. Although the amplification of Mcl1, Vegfc, 
Rbmx, Birc2, Ccl7 is very strong in the supernatant samples, only very weak signals 
were  detected  in  the  pellet  samples  (Fig.  6.4;  no  signal  detectable  for  Ccl7). 
Nevertheless, both HA-eIF4E and HA-eIF4E-S209A are able to interact with these 
mRNAs, although the detectable signal is very weak.  
There may be several reasons accounting for the low level of PCR products in the 
pellet sample. First, the efficiency of transfection may be too low. However, both the 
vectors gave excellent expression in HeLa cells (Fig. 6.5).  
Secondly, the efficiency of immunoprecipitation may be too  low, i.e. a large of 
amount of over-expressed HA-eIF4E/eIF4E-S209A remained in the supernatant rather 
than pulled down into the pellets. To assess this, the supernatant and the pellet samples 
from the RIP assay were subjected to HA immunoprecipitation and western blot (Fig. 
6.6). Although only a small proportion of supernatant was loaded onto SDS-PAGE for 
analysis, a significant amount of exogenous eIF4E was detected. Therefore, incomplete 
immunoprecipitation  probably  contributes  to  the  low  amplification  of  the  PCR 
products in the pellets.  
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Figure 6.4. RIP results of Mcl1, Vegfc, Rbmx, Birc2, Ccl7. 
Serum-replete  HeLa  cells  transfected  with  HA-eIF4E  or  HA-eIF4E-S209A  are 
crosslinked,  immunoprecipitated  and  analysed  by  RT-PCR  using  specific  primers. 
Primer details are described in Materials and Methods section 2.4.6. 
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Figure 6.5. The expression of HA-eIF4E and HA-eIF4E-S209A in HeLa cells. 
After transfected with the indicated DNAs, HeLa cells were starved of serum overnight 
and then stimulated with fresh serum (10%) for 30 min. The phosphorylation of eIF4E 
in  the  bound  material  was  tested  using  anti-eIF4E-pS209  antibody.  The  level  of 
exogenous and endogenous total eIF4E in whole cell lysate was examined using anti-
eIF4E. 
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Figure 6.6. Efficiency of HA immunoprecipitation. 
HeLa  cells  transfected  with  the  indicated  vectors  were  lysed  and  the  lysates  were 
subjected  to  immunoprecipitation  using  anti-HA;  one  tenth  of  supernatant  samples 
were analysed by western blotting. The positions of endogenous eIF4E and the light 
chain of the anti-HA antibody are indicated. EV: empty vector. 
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6.3  Discussion 
Despite the obligatory role of eIF4E in cap-dependent translation, it remains unclear 
how its activity is controlled. Although Xu et al. suggested the importance of eIF4E 
sumoylation  for  its  oncogenic  activity  (Xu  et  al.,  2010),  I  only  detected  a  tiny 
proportion of eIF4E which might be modified by SUMO-1 (even when exogenous 
eIF4E was introduced). Moreover, the Mnk inhibitor AZ‘9224 did not have an effect 
on these possible sumoylated eIF4E. My data do not support findings of Xu et al. 
(2010), suggesting that the interplay between eIF4E phosphorylation and sumoylation 
needs to be further investigated. 
I also studied the role of the Mnks in TNFʱ synthesis in RAW cells using the Mnk 
inhibitor  AZ‘9224.  Previous  work  has  been  done  to  define  how  p38  MAP  kinase 
controls TNFʱ production in macrophages (Salituro et al., 1999). Mnks have been 
identified as novel components in the control of TNFʱ biosynthesis in T cells (Buxade 
et al., 2005).  However, TNFʱ expression in RAW cells was not affected by treatment 
with the Mnk inhibitor AZ‘9224 even when eIF4E phosphorylation was inhibited. It 
may be that, unlike in T-cells, Mnks play a less important role in TNFʱ synthesis in 
RAW cells due to the reduced dependency on p38 MAPK.  
eIF4E  phosphorylation  has  also  been  implicated  in  promoting  tumourigenesis, 
possibly  through  its  control  on  the  translation  efficiency  of  a  subset  of  mRNAs 
encoding protumourigenic factors (Furic et al., 2010, Wendel et al., 2007). However, 
the mechanisms that render the translation of these mRNAs more sensitive to eIF4E 
phosphorylation are still undefined. By examining the interaction of different forms of 
eIF4E with a subset of mRNAs using RIP assays, both wild-type HA-eIF4E and HA-
eIF4E-S209A were found to bind to these mRNAs. It should be noted that since the 
PCR  performed  in  the  RIP  assay  is  not  quantitative,  any  differences  between  the 
association of eIF4E with HA-eIF4E and that with HA-eIF4E-S209A could not be 
assessed. Nevertheless, the RIP assay can be a more powerful tool to identify RNA-
protein interactions in vivo, for example, with the help of real-time quantitative RT-
PCR.  
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CHAPTER 7 
FINAL DISCUSSION 
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Distinct effects of rapamycin and mTOR-KIs on protein turnover 
The success of rapamycin and rapalogs on transplantation and some cancer therapies 
(e.g. kidney) has suggested that mTOR is an exciting target in the treatment of cancer 
and  other  diseases  (Yuan  et  al.,  2009).  However,  due  to  the  mode  of  action  of 
rapamycin and rapalogs (since they do not block the kinase activity of mTOR), they 
have  relatively  limited  clinical  utility,  leading  to  the  development  of  mTOR-KIs, 
which directly target the mTOR catalytic site. My study gives a detailed comparison of 
the effects of rapamycin and the newly-developed mTOR-KIs AZD8055 and PP242 
(Chresta et al., 2010, Feldman et al., 2009) on the mTOR signalling pathway, protein 
synthesis and degradation. 
    Compared with rapamycin, mTOR-KIs exerted significantly distinct effects on both 
mTORC1 and mTORC2.  In HeLa cells, mTOR-KIs inhibited the phosphorylation of 
4E-BP1 at multiple sites which are rather insensitive to rapamycin. With respect to the 
readouts of mTORC2 activity, mTOR-KIs substantially decreased the phosphorylation 
of  AKT  at  Ser473  whereas  rapamycin  actually  promoted  this  event.  The 
hyperactivation of Akt caused by rapamycin is a reflection of the relief of the negative 
feedback loop from S6K to IRS1 (Harrington et al., 2004, Um et al., 2004) as well as 
its lack of effect on mTORC2. Rapamycin and mTOR-KIs also displayed different 
effects  on the critical  step of cap-dependent  translation initiation, the formation  of 
eIF4F.  Treating  HeLa  cells  with  either  rapamycin  or  mTOR-KIs  increased  the 
association of eIF4E and 4E-BP1, although mTOR-KIs  did  this  to  a much greater 
extent.  However, the binding of eIF4G (and eIF4A) to eIF4E was modestly enhanced 
by  rapamycin  when  it  was  largely  abolished  by  mTOR-KIs.  Consistent  with  this, 
treatment  with  rapamycin  for  2h  or  6h  has  much  less  impact  on  the  rate  of 
[
35S]methionine incorporation than mTOR-KIs. The ability of rapamycin in causing 
superactivated  Akt  and  increased  eIF4G  binding  provides  useful  insights  into  the 
limited application of rapamycin and rapalogs in anti-cancer therapy. 
To  have  a  better  understanding  of  effects  of  mTOR  inhibition  caused  by  these 
inhibitors, a novel approach called pSILAC was applied to study this on a proteomic 
scale.  Grolleau and colleagues (2002) have combined microarray and [
35S]methionine 
labelling to study specific translational control by rapamycin in T cells. Their results 
have uncovered that the polysome-associated RNA levels of most of the expressed 
genes are partially reduced following rapamycin treatment, including a large number 
of ribosomal proteins and elongation factors. Their findings provided a comprehensive 188 
 
understanding  of  rapamycin‘s  molecular  mechanisms  in  T  cells.  However,  the 
approaches  employed  by  them  have  some  disadvantages.  For  example,  microarray 
only examines behaviours of mRNAs, and thus is not able to reflect the actual levels of 
individual proteins. pSILAC is a simple but powerful approach as it detects actual rates 
of  synthesis  of  individual  proteins.  Our  pSILAC  data  revealed  novel  features  of 
expression of mRNAs especially those containing a pyrimidine tract at their 5‘-end. 
The expression of these mRNAs, which are termed as 5‘-TOPs, was more sensitive to 
mTOR inhibition caused by mTOR-KIs than by rapamycin. Polysomal association of 
these  mRNAs  under  such  conditions  confirmed  the  increased  sensitivity  of  their 
translation to control by mTOR-KIs (the total transcript levels encoding these proteins 
did not change as measured by Dr Valentina Iadevaia). Moreover, this feature was 
shared by a subset of mRNAs which were found to contain a tract of pyrimidines at 
their 5‘-UTR after searching the DBTSS database (http://dbtss.hgc.jp), although the 
status of these mRNAs as possible 5‘-TOPs is yet to be determined.  
The bigger effects of mTOR-KIs on general protein synthesis and the synthesis of 
5‘-TOP mRNAs might be a reflection of inhibition of mTORC2 functions.  However, 
Torin1,  another  mTOR-KI,  has  been  shown  to  suppress  global  protein  synthesis 
through  an  mTORC2-independent  manner  (Thoreen  et  al.,  2009).  Therefore,  it  is 
possible that rapamycin-resistant functions of mTORC1 (e.g. 4E-BP1 phosphorylation) 
are required for the stronger inhibition of protein synthesis by mTOR-KIs. To test this 
hypothesis, wild type eIF4E was overexpressed in HeLa cells in order to introduce 
more ―free eIF4E‖ to eliminate effects of increased levels of hypophosphorylated 4E-
BP1.  But  eIF4E  overexpression  had  no  significant  impact  on  inhibition  of  either 
general protein synthesis or synthesis of specific mRNAs (Dr Valentina Iadevaia‘s 
data), demonstrating that eIF4E/4E-BP1 binding is not the main event resulting in the 
distinct effects of rapamycin and mTOR-KIs. Hence, it seems that the greater effects of 
mTOR-KIs are reflections of additional unidentified rapamycin-resistant functions of 
mTORC1 and/or a novel complex rather than the canonical mTORC1 and mTORC2 
(mTORC3? Fig. 7.1).  
   Interestingly, it was found that the stability of ribosomal proteins was increased upon 
mTOR inhibition, even though their synthesis was substantially impaired.  This finding 
is in line with the recent results of Schwanhausser et al. (2011) who also employed 
pSILAC  approach  to  study  gene  expression  control  in    mouse  fibroblasts.  They 
showed that under energy constraints, abundant proteins, such as ribosomal proteins 189 
 
were significantly more stable than less abundant ones. Moreover, the length of these 
abundant proteins is significantly shorter, which makes sense since protein half-lives 
and lengths are tightly related to theoretical energy consumption (Schwanhausser et al., 
2011).  
 
Physiological role of eIF4E phosphorylation  
eIF4E  phosphorylation  has  been  established  as  a  key  event  in  tumorigenesis,  thus 
raising the possibility that chemical compounds which prevent eIF4E phosphorylation 
(for example, Mnk inhibitors) could be used in cancer therapy (Furic et al., 2010, Ueda 
et al., 2010). Unfortunately, AZ‘9224 was found not to be a specific Mnk inhibitor in 
various mammalian cell lines.  
It  has  been  suggested  that  sumoylation  of  eIF4E  is  an  important  regulatory 
mechanism  for  cap-dependent  translation  and  oncogenic  transformation  and  eIF4E 
phosphorylation is required for its sumoylation in NIH-3T3 cells (Xu et al., 2010). 
However,  AZ‘9224  failed  to  have  an  effect  on  eIF4E  sumoylation  when  its 
phosphorylation was abolished in HeLa cells, suggesting that the interplay between 
these two events  needs  to  be further clarified in a wide  range of  cell  types. With 
respect to the role of Mnks on TNFʱ synthesis, they may be less important in RAW 
cells than in T cells (Buxade et al., 2005).  The effects of eIF4E phosphorylation on its 
interaction with specific mRNA were studied using RIP assay. The data are interesting 
since they showed that loss of eIF4E phosphorylation did not abolish its ability to bind 
to several transcripts. 
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Figure 7.1.  The mTOR signalling network. 
Multiple signals including growth factors, nutrients, energy and stress can regulate the 
activity of mTORC1 through the central regulator TSC1/2. The activation of mTORC1 
targets various downstream effectors which are involved in the control of ribosome 
biogenesis,  transcription,  translation  and  autophagy.  mTORC2  is  involved  in  the 
phosphorylation  of  HM  site  of  many  AGC  kinases  (for  example,  Ser473  in  Akt). 
Besides  regulated  by  4E-BP1,  eIF4E  is  also  phosphorylated  by  Mnks  which  are 
recruited to  eIF4G. A  more detailed summary of the mTOR  signalling network is 
given below. 
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As shown in Fig. 7.1, two complexes, mTORC1 and mTORC2, exist in mammals and 
the regulation and functions of mTORC1 are much better understood than those of 
mTORC2. mTORC1 regulates ribosome biogenesis, transcription, mRNA translation 
and autophagy by integrating signals that are generated by insulin and IGFs, amino 
acids, energy levels and various stressors such as hypoxia. TSC1/2 is the point where 
signal  integration  occurs.  As  a  tumour  suppressor,  TSC1/2  negatively  regulates 
mTORC1  through  its  GAP  (GTPase  activating  protein)  activity  towards  Rheb, 
converting Rheb to its inactive, GDP-bound form. Multiple upstream signalling inputs 
from  PI3K–Akt,  Ras–Erk–RSK,  LKB1–AMPK,  REDD1  and  Rag  proteins  either 
positively or negatively regulate mTORC1 signalling when stimulated by extracellular 
signals. Several kinases, including AKT, Erk and RSK phosphorylate TSC2 and result 
in  the  inhibition  of  the  GAP  activity  of  TSC2.  In  contrast,  AMPK-mediated 
phosphorylation positively regulates the GAP activity of TSC2 (where REDD1 was 
thought  to  sequester  14-3-3  proteins  away  from  TSC2).  Moreover,  some  of  these 
kinases  modulate  mTORC1  independently  of  TSC1/2,  such  as  Akt-mediated 
phosphorylation of the mTORC1 inhibitory factor, PRAS40. In addition, Rag proteins 
mediate  translocation  of  mTORC1  to  lysosomal  membranes  through  the  help  of  a 
trimeric complex, Ragulator, in response to amino acid sufficiency (not depicted in this 
figure). The activation of mTORC1 serves to control various downstream targets such 
as  S6K  and  4E-BP1.  4E-BP1  competes  with  eIF4G  to  bind  to  eIF4E,  leading  to 
inhibition of eIF4F formation. eIF4E activity is also regulated by phosphorylation by 
Mnks. S6K exerts a negative feedback loop towards IRS1, downregulating the activity 
of  components  of  the  insulin/PI3k/Akt  pathway.  mTORC2  has  been  demonstrated 
roles in the regulation of the actin cytoskeleton and the phosphorylation of some AGC 
kinases,  including  Akt,  PKC  and  SGK.  The  mode  of  action  of  mTOR-KIs  is 
distinguished from that of rapamycin, i.e. they directly target the kinase domain of 
mTOR  and  thus  block  both  mTORC1  and  mTOC2  activities.  MAPK  signalling 
promotes phosphorylation of eIF4E through Mnk1/2, which occurs when Mnks are 
recruited to eIF4G. 
 
The future directions of mTOR-KIs in cancer therapy  
mTOR  controls  many  aspects  of  cellular  physiology  by  coordinating  an  adequate 
response  to  changes  in  growth  factors,  nutrients  and  environmental  stresses  (a 192 
 
summary  of  the  mTOR  signalling  network  is  presented  in  Fig.  7.1).  Since  it  is 
frequently  dysregulated  in  many  diseases  such  as  cancer  and  metabolic  disorders, 
mTOR has been considered an exciting target in cancer therapy. My studies showed 
that mTOR  KIs,  AZD8055 and PP242, had stronger effects  on mTOR complexes, 
mRNA  translation  and  protein  degradation  compared  with  rapamycin.  In  addition,  
data from Sini et al. (2010) showed that AZD8055 also had greater impacts on the 
induction of autophagy and cell death than rapamycin did in some cell lines. PP242 
has  also  been  demonstrated  to  have  a  marked  therapeutic  response  in  rapamycin-
resistant tumours (Hsieh et al., 2010). As such, mTOR-KIs, which inhibit both mTOR 
complexes,  may  offer  therapeutic  advantages  to  rapamycin  and  its  analogs.  In  the 
recent  years, the field of the development of mTOR-KIs has matured with several 
compounds currently in the early stages of clinical trials, including AZD8055 (Chresta 
et al., 2010), OSI-027 (Bhagwat et al., 2011) and CCI-223 (Zask et al., 2011). 
    It is note worthy that, besides the mTOR pathway, oncogenic activation can also 
induce  other  signalling  pathways  such as  MAPKs.  Therefore,  combined treatments 
which target multiple pathways may maximize the inhibition of the oncogenic activity 
and tumorigenesis.  
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